6	PRADAXA.xml:S1:4:1	O
ADVERSE	PRADAXA.xml:S1:7:7	O
REACTIONS	PRADAXA.xml:S1:15:9	O

The	PRADAXA.xml:S1:28:3	O
most	PRADAXA.xml:S1:32:4	O
serious	PRADAXA.xml:S1:37:7	O
adverse	PRADAXA.xml:S1:45:7	O
reactions	PRADAXA.xml:S1:53:9	O
reported	PRADAXA.xml:S1:63:8	O
with	PRADAXA.xml:S1:72:4	O
PRADAXA	PRADAXA.xml:S1:77:7	O
were	PRADAXA.xml:S1:85:4	O
related	PRADAXA.xml:S1:90:7	O
to	PRADAXA.xml:S1:98:2	O
bleeding	PRADAXA.xml:S1:101:8	B-AdverseReaction
[	PRADAXA.xml:S1:111:1	O
see	PRADAXA.xml:S1:112:3	O
Warnings	PRADAXA.xml:S1:116:8	O
and	PRADAXA.xml:S1:125:3	O
Precautions	PRADAXA.xml:S1:129:11	O
(	PRADAXA.xml:S1:142:1	O
5.2	PRADAXA.xml:S1:143:3	O
)	PRADAXA.xml:S1:146:1	O
]	PRADAXA.xml:S1:149:1	O
.	PRADAXA.xml:S1:152:1	O

EXCERPT	PRADAXA.xml:S1:160:7	O
:	PRADAXA.xml:S1:167:1	O
Most	PRADAXA.xml:S1:171:4	O
common	PRADAXA.xml:S1:176:6	O
adverse	PRADAXA.xml:S1:183:7	O
reactions	PRADAXA.xml:S1:191:9	O
(	PRADAXA.xml:S1:201:1	O
15%	PRADAXA.xml:S1:203:3	O
)	PRADAXA.xml:S1:206:1	O
are	PRADAXA.xml:S1:208:3	O
gastritis	PRADAXA.xml:S1:212:9	B-AdverseReaction
-	PRADAXA.xml:S1:221:1	O
like	PRADAXA.xml:S1:222:4	O
symptoms	PRADAXA.xml:S1:227:8	O
and	PRADAXA.xml:S1:236:3	O
bleeding	PRADAXA.xml:S1:240:8	B-AdverseReaction
(	PRADAXA.xml:S1:250:1	O
6.1	PRADAXA.xml:S1:251:3	O
)	PRADAXA.xml:S1:254:1	O

To	PRADAXA.xml:S1:266:2	O
report	PRADAXA.xml:S1:269:6	O
SUSPECTED	PRADAXA.xml:S1:276:9	O
ADVERSE	PRADAXA.xml:S1:286:7	O
REACTIONS	PRADAXA.xml:S1:294:9	O
,	PRADAXA.xml:S1:303:1	O
contact	PRADAXA.xml:S1:305:7	O
Boehringer	PRADAXA.xml:S1:313:10	O
Ingelheim	PRADAXA.xml:S1:324:9	O
Pharmaceuticals	PRADAXA.xml:S1:334:15	O
,	PRADAXA.xml:S1:349:1	O
Inc	PRADAXA.xml:S1:351:3	O
.	PRADAXA.xml:S1:354:1	O

at	PRADAXA.xml:S1:356:2	O
(	PRADAXA.xml:S1:359:1	O
800	PRADAXA.xml:S1:360:3	O
)	PRADAXA.xml:S1:363:1	O
542	PRADAXA.xml:S1:365:3	O
-	PRADAXA.xml:S1:368:1	O
6257	PRADAXA.xml:S1:369:4	O
or	PRADAXA.xml:S1:374:2	O
(	PRADAXA.xml:S1:377:1	O
800	PRADAXA.xml:S1:378:3	O
)	PRADAXA.xml:S1:381:1	O
459	PRADAXA.xml:S1:383:3	O
-	PRADAXA.xml:S1:386:1	O
9906	PRADAXA.xml:S1:387:4	O
TTY	PRADAXA.xml:S1:392:3	O
or	PRADAXA.xml:S1:396:2	O
FDA	PRADAXA.xml:S1:399:3	O
at	PRADAXA.xml:S1:403:2	O
1	PRADAXA.xml:S1:406:1	O
-	PRADAXA.xml:S1:407:1	O
800	PRADAXA.xml:S1:408:3	O
-	PRADAXA.xml:S1:411:1	O
FDA	PRADAXA.xml:S1:412:3	O
-	PRADAXA.xml:S1:415:1	O
1088	PRADAXA.xml:S1:416:4	O
or	PRADAXA.xml:S1:421:2	O
www	PRADAXA.xml:S1:431:3	O
.	PRADAXA.xml:S1:434:1	O
fda	PRADAXA.xml:S1:435:3	O
.	PRADAXA.xml:S1:438:1	O
gov	PRADAXA.xml:S1:439:3	O
medwatch	PRADAXA.xml:S1:443:8	O
.	PRADAXA.xml:S1:455:1	O

6.1	PRADAXA.xml:S1:465:3	O

Clinical	PRADAXA.xml:S1:469:8	O
Trials	PRADAXA.xml:S1:478:6	O
Experience	PRADAXA.xml:S1:485:10	O

Because	PRADAXA.xml:S1:499:7	O
clinical	PRADAXA.xml:S1:507:8	O
trials	PRADAXA.xml:S1:516:6	O
are	PRADAXA.xml:S1:523:3	O
conducted	PRADAXA.xml:S1:527:9	O
under	PRADAXA.xml:S1:537:5	O
widely	PRADAXA.xml:S1:543:6	O
varying	PRADAXA.xml:S1:550:7	O
conditions	PRADAXA.xml:S1:558:10	O
,	PRADAXA.xml:S1:568:1	O
adverse	PRADAXA.xml:S1:570:7	O
reactions	PRADAXA.xml:S1:578:9	O
rates	PRADAXA.xml:S1:588:5	O
observed	PRADAXA.xml:S1:594:8	O
in	PRADAXA.xml:S1:603:2	O
the	PRADAXA.xml:S1:606:3	O
clinical	PRADAXA.xml:S1:610:8	O
trials	PRADAXA.xml:S1:619:6	O
of	PRADAXA.xml:S1:626:2	O
a	PRADAXA.xml:S1:629:1	O
drug	PRADAXA.xml:S1:631:4	O
cannot	PRADAXA.xml:S1:636:6	O
be	PRADAXA.xml:S1:643:2	O
directly	PRADAXA.xml:S1:646:8	O
compared	PRADAXA.xml:S1:655:8	O
to	PRADAXA.xml:S1:664:2	O
rates	PRADAXA.xml:S1:667:5	O
in	PRADAXA.xml:S1:673:2	O
the	PRADAXA.xml:S1:676:3	O
clinical	PRADAXA.xml:S1:680:8	O
trials	PRADAXA.xml:S1:689:6	O
of	PRADAXA.xml:S1:696:2	O
another	PRADAXA.xml:S1:699:7	O
drug	PRADAXA.xml:S1:707:4	O
and	PRADAXA.xml:S1:712:3	O
may	PRADAXA.xml:S1:716:3	O
not	PRADAXA.xml:S1:720:3	O
reflect	PRADAXA.xml:S1:724:7	O
the	PRADAXA.xml:S1:732:3	O
rates	PRADAXA.xml:S1:736:5	O
observed	PRADAXA.xml:S1:742:8	O
in	PRADAXA.xml:S1:751:2	O
practice	PRADAXA.xml:S1:754:8	O
.	PRADAXA.xml:S1:762:1	O

Reduction	PRADAXA.xml:S1:772:9	O
of	PRADAXA.xml:S1:782:2	O
Risk	PRADAXA.xml:S1:785:4	O
of	PRADAXA.xml:S1:790:2	O
Stroke	PRADAXA.xml:S1:793:6	O
and	PRADAXA.xml:S1:800:3	O
Systemic	PRADAXA.xml:S1:804:8	O
Embolism	PRADAXA.xml:S1:813:8	O
in	PRADAXA.xml:S1:822:2	O
Non	PRADAXA.xml:S1:825:3	O
-	PRADAXA.xml:S1:828:1	O
valvular	PRADAXA.xml:S1:829:8	O
Atrial	PRADAXA.xml:S1:838:6	O
Fibrillation	PRADAXA.xml:S1:845:12	O

The	PRADAXA.xml:S1:866:3	O
RE	PRADAXA.xml:S1:870:2	O
-	PRADAXA.xml:S1:872:1	O
LY	PRADAXA.xml:S1:873:2	O
(	PRADAXA.xml:S1:876:1	O
Randomized	PRADAXA.xml:S1:877:10	O
Evaluation	PRADAXA.xml:S1:888:10	O
of	PRADAXA.xml:S1:899:2	O
Long	PRADAXA.xml:S1:902:4	O
-	PRADAXA.xml:S1:906:1	O
term	PRADAXA.xml:S1:907:4	O
Anticoagulant	PRADAXA.xml:S1:912:13	O
Therapy	PRADAXA.xml:S1:926:7	O
)	PRADAXA.xml:S1:933:1	O
study	PRADAXA.xml:S1:935:5	O
provided	PRADAXA.xml:S1:941:8	O
safety	PRADAXA.xml:S1:950:6	O
information	PRADAXA.xml:S1:957:11	O
on	PRADAXA.xml:S1:969:2	O
the	PRADAXA.xml:S1:972:3	O
use	PRADAXA.xml:S1:976:3	O
of	PRADAXA.xml:S1:980:2	O
two	PRADAXA.xml:S1:983:3	O
doses	PRADAXA.xml:S1:987:5	O
of	PRADAXA.xml:S1:993:2	O
PRADAXA	PRADAXA.xml:S1:996:7	O
and	PRADAXA.xml:S1:1004:3	O
warfarin	PRADAXA.xml:S1:1008:8	O
[	PRADAXA.xml:S1:1018:1	O
see	PRADAXA.xml:S1:1019:3	O
Clinical	PRADAXA.xml:S1:1023:8	O
Studies	PRADAXA.xml:S1:1032:7	O
(	PRADAXA.xml:S1:1041:1	O
14.1	PRADAXA.xml:S1:1042:4	O
)	PRADAXA.xml:S1:1046:1	O
]	PRADAXA.xml:S1:1049:1	O
.	PRADAXA.xml:S1:1052:1	O

The	PRADAXA.xml:S1:1054:3	O
numbers	PRADAXA.xml:S1:1058:7	O
of	PRADAXA.xml:S1:1066:2	O
patients	PRADAXA.xml:S1:1069:8	O
and	PRADAXA.xml:S1:1078:3	O
their	PRADAXA.xml:S1:1082:5	O
exposures	PRADAXA.xml:S1:1088:9	O
are	PRADAXA.xml:S1:1098:3	O
described	PRADAXA.xml:S1:1102:9	O
in	PRADAXA.xml:S1:1112:2	O
Table	PRADAXA.xml:S1:1115:5	O
1	PRADAXA.xml:S1:1121:1	O
.	PRADAXA.xml:S1:1122:1	O

Limited	PRADAXA.xml:S1:1124:7	O
information	PRADAXA.xml:S1:1132:11	O
is	PRADAXA.xml:S1:1144:2	O
presented	PRADAXA.xml:S1:1147:9	O
on	PRADAXA.xml:S1:1157:2	O
the	PRADAXA.xml:S1:1160:3	O
110	PRADAXA.xml:S1:1164:3	O
mg	PRADAXA.xml:S1:1168:2	O
dosing	PRADAXA.xml:S1:1171:6	O
arm	PRADAXA.xml:S1:1178:3	O
because	PRADAXA.xml:S1:1182:7	O
this	PRADAXA.xml:S1:1190:4	O
dose	PRADAXA.xml:S1:1195:4	O
is	PRADAXA.xml:S1:1200:2	O
not	PRADAXA.xml:S1:1203:3	O
approved	PRADAXA.xml:S1:1207:8	O
.	PRADAXA.xml:S1:1215:1	O

Table	PRADAXA.xml:S1:1221:5	O
1	PRADAXA.xml:S1:1227:1	O
Summary	PRADAXA.xml:S1:1229:7	O
of	PRADAXA.xml:S1:1237:2	O
Treatment	PRADAXA.xml:S1:1240:9	O
Exposure	PRADAXA.xml:S1:1250:8	O
in	PRADAXA.xml:S1:1259:2	O
RE	PRADAXA.xml:S1:1262:2	O
-	PRADAXA.xml:S1:1264:1	O
LY	PRADAXA.xml:S1:1265:2	O

PRADAXA	PRADAXA.xml:S1:1283:7	O
110	PRADAXA.xml:S1:1291:3	O
mg	PRADAXA.xml:S1:1295:2	O
twice	PRADAXA.xml:S1:1298:5	O
daily	PRADAXA.xml:S1:1304:5	O
PRADAXA	PRADAXA.xml:S1:1319:7	O
150	PRADAXA.xml:S1:1327:3	O
mg	PRADAXA.xml:S1:1331:2	O
twice	PRADAXA.xml:S1:1334:5	O
daily	PRADAXA.xml:S1:1340:5	O
Warfarin	PRADAXA.xml:S1:1359:8	O

Total	PRADAXA.xml:S1:1381:5	O
number	PRADAXA.xml:S1:1387:6	O
treated	PRADAXA.xml:S1:1394:7	O
5983	PRADAXA.xml:S1:1403:4	O
6059	PRADAXA.xml:S1:1430:4	O
5998	PRADAXA.xml:S1:1457:4	O

Exposure	PRADAXA.xml:S1:1477:8	O

12	PRADAXA.xml:S1:1572:2	O
months	PRADAXA.xml:S1:1575:6	O
4936	PRADAXA.xml:S1:1597:4	O
4939	PRADAXA.xml:S1:1624:4	O
5193	PRADAXA.xml:S1:1651:4	O

24	PRADAXA.xml:S1:1682:2	O
months	PRADAXA.xml:S1:1685:6	O
2387	PRADAXA.xml:S1:1707:4	O
2405	PRADAXA.xml:S1:1734:4	O
2470	PRADAXA.xml:S1:1761:4	O

Mean	PRADAXA.xml:S1:1781:4	O
exposure	PRADAXA.xml:S1:1786:8	O
(	PRADAXA.xml:S1:1795:1	O
months	PRADAXA.xml:S1:1796:6	O
)	PRADAXA.xml:S1:1802:1	O
20.5	PRADAXA.xml:S1:1805:4	O
20.3	PRADAXA.xml:S1:1832:4	O
21.3	PRADAXA.xml:S1:1859:4	O

Total	PRADAXA.xml:S1:1879:5	O
patient	PRADAXA.xml:S1:1885:7	O
-	PRADAXA.xml:S1:1892:1	O
years	PRADAXA.xml:S1:1893:5	O
10	PRADAXA.xml:S1:1900:2	O
,	PRADAXA.xml:S1:1902:1	O
242	PRADAXA.xml:S1:1903:3	O
10	PRADAXA.xml:S1:1926:2	O
,	PRADAXA.xml:S1:1928:1	O
261	PRADAXA.xml:S1:1929:3	O
10	PRADAXA.xml:S1:1953:2	O
,	PRADAXA.xml:S1:1955:1	O
659	PRADAXA.xml:S1:1956:3	O

Drug	PRADAXA.xml:S1:1991:4	O

Discontinuation	PRADAXA.xml:S1:1996:15	O
in	PRADAXA.xml:S1:2012:2	O
RE	PRADAXA.xml:S1:2015:2	O
-	PRADAXA.xml:S1:2017:1	O
LY	PRADAXA.xml:S1:2018:2	O

The	PRADAXA.xml:S1:2031:3	O
rates	PRADAXA.xml:S1:2035:5	O
of	PRADAXA.xml:S1:2041:2	O
adverse	PRADAXA.xml:S1:2044:7	O
reactions	PRADAXA.xml:S1:2052:9	O
leading	PRADAXA.xml:S1:2062:7	O
to	PRADAXA.xml:S1:2070:2	O
treatment	PRADAXA.xml:S1:2073:9	O
discontinuation	PRADAXA.xml:S1:2083:15	O
were	PRADAXA.xml:S1:2099:4	O
21%	PRADAXA.xml:S1:2104:3	O
for	PRADAXA.xml:S1:2108:3	O
PRADAXA	PRADAXA.xml:S1:2112:7	O
150	PRADAXA.xml:S1:2120:3	O
mg	PRADAXA.xml:S1:2124:2	O
and	PRADAXA.xml:S1:2127:3	O
16%	PRADAXA.xml:S1:2131:3	O
for	PRADAXA.xml:S1:2135:3	O
warfarin	PRADAXA.xml:S1:2139:8	O
.	PRADAXA.xml:S1:2147:1	O

The	PRADAXA.xml:S1:2149:3	O
most	PRADAXA.xml:S1:2153:4	O
frequent	PRADAXA.xml:S1:2158:8	O
adverse	PRADAXA.xml:S1:2167:7	O
reactions	PRADAXA.xml:S1:2175:9	O
leading	PRADAXA.xml:S1:2185:7	O
to	PRADAXA.xml:S1:2193:2	O
discontinuation	PRADAXA.xml:S1:2196:15	O
of	PRADAXA.xml:S1:2212:2	O
PRADAXA	PRADAXA.xml:S1:2215:7	O
were	PRADAXA.xml:S1:2223:4	O
bleeding	PRADAXA.xml:S1:2228:8	B-AdverseReaction
and	PRADAXA.xml:S1:2237:3	O
gastrointestinal	PRADAXA.xml:S1:2241:16	B-AdverseReaction
events	PRADAXA.xml:S1:2258:6	I-AdverseReaction
(	PRADAXA.xml:S1:2265:1	O
i	PRADAXA.xml:S1:2266:1	O
.	PRADAXA.xml:S1:2267:1	O
e	PRADAXA.xml:S1:2268:1	O
.	PRADAXA.xml:S1:2269:1	O
,	PRADAXA.xml:S1:2270:1	O
dyspepsia	PRADAXA.xml:S1:2272:9	B-AdverseReaction
,	PRADAXA.xml:S1:2281:1	O
nausea	PRADAXA.xml:S1:2283:6	B-AdverseReaction
,	PRADAXA.xml:S1:2289:1	O
upper	PRADAXA.xml:S1:2291:5	B-AdverseReaction
abdominal	PRADAXA.xml:S1:2297:9	I-AdverseReaction
pain	PRADAXA.xml:S1:2307:4	I-AdverseReaction
,	PRADAXA.xml:S1:2311:1	O
gastrointestinal	PRADAXA.xml:S1:2313:16	B-AdverseReaction
hemorrhage	PRADAXA.xml:S1:2330:10	I-AdverseReaction
,	PRADAXA.xml:S1:2340:1	O
and	PRADAXA.xml:S1:2342:3	O
diarrhea	PRADAXA.xml:S1:2346:8	B-AdverseReaction
)	PRADAXA.xml:S1:2354:1	O
.	PRADAXA.xml:S1:2355:1	O

Bleeding	PRADAXA.xml:S1:2373:8	O

[	PRADAXA.xml:S1:2391:1	O
see	PRADAXA.xml:S1:2392:3	O
Warnings	PRADAXA.xml:S1:2396:8	O
and	PRADAXA.xml:S1:2405:3	O
Precautions	PRADAXA.xml:S1:2409:11	O
(	PRADAXA.xml:S1:2422:1	O
5.2	PRADAXA.xml:S1:2423:3	O
)	PRADAXA.xml:S1:2426:1	O
]	PRADAXA.xml:S1:2429:1	O

Table	PRADAXA.xml:S1:2439:5	O
2	PRADAXA.xml:S1:2445:1	O
shows	PRADAXA.xml:S1:2447:5	O
the	PRADAXA.xml:S1:2453:3	O
number	PRADAXA.xml:S1:2457:6	O
of	PRADAXA.xml:S1:2464:2	O
adjudicated	PRADAXA.xml:S1:2467:11	O
major	PRADAXA.xml:S1:2479:5	B-Severity
bleeding	PRADAXA.xml:S1:2485:8	B-AdverseReaction
events	PRADAXA.xml:S1:2494:6	O
during	PRADAXA.xml:S1:2501:6	O
the	PRADAXA.xml:S1:2508:3	O
treatment	PRADAXA.xml:S1:2512:9	O
period	PRADAXA.xml:S1:2522:6	O
in	PRADAXA.xml:S1:2529:2	O
the	PRADAXA.xml:S1:2532:3	O
RE	PRADAXA.xml:S1:2536:2	O
-	PRADAXA.xml:S1:2538:1	O
LY	PRADAXA.xml:S1:2539:2	O
study	PRADAXA.xml:S1:2542:5	O
,	PRADAXA.xml:S1:2547:1	O
with	PRADAXA.xml:S1:2549:4	O
the	PRADAXA.xml:S1:2554:3	O
bleeding	PRADAXA.xml:S1:2558:8	B-AdverseReaction
rate	PRADAXA.xml:S1:2567:4	O
per	PRADAXA.xml:S1:2572:3	O
100	PRADAXA.xml:S1:2576:3	O
subject	PRADAXA.xml:S1:2580:7	O
-	PRADAXA.xml:S1:2587:1	O
years	PRADAXA.xml:S1:2588:5	O
(	PRADAXA.xml:S1:2594:1	O
)	PRADAXA.xml:S1:2596:1	O
.	PRADAXA.xml:S1:2597:1	O

Major	PRADAXA.xml:S1:2599:5	B-Severity
bleeding	PRADAXA.xml:S1:2605:8	B-AdverseReaction
is	PRADAXA.xml:S1:2614:2	O
defined	PRADAXA.xml:S1:2617:7	O
as	PRADAXA.xml:S1:2625:2	O
bleeding	PRADAXA.xml:S1:2628:8	B-AdverseReaction
accompanied	PRADAXA.xml:S1:2637:11	O
by	PRADAXA.xml:S1:2649:2	O
one	PRADAXA.xml:S1:2652:3	O
or	PRADAXA.xml:S1:2656:2	O
more	PRADAXA.xml:S1:2659:4	O
of	PRADAXA.xml:S1:2664:2	O
the	PRADAXA.xml:S1:2667:3	O
following	PRADAXA.xml:S1:2671:9	O
:	PRADAXA.xml:S1:2680:1	O
a	PRADAXA.xml:S1:2682:1	O
decrease	PRADAXA.xml:S1:2684:8	B-AdverseReaction
in	PRADAXA.xml:S1:2693:2	I-AdverseReaction
hemoglobin	PRADAXA.xml:S1:2696:10	I-AdverseReaction
of	PRADAXA.xml:S1:2707:2	O
2	PRADAXA.xml:S1:2712:1	B-Severity
g	PRADAXA.xml:S1:2714:1	I-Severity
dL	PRADAXA.xml:S1:2716:2	I-Severity
,	PRADAXA.xml:S1:2718:1	O
a	PRADAXA.xml:S1:2720:1	O
transfusion	PRADAXA.xml:S1:2722:11	O
of	PRADAXA.xml:S1:2734:2	O
2	PRADAXA.xml:S1:2739:1	O
units	PRADAXA.xml:S1:2741:5	O
of	PRADAXA.xml:S1:2747:2	O
packed	PRADAXA.xml:S1:2750:6	O
red	PRADAXA.xml:S1:2757:3	O
blood	PRADAXA.xml:S1:2761:5	O
cells	PRADAXA.xml:S1:2767:5	O
,	PRADAXA.xml:S1:2772:1	O
bleeding	PRADAXA.xml:S1:2774:8	B-AdverseReaction
at	PRADAXA.xml:S1:2783:2	I-AdverseReaction
a	PRADAXA.xml:S1:2786:1	I-AdverseReaction
critical	PRADAXA.xml:S1:2788:8	I-AdverseReaction
site	PRADAXA.xml:S1:2797:4	I-AdverseReaction
or	PRADAXA.xml:S1:2802:2	O
with	PRADAXA.xml:S1:2805:4	O
a	PRADAXA.xml:S1:2810:1	O
fatal	PRADAXA.xml:S1:2812:5	B-AdverseReaction
outcome	PRADAXA.xml:S1:2818:7	O
.	PRADAXA.xml:S1:2825:1	O

Intracranial	PRADAXA.xml:S1:2827:12	B-AdverseReaction
hemorrhage	PRADAXA.xml:S1:2840:10	I-AdverseReaction
included	PRADAXA.xml:S1:2851:8	O
intracerebral	PRADAXA.xml:S1:2860:13	B-AdverseReaction
(	PRADAXA.xml:S1:2874:1	O
hemorrhagic	PRADAXA.xml:S1:2875:11	B-AdverseReaction
stroke	PRADAXA.xml:S1:2887:6	I-AdverseReaction
)	PRADAXA.xml:S1:2893:1	O
,	PRADAXA.xml:S1:2894:1	O
subarachnoid	PRADAXA.xml:S1:2896:12	B-AdverseReaction
,	PRADAXA.xml:S1:2908:1	O
and	PRADAXA.xml:S1:2910:3	O
subdural	PRADAXA.xml:S1:2914:8	B-AdverseReaction
bleeds	PRADAXA.xml:S1:2923:6	I-AdverseReaction
.	PRADAXA.xml:S1:2929:1	O

Table	PRADAXA.xml:S1:2935:5	O
2	PRADAXA.xml:S1:2941:1	O
Adjudicated	PRADAXA.xml:S1:2943:11	O
Major	PRADAXA.xml:S1:2955:5	B-Severity
Bleeding	PRADAXA.xml:S1:2961:8	B-AdverseReaction
Events	PRADAXA.xml:S1:2970:6	O
in	PRADAXA.xml:S1:2977:2	O
Treated	PRADAXA.xml:S1:2980:7	O
Patientsa	PRADAXA.xml:S1:2988:9	O

aPatients	PRADAXA.xml:S1:3001:9	O
during	PRADAXA.xml:S1:3011:6	O
treatment	PRADAXA.xml:S1:3018:9	O
or	PRADAXA.xml:S1:3028:2	O
within	PRADAXA.xml:S1:3031:6	O
2	PRADAXA.xml:S1:3038:1	O
days	PRADAXA.xml:S1:3040:4	O
of	PRADAXA.xml:S1:3045:2	O
stopping	PRADAXA.xml:S1:3048:8	O
study	PRADAXA.xml:S1:3057:5	O
treatment	PRADAXA.xml:S1:3063:9	O
.	PRADAXA.xml:S1:3072:1	O

Major	PRADAXA.xml:S1:3074:5	B-Severity
bleeding	PRADAXA.xml:S1:3080:8	B-AdverseReaction
events	PRADAXA.xml:S1:3089:6	O
within	PRADAXA.xml:S1:3096:6	O
each	PRADAXA.xml:S1:3103:4	O
subcategory	PRADAXA.xml:S1:3108:11	O
were	PRADAXA.xml:S1:3120:4	O
counted	PRADAXA.xml:S1:3125:7	O
once	PRADAXA.xml:S1:3133:4	O
per	PRADAXA.xml:S1:3138:3	O
patient	PRADAXA.xml:S1:3142:7	O
,	PRADAXA.xml:S1:3149:1	O
but	PRADAXA.xml:S1:3151:3	O
patients	PRADAXA.xml:S1:3155:8	O
may	PRADAXA.xml:S1:3164:3	O
have	PRADAXA.xml:S1:3168:4	O
contributed	PRADAXA.xml:S1:3173:11	O
events	PRADAXA.xml:S1:3185:6	O
to	PRADAXA.xml:S1:3192:2	O
multiple	PRADAXA.xml:S1:3195:8	O
subcategories	PRADAXA.xml:S1:3204:13	O
.	PRADAXA.xml:S1:3217:1	O

bAnnual	PRADAXA.xml:S1:3220:7	O
event	PRADAXA.xml:S1:3228:5	O
rate	PRADAXA.xml:S1:3234:4	O
per	PRADAXA.xml:S1:3239:3	O
100	PRADAXA.xml:S1:3243:3	O
pt	PRADAXA.xml:S1:3247:2	O
-	PRADAXA.xml:S1:3249:1	O
years	PRADAXA.xml:S1:3250:5	O
100	PRADAXA.xml:S1:3258:3	O
number	PRADAXA.xml:S1:3264:6	O
of	PRADAXA.xml:S1:3271:2	O
subjects	PRADAXA.xml:S1:3274:8	O
with	PRADAXA.xml:S1:3283:4	O
event	PRADAXA.xml:S1:3288:5	O
subject	PRADAXA.xml:S1:3294:7	O
-	PRADAXA.xml:S1:3301:1	O
years	PRADAXA.xml:S1:3302:5	O
.	PRADAXA.xml:S1:3307:1	O

Subject	PRADAXA.xml:S1:3309:7	O
-	PRADAXA.xml:S1:3316:1	O
years	PRADAXA.xml:S1:3317:5	O
is	PRADAXA.xml:S1:3323:2	O
defined	PRADAXA.xml:S1:3326:7	O
as	PRADAXA.xml:S1:3334:2	O
cumulative	PRADAXA.xml:S1:3337:10	O
number	PRADAXA.xml:S1:3348:6	O
of	PRADAXA.xml:S1:3355:2	O
days	PRADAXA.xml:S1:3358:4	O
from	PRADAXA.xml:S1:3363:4	O
first	PRADAXA.xml:S1:3368:5	O
drug	PRADAXA.xml:S1:3374:4	O
intake	PRADAXA.xml:S1:3379:6	O
to	PRADAXA.xml:S1:3386:2	O
event	PRADAXA.xml:S1:3389:5	O
date	PRADAXA.xml:S1:3395:4	O
,	PRADAXA.xml:S1:3399:1	O
date	PRADAXA.xml:S1:3401:4	O
of	PRADAXA.xml:S1:3406:2	O
last	PRADAXA.xml:S1:3409:4	O
drug	PRADAXA.xml:S1:3414:4	O
intake	PRADAXA.xml:S1:3419:6	O
2	PRADAXA.xml:S1:3428:1	O
,	PRADAXA.xml:S1:3429:1	O
death	PRADAXA.xml:S1:3431:5	O
date	PRADAXA.xml:S1:3437:4	O
(	PRADAXA.xml:S1:3442:1	O
whatever	PRADAXA.xml:S1:3443:8	O
occurred	PRADAXA.xml:S1:3452:8	O
first	PRADAXA.xml:S1:3461:5	O
)	PRADAXA.xml:S1:3466:1	O
across	PRADAXA.xml:S1:3468:6	O
all	PRADAXA.xml:S1:3475:3	O
treated	PRADAXA.xml:S1:3479:7	O
subjects	PRADAXA.xml:S1:3487:8	O
divided	PRADAXA.xml:S1:3496:7	O
by	PRADAXA.xml:S1:3504:2	O
365.25	PRADAXA.xml:S1:3507:6	O
.	PRADAXA.xml:S1:3513:1	O

In	PRADAXA.xml:S1:3515:2	O
case	PRADAXA.xml:S1:3518:4	O
of	PRADAXA.xml:S1:3523:2	O
recurrent	PRADAXA.xml:S1:3526:9	O
events	PRADAXA.xml:S1:3536:6	O
of	PRADAXA.xml:S1:3543:2	O
the	PRADAXA.xml:S1:3546:3	O
same	PRADAXA.xml:S1:3550:4	O
category	PRADAXA.xml:S1:3555:8	O
,	PRADAXA.xml:S1:3563:1	O
the	PRADAXA.xml:S1:3565:3	O
first	PRADAXA.xml:S1:3569:5	O
event	PRADAXA.xml:S1:3575:5	O
was	PRADAXA.xml:S1:3581:3	O
considered	PRADAXA.xml:S1:3585:10	O
.	PRADAXA.xml:S1:3595:1	O

cDefined	PRADAXA.xml:S1:3598:8	O
as	PRADAXA.xml:S1:3607:2	O
bleeding	PRADAXA.xml:S1:3610:8	B-AdverseReaction
accompanied	PRADAXA.xml:S1:3619:11	O
by	PRADAXA.xml:S1:3631:2	O
one	PRADAXA.xml:S1:3634:3	O
or	PRADAXA.xml:S1:3638:2	O
more	PRADAXA.xml:S1:3641:4	O
of	PRADAXA.xml:S1:3646:2	O
the	PRADAXA.xml:S1:3649:3	O
following	PRADAXA.xml:S1:3653:9	O
:	PRADAXA.xml:S1:3662:1	O
a	PRADAXA.xml:S1:3664:1	O
decrease	PRADAXA.xml:S1:3666:8	B-AdverseReaction
in	PRADAXA.xml:S1:3675:2	I-AdverseReaction
hemoglobin	PRADAXA.xml:S1:3678:10	I-AdverseReaction
of	PRADAXA.xml:S1:3689:2	O
2	PRADAXA.xml:S1:3694:1	B-Severity
g	PRADAXA.xml:S1:3696:1	I-Severity
dL	PRADAXA.xml:S1:3698:2	I-Severity
,	PRADAXA.xml:S1:3700:1	O
a	PRADAXA.xml:S1:3702:1	O
transfusion	PRADAXA.xml:S1:3704:11	O
of	PRADAXA.xml:S1:3716:2	O
2	PRADAXA.xml:S1:3719:1	O
or	PRADAXA.xml:S1:3721:2	O
more	PRADAXA.xml:S1:3724:4	O
units	PRADAXA.xml:S1:3729:5	O
of	PRADAXA.xml:S1:3735:2	O
packed	PRADAXA.xml:S1:3738:6	O
red	PRADAXA.xml:S1:3745:3	O
blood	PRADAXA.xml:S1:3749:5	O
cells	PRADAXA.xml:S1:3755:5	O
,	PRADAXA.xml:S1:3760:1	O
bleeding	PRADAXA.xml:S1:3762:8	B-AdverseReaction
at	PRADAXA.xml:S1:3771:2	I-AdverseReaction
a	PRADAXA.xml:S1:3774:1	I-AdverseReaction
critical	PRADAXA.xml:S1:3776:8	I-AdverseReaction
site	PRADAXA.xml:S1:3785:4	I-AdverseReaction
or	PRADAXA.xml:S1:3790:2	O
with	PRADAXA.xml:S1:3793:4	O
fatal	PRADAXA.xml:S1:3798:5	B-AdverseReaction
outcome	PRADAXA.xml:S1:3804:7	O
.	PRADAXA.xml:S1:3811:1	O

dIntracranial	PRADAXA.xml:S1:3814:13	B-AdverseReaction
bleed	PRADAXA.xml:S1:3828:5	I-AdverseReaction
included	PRADAXA.xml:S1:3834:8	O
intracerebral	PRADAXA.xml:S1:3843:13	B-AdverseReaction
(	PRADAXA.xml:S1:3857:1	O
hemorrhagic	PRADAXA.xml:S1:3858:11	B-AdverseReaction
stroke	PRADAXA.xml:S1:3870:6	I-AdverseReaction
)	PRADAXA.xml:S1:3876:1	O
,	PRADAXA.xml:S1:3877:1	O
subarachnoid	PRADAXA.xml:S1:3879:12	B-AdverseReaction
,	PRADAXA.xml:S1:3891:1	O
and	PRADAXA.xml:S1:3893:3	O
subdural	PRADAXA.xml:S1:3897:8	B-AdverseReaction
bleeds	PRADAXA.xml:S1:3906:6	I-AdverseReaction
.	PRADAXA.xml:S1:3912:1	O

eOn	PRADAXA.xml:S1:3915:3	O
-	PRADAXA.xml:S1:3918:1	O
treatment	PRADAXA.xml:S1:3919:9	O
analysis	PRADAXA.xml:S1:3929:8	O
based	PRADAXA.xml:S1:3938:5	O
on	PRADAXA.xml:S1:3944:2	O
the	PRADAXA.xml:S1:3947:3	O
safety	PRADAXA.xml:S1:3951:6	O
population	PRADAXA.xml:S1:3958:10	O
,	PRADAXA.xml:S1:3968:1	O
compared	PRADAXA.xml:S1:3970:8	O
to	PRADAXA.xml:S1:3979:2	O
ITT	PRADAXA.xml:S1:3982:3	O
analysis	PRADAXA.xml:S1:3986:8	O
presented	PRADAXA.xml:S1:3995:9	O
in	PRADAXA.xml:S1:4005:2	O
Section	PRADAXA.xml:S1:4008:7	O
14	PRADAXA.xml:S1:4016:2	O
Clinical	PRADAXA.xml:S1:4019:8	O
Studies	PRADAXA.xml:S1:4028:7	O
.	PRADAXA.xml:S1:4035:1	O

fFatal	PRADAXA.xml:S1:4038:6	B-AdverseReaction
bleed	PRADAXA.xml:S1:4045:5	B-AdverseReaction
:	PRADAXA.xml:S1:4050:1	O
Adjudicated	PRADAXA.xml:S1:4052:11	O
major	PRADAXA.xml:S1:4064:5	B-Severity
bleed	PRADAXA.xml:S1:4070:5	B-AdverseReaction
as	PRADAXA.xml:S1:4076:2	O
defined	PRADAXA.xml:S1:4079:7	O
above	PRADAXA.xml:S1:4087:5	O
with	PRADAXA.xml:S1:4093:4	O
investigator	PRADAXA.xml:S1:4098:12	O
reported	PRADAXA.xml:S1:4111:8	O
fatal	PRADAXA.xml:S1:4120:5	B-AdverseReaction
outcome	PRADAXA.xml:S1:4126:7	O
and	PRADAXA.xml:S1:4134:3	O
adjudicated	PRADAXA.xml:S1:4138:11	O
death	PRADAXA.xml:S1:4150:5	B-AdverseReaction
with	PRADAXA.xml:S1:4156:4	O
primary	PRADAXA.xml:S1:4161:7	O
cause	PRADAXA.xml:S1:4169:5	O
from	PRADAXA.xml:S1:4175:4	O
bleeding	PRADAXA.xml:S1:4180:8	B-AdverseReaction
.	PRADAXA.xml:S1:4188:1	O

gNon	PRADAXA.xml:S1:4191:4	B-AdverseReaction
-	PRADAXA.xml:S1:4195:1	I-AdverseReaction
intracranial	PRADAXA.xml:S1:4196:12	I-AdverseReaction
fatal	PRADAXA.xml:S1:4209:5	B-AdverseReaction
bleed	PRADAXA.xml:S1:4215:5	I-AdverseReaction
:	PRADAXA.xml:S1:4220:1	O
Adjudicated	PRADAXA.xml:S1:4222:11	O
major	PRADAXA.xml:S1:4234:5	B-Severity
bleed	PRADAXA.xml:S1:4240:5	B-AdverseReaction
as	PRADAXA.xml:S1:4246:2	O
defined	PRADAXA.xml:S1:4249:7	O
above	PRADAXA.xml:S1:4257:5	O
and	PRADAXA.xml:S1:4263:3	O
adjudicated	PRADAXA.xml:S1:4267:11	O
death	PRADAXA.xml:S1:4279:5	B-AdverseReaction
with	PRADAXA.xml:S1:4285:4	O
primary	PRADAXA.xml:S1:4290:7	O
cause	PRADAXA.xml:S1:4298:5	O
from	PRADAXA.xml:S1:4304:4	O
bleeding	PRADAXA.xml:S1:4309:8	B-AdverseReaction
but	PRADAXA.xml:S1:4318:3	O
without	PRADAXA.xml:S1:4322:7	B-Negation
symptomatic	PRADAXA.xml:S1:4330:11	B-AdverseReaction
intracranial	PRADAXA.xml:S1:4342:12	I-AdverseReaction
bleed	PRADAXA.xml:S1:4355:5	I-AdverseReaction
based	PRADAXA.xml:S1:4361:5	O
on	PRADAXA.xml:S1:4367:2	O
investigator	PRADAXA.xml:S1:4370:12	O
's	PRADAXA.xml:S1:4382:2	O
clinical	PRADAXA.xml:S1:4385:8	O
assessment	PRADAXA.xml:S1:4394:10	O
.	PRADAXA.xml:S1:4404:1	O

Event	PRADAXA.xml:S1:4417:5	O

PRADAXA	PRADAXA.xml:S1:4443:7	O
150	PRADAXA.xml:S1:4451:3	O
mgN	PRADAXA.xml:S1:4455:3	O
6059	PRADAXA.xml:S1:4461:4	O
n	PRADAXA.xml:S1:4465:1	O
(	PRADAXA.xml:S1:4468:1	O
year	PRADAXA.xml:S1:4471:4	O
b	PRADAXA.xml:S1:4477:1	O
)	PRADAXA.xml:S1:4480:1	O
WarfarinN	PRADAXA.xml:S1:4487:9	O
5998	PRADAXA.xml:S1:4499:4	O
n	PRADAXA.xml:S1:4503:1	O
(	PRADAXA.xml:S1:4505:1	O
year	PRADAXA.xml:S1:4508:4	O
b	PRADAXA.xml:S1:4514:1	O
)	PRADAXA.xml:S1:4517:1	O
PRADAXA	PRADAXA.xml:S1:4524:7	O
150	PRADAXA.xml:S1:4532:3	O
mgvs	PRADAXA.xml:S1:4536:4	O
.	PRADAXA.xml:S1:4540:1	O

WarfarinHR	PRADAXA.xml:S1:4542:10	O
(	PRADAXA.xml:S1:4553:1	O
95%	PRADAXA.xml:S1:4554:3	O
CI	PRADAXA.xml:S1:4558:2	O
)	PRADAXA.xml:S1:4560:1	O

Major	PRADAXA.xml:S1:4568:5	B-Severity
Bleeding	PRADAXA.xml:S1:4574:8	B-AdverseReaction
c	PRADAXA.xml:S1:4584:1	O
350	PRADAXA.xml:S1:4602:3	O
(	PRADAXA.xml:S1:4606:1	O
3.47	PRADAXA.xml:S1:4607:4	O
)	PRADAXA.xml:S1:4611:1	O
374	PRADAXA.xml:S1:4629:3	O
(	PRADAXA.xml:S1:4633:1	O
3.58	PRADAXA.xml:S1:4634:4	O
)	PRADAXA.xml:S1:4638:1	O
0.97	PRADAXA.xml:S1:4653:4	O
(	PRADAXA.xml:S1:4658:1	O
0.84	PRADAXA.xml:S1:4659:4	O
,	PRADAXA.xml:S1:4663:1	O
1.12	PRADAXA.xml:S1:4665:4	O
)	PRADAXA.xml:S1:4669:1	O

Intracranial	PRADAXA.xml:S1:4682:12	B-AdverseReaction
Hemorrhage	PRADAXA.xml:S1:4695:10	I-AdverseReaction
(	PRADAXA.xml:S1:4706:1	O
ICH	PRADAXA.xml:S1:4707:3	B-AdverseReaction
)	PRADAXA.xml:S1:4710:1	O
d	PRADAXA.xml:S1:4713:1	O
23	PRADAXA.xml:S1:4726:2	O
(	PRADAXA.xml:S1:4729:1	O
0.22	PRADAXA.xml:S1:4730:4	O
)	PRADAXA.xml:S1:4734:1	O
82	PRADAXA.xml:S1:4753:2	O
(	PRADAXA.xml:S1:4756:1	O
0.77	PRADAXA.xml:S1:4757:4	O
)	PRADAXA.xml:S1:4761:1	O
0.29	PRADAXA.xml:S1:4775:4	O
(	PRADAXA.xml:S1:4780:1	O
0.18	PRADAXA.xml:S1:4781:4	O
,	PRADAXA.xml:S1:4785:1	O
0.46	PRADAXA.xml:S1:4787:4	O
)	PRADAXA.xml:S1:4791:1	O

Hemorrhagic	PRADAXA.xml:S1:4808:11	B-AdverseReaction
Stroke	PRADAXA.xml:S1:4820:6	I-AdverseReaction
e	PRADAXA.xml:S1:4828:1	O
6	PRADAXA.xml:S1:4841:1	O
(	PRADAXA.xml:S1:4843:1	O
0.06	PRADAXA.xml:S1:4844:4	O
)	PRADAXA.xml:S1:4848:1	O
40	PRADAXA.xml:S1:4868:2	O
(	PRADAXA.xml:S1:4871:1	O
0.37	PRADAXA.xml:S1:4872:4	O
)	PRADAXA.xml:S1:4876:1	O
0.16	PRADAXA.xml:S1:4890:4	O
(	PRADAXA.xml:S1:4895:1	O
0.07	PRADAXA.xml:S1:4896:4	O
,	PRADAXA.xml:S1:4900:1	O
0.37	PRADAXA.xml:S1:4902:4	O
)	PRADAXA.xml:S1:4906:1	O

Other	PRADAXA.xml:S1:4923:5	O
ICH	PRADAXA.xml:S1:4929:3	B-AdverseReaction
17	PRADAXA.xml:S1:4952:2	O
(	PRADAXA.xml:S1:4955:1	O
0.17	PRADAXA.xml:S1:4956:4	O
)	PRADAXA.xml:S1:4960:1	O
46	PRADAXA.xml:S1:4979:2	O
(	PRADAXA.xml:S1:4982:1	O
0.43	PRADAXA.xml:S1:4983:4	O
)	PRADAXA.xml:S1:4987:1	O
0.38	PRADAXA.xml:S1:5002:4	O
(	PRADAXA.xml:S1:5007:1	O
0.22	PRADAXA.xml:S1:5008:4	O
,	PRADAXA.xml:S1:5012:1	O
0.67	PRADAXA.xml:S1:5014:4	O
)	PRADAXA.xml:S1:5018:1	O

Gastrointestinal	PRADAXA.xml:S1:5031:16	O
162	PRADAXA.xml:S1:5062:3	O
(	PRADAXA.xml:S1:5066:1	O
1.59	PRADAXA.xml:S1:5067:4	O
)	PRADAXA.xml:S1:5071:1	O
111	PRADAXA.xml:S1:5089:3	O
(	PRADAXA.xml:S1:5093:1	O
1.05	PRADAXA.xml:S1:5094:4	O
)	PRADAXA.xml:S1:5098:1	O
1.51	PRADAXA.xml:S1:5113:4	O
(	PRADAXA.xml:S1:5118:1	O
1.19	PRADAXA.xml:S1:5119:4	O
,	PRADAXA.xml:S1:5123:1	O
1.92	PRADAXA.xml:S1:5125:4	O
)	PRADAXA.xml:S1:5129:1	O

Fatal	PRADAXA.xml:S1:5142:5	B-AdverseReaction
Bleeding	PRADAXA.xml:S1:5148:8	B-AdverseReaction
f	PRADAXA.xml:S1:5158:1	O
7	PRADAXA.xml:S1:5174:1	O
(	PRADAXA.xml:S1:5176:1	O
0.07	PRADAXA.xml:S1:5177:4	O
)	PRADAXA.xml:S1:5181:1	O
16	PRADAXA.xml:S1:5201:2	O
(	PRADAXA.xml:S1:5204:1	O
0.15	PRADAXA.xml:S1:5205:4	O
)	PRADAXA.xml:S1:5209:1	O
0.45	PRADAXA.xml:S1:5224:4	O
(	PRADAXA.xml:S1:5229:1	O
0.19	PRADAXA.xml:S1:5230:4	O
,	PRADAXA.xml:S1:5234:1	O
1.10	PRADAXA.xml:S1:5236:4	O
)	PRADAXA.xml:S1:5240:1	O

ICH	PRADAXA.xml:S1:5256:3	B-AdverseReaction
3	PRADAXA.xml:S1:5285:1	O
(	PRADAXA.xml:S1:5287:1	O
0.03	PRADAXA.xml:S1:5288:4	O
)	PRADAXA.xml:S1:5292:1	O
9	PRADAXA.xml:S1:5312:1	O
(	PRADAXA.xml:S1:5314:1	O
0.08	PRADAXA.xml:S1:5315:4	O
)	PRADAXA.xml:S1:5319:1	O
0.35	PRADAXA.xml:S1:5335:4	O
(	PRADAXA.xml:S1:5340:1	O
0.09	PRADAXA.xml:S1:5341:4	O
,	PRADAXA.xml:S1:5345:1	O
1.28	PRADAXA.xml:S1:5347:4	O
)	PRADAXA.xml:S1:5351:1	O

Non	PRADAXA.xml:S1:5367:3	O
-	PRADAXA.xml:S1:5370:1	O
intracranial	PRADAXA.xml:S1:5371:12	O
g	PRADAXA.xml:S1:5385:1	O
4	PRADAXA.xml:S1:5398:1	O
(	PRADAXA.xml:S1:5400:1	O
0.04	PRADAXA.xml:S1:5401:4	O
)	PRADAXA.xml:S1:5405:1	O
7	PRADAXA.xml:S1:5425:1	O
(	PRADAXA.xml:S1:5427:1	O
0.07	PRADAXA.xml:S1:5428:4	O
)	PRADAXA.xml:S1:5432:1	O
0.59	PRADAXA.xml:S1:5448:4	O
(	PRADAXA.xml:S1:5453:1	O
0.17	PRADAXA.xml:S1:5454:4	O
,	PRADAXA.xml:S1:5458:1	O
2.02	PRADAXA.xml:S1:5460:4	O
)	PRADAXA.xml:S1:5464:1	O

There	PRADAXA.xml:S1:5479:5	O
was	PRADAXA.xml:S1:5485:3	O
a	PRADAXA.xml:S1:5489:1	O
higher	PRADAXA.xml:S1:5491:6	O
rate	PRADAXA.xml:S1:5498:4	O
of	PRADAXA.xml:S1:5503:2	O
any	PRADAXA.xml:S1:5506:3	O
gastrointestinal	PRADAXA.xml:S1:5510:16	B-AdverseReaction
bleeds	PRADAXA.xml:S1:5527:6	I-AdverseReaction
in	PRADAXA.xml:S1:5534:2	O
patients	PRADAXA.xml:S1:5537:8	O
receiving	PRADAXA.xml:S1:5546:9	O
PRADAXA	PRADAXA.xml:S1:5556:7	O
150	PRADAXA.xml:S1:5564:3	O
mg	PRADAXA.xml:S1:5568:2	O
than	PRADAXA.xml:S1:5571:4	O
in	PRADAXA.xml:S1:5576:2	O
patients	PRADAXA.xml:S1:5579:8	O
receiving	PRADAXA.xml:S1:5588:9	O
warfarin	PRADAXA.xml:S1:5598:8	O
(	PRADAXA.xml:S1:5607:1	O
6.6%	PRADAXA.xml:S1:5608:4	O
vs	PRADAXA.xml:S1:5613:2	O
.	PRADAXA.xml:S1:5615:1	O

4.2%	PRADAXA.xml:S1:5617:4	O
,	PRADAXA.xml:S1:5621:1	O
respectively	PRADAXA.xml:S1:5623:12	O
)	PRADAXA.xml:S1:5635:1	O
.	PRADAXA.xml:S1:5636:1	O

The	PRADAXA.xml:S1:5642:3	O

risk	PRADAXA.xml:S1:5646:4	B-Factor
of	PRADAXA.xml:S1:5651:2	O
major	PRADAXA.xml:S1:5654:5	B-Severity
bleeds	PRADAXA.xml:S1:5660:6	B-AdverseReaction
was	PRADAXA.xml:S1:5667:3	O
similar	PRADAXA.xml:S1:5671:7	O
with	PRADAXA.xml:S1:5679:4	O
PRADAXA	PRADAXA.xml:S1:5684:7	O
150	PRADAXA.xml:S1:5692:3	O
mg	PRADAXA.xml:S1:5696:2	O
and	PRADAXA.xml:S1:5699:3	O
warfarin	PRADAXA.xml:S1:5703:8	O
across	PRADAXA.xml:S1:5712:6	O
major	PRADAXA.xml:S1:5719:5	O
subgroups	PRADAXA.xml:S1:5725:9	O
defined	PRADAXA.xml:S1:5735:7	O
by	PRADAXA.xml:S1:5743:2	O
baseline	PRADAXA.xml:S1:5746:8	O
characteristics	PRADAXA.xml:S1:5755:15	O
(	PRADAXA.xml:S1:5771:1	O
see	PRADAXA.xml:S1:5772:3	O
Figure	PRADAXA.xml:S1:5776:6	O
1	PRADAXA.xml:S1:5783:1	O
)	PRADAXA.xml:S1:5784:1	O
,	PRADAXA.xml:S1:5785:1	O
with	PRADAXA.xml:S1:5787:4	O
the	PRADAXA.xml:S1:5792:3	O
exception	PRADAXA.xml:S1:5796:9	O
of	PRADAXA.xml:S1:5806:2	O
age	PRADAXA.xml:S1:5809:3	O
,	PRADAXA.xml:S1:5812:1	O
where	PRADAXA.xml:S1:5814:5	O
there	PRADAXA.xml:S1:5820:5	O
was	PRADAXA.xml:S1:5826:3	O
a	PRADAXA.xml:S1:5830:1	O
trend	PRADAXA.xml:S1:5832:5	O
towards	PRADAXA.xml:S1:5838:7	O
a	PRADAXA.xml:S1:5846:1	O
higher	PRADAXA.xml:S1:5848:6	O
incidence	PRADAXA.xml:S1:5855:9	O
of	PRADAXA.xml:S1:5865:2	O
major	PRADAXA.xml:S1:5868:5	B-Severity
bleeding	PRADAXA.xml:S1:5874:8	B-AdverseReaction
on	PRADAXA.xml:S1:5883:2	O
PRADAXA	PRADAXA.xml:S1:5886:7	O
(	PRADAXA.xml:S1:5894:1	O
hazard	PRADAXA.xml:S1:5895:6	O
ratio	PRADAXA.xml:S1:5902:5	O
1.2	PRADAXA.xml:S1:5908:3	O
,	PRADAXA.xml:S1:5911:1	O
95%	PRADAXA.xml:S1:5913:3	O
CI	PRADAXA.xml:S1:5917:2	O
:	PRADAXA.xml:S1:5919:1	O
1.0	PRADAXA.xml:S1:5921:3	O
to	PRADAXA.xml:S1:5925:2	O
1.5	PRADAXA.xml:S1:5928:3	O
)	PRADAXA.xml:S1:5931:1	O
for	PRADAXA.xml:S1:5933:3	O
patients	PRADAXA.xml:S1:5937:8	O
75	PRADAXA.xml:S1:5948:2	O
years	PRADAXA.xml:S1:5951:5	O
of	PRADAXA.xml:S1:5957:2	O
age	PRADAXA.xml:S1:5960:3	O
.	PRADAXA.xml:S1:5963:1	O

Figure	PRADAXA.xml:S1:5971:6	O
1	PRADAXA.xml:S1:5978:1	O
Adjudicated	PRADAXA.xml:S1:5980:11	O
Major	PRADAXA.xml:S1:5992:5	B-Severity
Bleeding	PRADAXA.xml:S1:5998:8	B-AdverseReaction
by	PRADAXA.xml:S1:6007:2	O
Baseline	PRADAXA.xml:S1:6010:8	O
Characteristics	PRADAXA.xml:S1:6019:15	O
Including	PRADAXA.xml:S1:6035:9	O
Hemorrhagic	PRADAXA.xml:S1:6045:11	O
Stroke	PRADAXA.xml:S1:6057:6	O
Treated	PRADAXA.xml:S1:6064:7	O
Patients	PRADAXA.xml:S1:6072:8	O

Note	PRADAXA.xml:S1:6087:4	O
:	PRADAXA.xml:S1:6091:1	O
The	PRADAXA.xml:S1:6093:3	O
figure	PRADAXA.xml:S1:6097:6	O
above	PRADAXA.xml:S1:6104:5	O
presents	PRADAXA.xml:S1:6110:8	O
effects	PRADAXA.xml:S1:6119:7	O
in	PRADAXA.xml:S1:6127:2	O
various	PRADAXA.xml:S1:6130:7	O
subgroups	PRADAXA.xml:S1:6138:9	O
all	PRADAXA.xml:S1:6148:3	O
of	PRADAXA.xml:S1:6152:2	O
which	PRADAXA.xml:S1:6155:5	O
are	PRADAXA.xml:S1:6161:3	O
baseline	PRADAXA.xml:S1:6165:8	O
characteristics	PRADAXA.xml:S1:6174:15	O
and	PRADAXA.xml:S1:6190:3	O
all	PRADAXA.xml:S1:6194:3	O
of	PRADAXA.xml:S1:6198:2	O
which	PRADAXA.xml:S1:6201:5	O
were	PRADAXA.xml:S1:6207:4	O
pre	PRADAXA.xml:S1:6212:3	O
-	PRADAXA.xml:S1:6215:1	O
specified	PRADAXA.xml:S1:6216:9	O
.	PRADAXA.xml:S1:6225:1	O

The	PRADAXA.xml:S1:6227:3	O
95%	PRADAXA.xml:S1:6231:3	O
confidence	PRADAXA.xml:S1:6235:10	O
limits	PRADAXA.xml:S1:6246:6	O
that	PRADAXA.xml:S1:6253:4	O
are	PRADAXA.xml:S1:6258:3	O
shown	PRADAXA.xml:S1:6262:5	O
do	PRADAXA.xml:S1:6268:2	O
not	PRADAXA.xml:S1:6271:3	O
take	PRADAXA.xml:S1:6275:4	O
into	PRADAXA.xml:S1:6280:4	O
account	PRADAXA.xml:S1:6285:7	O
how	PRADAXA.xml:S1:6293:3	O
many	PRADAXA.xml:S1:6297:4	O
comparisons	PRADAXA.xml:S1:6302:11	O
were	PRADAXA.xml:S1:6314:4	O
made	PRADAXA.xml:S1:6319:4	O
,	PRADAXA.xml:S1:6323:1	O
nor	PRADAXA.xml:S1:6325:3	O
do	PRADAXA.xml:S1:6329:2	O
they	PRADAXA.xml:S1:6332:4	O
reflect	PRADAXA.xml:S1:6337:7	O
the	PRADAXA.xml:S1:6345:3	O
effect	PRADAXA.xml:S1:6349:6	O
of	PRADAXA.xml:S1:6356:2	O
a	PRADAXA.xml:S1:6359:1	O
particular	PRADAXA.xml:S1:6361:10	O
factor	PRADAXA.xml:S1:6372:6	O
after	PRADAXA.xml:S1:6379:5	O
adjustment	PRADAXA.xml:S1:6385:10	O
for	PRADAXA.xml:S1:6396:3	O
all	PRADAXA.xml:S1:6400:3	O
other	PRADAXA.xml:S1:6404:5	O
factors	PRADAXA.xml:S1:6410:7	O
.	PRADAXA.xml:S1:6417:1	O

Apparent	PRADAXA.xml:S1:6419:8	O
homogeneity	PRADAXA.xml:S1:6428:11	O
or	PRADAXA.xml:S1:6440:2	O
heterogeneity	PRADAXA.xml:S1:6443:13	O
among	PRADAXA.xml:S1:6457:5	O
groups	PRADAXA.xml:S1:6463:6	O
should	PRADAXA.xml:S1:6470:6	O
not	PRADAXA.xml:S1:6477:3	O
be	PRADAXA.xml:S1:6481:2	O
over	PRADAXA.xml:S1:6484:4	O
-	PRADAXA.xml:S1:6488:1	O
interpreted	PRADAXA.xml:S1:6489:11	O
.	PRADAXA.xml:S1:6500:1	O

Figure	PRADAXA.xml:S1:6507:6	O
1	PRADAXA.xml:S1:6514:1	O

Gastrointestinal	PRADAXA.xml:S1:6528:16	O
Adverse	PRADAXA.xml:S1:6545:7	O
Reactions	PRADAXA.xml:S1:6553:9	O

Patients	PRADAXA.xml:S1:6573:8	O
on	PRADAXA.xml:S1:6582:2	O
PRADAXA	PRADAXA.xml:S1:6585:7	O
150	PRADAXA.xml:S1:6593:3	O
mg	PRADAXA.xml:S1:6597:2	O
had	PRADAXA.xml:S1:6600:3	O
an	PRADAXA.xml:S1:6604:2	O
increased	PRADAXA.xml:S1:6607:9	O
incidence	PRADAXA.xml:S1:6617:9	O
of	PRADAXA.xml:S1:6627:2	O
gastrointestinal	PRADAXA.xml:S1:6630:16	B-AdverseReaction
adverse	PRADAXA.xml:S1:6647:7	I-AdverseReaction
reactions	PRADAXA.xml:S1:6655:9	I-AdverseReaction
(	PRADAXA.xml:S1:6665:1	O
35%	PRADAXA.xml:S1:6666:3	O
vs	PRADAXA.xml:S1:6670:2	O
.	PRADAXA.xml:S1:6672:1	O

24%	PRADAXA.xml:S1:6674:3	O
on	PRADAXA.xml:S1:6678:2	O
warfarin	PRADAXA.xml:S1:6681:8	O
)	PRADAXA.xml:S1:6689:1	O
.	PRADAXA.xml:S1:6690:1	O

These	PRADAXA.xml:S1:6692:5	O
were	PRADAXA.xml:S1:6698:4	O
commonly	PRADAXA.xml:S1:6703:8	O
dyspepsia	PRADAXA.xml:S1:6712:9	B-AdverseReaction
(	PRADAXA.xml:S1:6722:1	O
including	PRADAXA.xml:S1:6723:9	O
abdominal	PRADAXA.xml:S1:6733:9	B-AdverseReaction
pain	PRADAXA.xml:S1:6743:4	I-AdverseReaction
upper	PRADAXA.xml:S1:6748:5	I-AdverseReaction
,	PRADAXA.xml:S1:6753:1	O
abdominal	PRADAXA.xml:S1:6755:9	B-AdverseReaction
pain	PRADAXA.xml:S1:6765:4	I-AdverseReaction
,	PRADAXA.xml:S1:6769:1	O
abdominal	PRADAXA.xml:S1:6771:9	B-AdverseReaction
discomfort	PRADAXA.xml:S1:6781:10	I-AdverseReaction
,	PRADAXA.xml:S1:6791:1	O
and	PRADAXA.xml:S1:6793:3	O
epigastric	PRADAXA.xml:S1:6797:10	B-AdverseReaction
discomfort	PRADAXA.xml:S1:6808:10	I-AdverseReaction
)	PRADAXA.xml:S1:6818:1	O
and	PRADAXA.xml:S1:6820:3	O
gastritis	PRADAXA.xml:S1:6824:9	B-AdverseReaction
-	PRADAXA.xml:S1:6833:1	O
like	PRADAXA.xml:S1:6834:4	O
symptoms	PRADAXA.xml:S1:6839:8	O
(	PRADAXA.xml:S1:6848:1	O
including	PRADAXA.xml:S1:6849:9	O
GERD	PRADAXA.xml:S1:6859:4	B-AdverseReaction
,	PRADAXA.xml:S1:6863:1	O
esophagitis	PRADAXA.xml:S1:6865:11	B-AdverseReaction
,	PRADAXA.xml:S1:6876:1	O
erosive	PRADAXA.xml:S1:6878:7	B-AdverseReaction
gastritis	PRADAXA.xml:S1:6886:9	I-AdverseReaction
,	PRADAXA.xml:S1:6895:1	O
gastric	PRADAXA.xml:S1:6897:7	B-AdverseReaction
hemorrhage	PRADAXA.xml:S1:6905:10	I-AdverseReaction
,	PRADAXA.xml:S1:6915:1	O
hemorrhagic	PRADAXA.xml:S1:6917:11	B-AdverseReaction
gastritis	PRADAXA.xml:S1:6929:9	I-AdverseReaction
,	PRADAXA.xml:S1:6938:1	O
hemorrhagic	PRADAXA.xml:S1:6940:11	B-AdverseReaction
erosive	PRADAXA.xml:S1:6952:7	I-AdverseReaction
gastritis	PRADAXA.xml:S1:6960:9	I-AdverseReaction
,	PRADAXA.xml:S1:6969:1	O
and	PRADAXA.xml:S1:6971:3	O
gastrointestinal	PRADAXA.xml:S1:6975:16	B-AdverseReaction
ulcer	PRADAXA.xml:S1:6992:5	I-AdverseReaction
)	PRADAXA.xml:S1:6997:1	O
.	PRADAXA.xml:S1:6998:1	O

Hypersensitivity	PRADAXA.xml:S1:7016:16	O

Reactions	PRADAXA.xml:S1:7033:9	O

In	PRADAXA.xml:S1:7053:2	O
the	PRADAXA.xml:S1:7056:3	O
RE	PRADAXA.xml:S1:7060:2	O
-	PRADAXA.xml:S1:7062:1	O
LY	PRADAXA.xml:S1:7063:2	O
study	PRADAXA.xml:S1:7066:5	O
,	PRADAXA.xml:S1:7071:1	O
drug	PRADAXA.xml:S1:7073:4	O
hypersensitivity	PRADAXA.xml:S1:7078:16	B-AdverseReaction
(	PRADAXA.xml:S1:7095:1	O
including	PRADAXA.xml:S1:7096:9	O
urticaria	PRADAXA.xml:S1:7106:9	B-AdverseReaction
,	PRADAXA.xml:S1:7115:1	O
rash	PRADAXA.xml:S1:7117:4	B-AdverseReaction
,	PRADAXA.xml:S1:7121:1	O
and	PRADAXA.xml:S1:7123:3	O
pruritus	PRADAXA.xml:S1:7127:8	B-AdverseReaction
)	PRADAXA.xml:S1:7135:1	O
,	PRADAXA.xml:S1:7136:1	O
allergic	PRADAXA.xml:S1:7138:8	B-AdverseReaction
edema	PRADAXA.xml:S1:7147:5	I-AdverseReaction
,	PRADAXA.xml:S1:7152:1	O
anaphylactic	PRADAXA.xml:S1:7154:12	B-AdverseReaction
reaction	PRADAXA.xml:S1:7167:8	I-AdverseReaction
,	PRADAXA.xml:S1:7175:1	O
and	PRADAXA.xml:S1:7177:3	O
anaphylactic	PRADAXA.xml:S1:7181:12	B-AdverseReaction
shock	PRADAXA.xml:S1:7194:5	I-AdverseReaction
were	PRADAXA.xml:S1:7200:4	O
reported	PRADAXA.xml:S1:7205:8	O
in	PRADAXA.xml:S1:7214:2	O
0.1%	PRADAXA.xml:S1:7218:4	O
of	PRADAXA.xml:S1:7223:2	O
patients	PRADAXA.xml:S1:7226:8	O
receiving	PRADAXA.xml:S1:7235:9	O
PRADAXA	PRADAXA.xml:S1:7245:7	O
.	PRADAXA.xml:S1:7252:1	O

Treatment	PRADAXA.xml:S1:7268:9	O

and	PRADAXA.xml:S1:7278:3	O
Reduction	PRADAXA.xml:S1:7282:9	O
in	PRADAXA.xml:S1:7292:2	O
the	PRADAXA.xml:S1:7295:3	O
Risk	PRADAXA.xml:S1:7299:4	O
of	PRADAXA.xml:S1:7304:2	O
Recurrence	PRADAXA.xml:S1:7307:10	O
of	PRADAXA.xml:S1:7318:2	O
Deep	PRADAXA.xml:S1:7321:4	O
Venous	PRADAXA.xml:S1:7326:6	O
Thrombosis	PRADAXA.xml:S1:7333:10	O
and	PRADAXA.xml:S1:7344:3	O
Pulmonary	PRADAXA.xml:S1:7348:9	O
Embolism	PRADAXA.xml:S1:7358:8	O

PRADAXA	PRADAXA.xml:S1:7375:7	O
was	PRADAXA.xml:S1:7383:3	O
studied	PRADAXA.xml:S1:7387:7	O
in	PRADAXA.xml:S1:7395:2	O
4387	PRADAXA.xml:S1:7398:4	O
patients	PRADAXA.xml:S1:7403:8	O
in	PRADAXA.xml:S1:7412:2	O
4	PRADAXA.xml:S1:7415:1	O
pivotal	PRADAXA.xml:S1:7417:7	O
,	PRADAXA.xml:S1:7424:1	O
parallel	PRADAXA.xml:S1:7426:8	O
,	PRADAXA.xml:S1:7434:1	O
randomized	PRADAXA.xml:S1:7436:10	O
,	PRADAXA.xml:S1:7446:1	O
double	PRADAXA.xml:S1:7448:6	O
-	PRADAXA.xml:S1:7454:1	O
blind	PRADAXA.xml:S1:7455:5	O
trials	PRADAXA.xml:S1:7461:6	O
.	PRADAXA.xml:S1:7467:1	O

Three	PRADAXA.xml:S1:7469:5	O
of	PRADAXA.xml:S1:7475:2	O
these	PRADAXA.xml:S1:7478:5	O
trials	PRADAXA.xml:S1:7484:6	O
were	PRADAXA.xml:S1:7491:4	O
active	PRADAXA.xml:S1:7496:6	O
-	PRADAXA.xml:S1:7502:1	O
controlled	PRADAXA.xml:S1:7503:10	O
(	PRADAXA.xml:S1:7514:1	O
warfarin	PRADAXA.xml:S1:7515:8	O
)	PRADAXA.xml:S1:7523:1	O
(	PRADAXA.xml:S1:7525:1	O
RE	PRADAXA.xml:S1:7526:2	O
-	PRADAXA.xml:S1:7528:1	O
COVER	PRADAXA.xml:S1:7529:5	O
,	PRADAXA.xml:S1:7534:1	O
RE	PRADAXA.xml:S1:7536:2	O
-	PRADAXA.xml:S1:7538:1	O
COVER	PRADAXA.xml:S1:7539:5	O
II	PRADAXA.xml:S1:7545:2	O
,	PRADAXA.xml:S1:7547:1	O
and	PRADAXA.xml:S1:7549:3	O
RE	PRADAXA.xml:S1:7553:2	O
-	PRADAXA.xml:S1:7555:1	O
MEDY	PRADAXA.xml:S1:7556:4	O
)	PRADAXA.xml:S1:7560:1	O
,	PRADAXA.xml:S1:7561:1	O
and	PRADAXA.xml:S1:7563:3	O
one	PRADAXA.xml:S1:7567:3	O
study	PRADAXA.xml:S1:7571:5	O
(	PRADAXA.xml:S1:7577:1	O
RE	PRADAXA.xml:S1:7578:2	O
-	PRADAXA.xml:S1:7580:1	O
SONATE	PRADAXA.xml:S1:7581:6	O
)	PRADAXA.xml:S1:7587:1	O
was	PRADAXA.xml:S1:7589:3	O
placebo	PRADAXA.xml:S1:7593:7	O
-	PRADAXA.xml:S1:7600:1	O
controlled	PRADAXA.xml:S1:7601:10	O
.	PRADAXA.xml:S1:7611:1	O

The	PRADAXA.xml:S1:7613:3	O
demographic	PRADAXA.xml:S1:7617:11	O
characteristics	PRADAXA.xml:S1:7629:15	O
were	PRADAXA.xml:S1:7645:4	O
similar	PRADAXA.xml:S1:7650:7	O
among	PRADAXA.xml:S1:7658:5	O
the	PRADAXA.xml:S1:7664:3	O
4	PRADAXA.xml:S1:7668:1	O
pivotal	PRADAXA.xml:S1:7670:7	O
studies	PRADAXA.xml:S1:7678:7	O
and	PRADAXA.xml:S1:7686:3	O
between	PRADAXA.xml:S1:7690:7	O
the	PRADAXA.xml:S1:7698:3	O
treatment	PRADAXA.xml:S1:7702:9	O
groups	PRADAXA.xml:S1:7712:6	O
within	PRADAXA.xml:S1:7719:6	O
these	PRADAXA.xml:S1:7726:5	O
studies	PRADAXA.xml:S1:7732:7	O
.	PRADAXA.xml:S1:7739:1	O

Approximately	PRADAXA.xml:S1:7741:13	O
60%	PRADAXA.xml:S1:7755:3	O
of	PRADAXA.xml:S1:7759:2	O
the	PRADAXA.xml:S1:7762:3	O
treated	PRADAXA.xml:S1:7766:7	O
patients	PRADAXA.xml:S1:7774:8	O
were	PRADAXA.xml:S1:7783:4	O
male	PRADAXA.xml:S1:7788:4	O
,	PRADAXA.xml:S1:7792:1	O
with	PRADAXA.xml:S1:7794:4	O
a	PRADAXA.xml:S1:7799:1	O
mean	PRADAXA.xml:S1:7801:4	O
age	PRADAXA.xml:S1:7806:3	O
of	PRADAXA.xml:S1:7810:2	O
55.1	PRADAXA.xml:S1:7813:4	O
years	PRADAXA.xml:S1:7818:5	O
.	PRADAXA.xml:S1:7823:1	O

The	PRADAXA.xml:S1:7825:3	O
majority	PRADAXA.xml:S1:7829:8	O
of	PRADAXA.xml:S1:7838:2	O
the	PRADAXA.xml:S1:7841:3	O
patients	PRADAXA.xml:S1:7845:8	O
were	PRADAXA.xml:S1:7854:4	O
white	PRADAXA.xml:S1:7859:5	O
(	PRADAXA.xml:S1:7865:1	O
87.7%	PRADAXA.xml:S1:7866:5	O
)	PRADAXA.xml:S1:7871:1	O
,	PRADAXA.xml:S1:7872:1	O
10.3%	PRADAXA.xml:S1:7874:5	O
were	PRADAXA.xml:S1:7880:4	O
Asian	PRADAXA.xml:S1:7885:5	O
,	PRADAXA.xml:S1:7890:1	O
and	PRADAXA.xml:S1:7892:3	O
1.9%	PRADAXA.xml:S1:7896:4	O
were	PRADAXA.xml:S1:7901:4	O
black	PRADAXA.xml:S1:7906:5	O
with	PRADAXA.xml:S1:7912:4	O
a	PRADAXA.xml:S1:7917:1	O
mean	PRADAXA.xml:S1:7919:4	O
CrCl	PRADAXA.xml:S1:7924:4	O
of	PRADAXA.xml:S1:7929:2	O
105.6	PRADAXA.xml:S1:7932:5	O
mL	PRADAXA.xml:S1:7938:2	O
min	PRADAXA.xml:S1:7941:3	O
.	PRADAXA.xml:S1:7944:1	O

Bleeding	PRADAXA.xml:S1:7950:8	B-AdverseReaction
events	PRADAXA.xml:S1:7959:6	O
for	PRADAXA.xml:S1:7966:3	O
the	PRADAXA.xml:S1:7970:3	O
4	PRADAXA.xml:S1:7974:1	O
pivotal	PRADAXA.xml:S1:7976:7	O
studies	PRADAXA.xml:S1:7984:7	O
were	PRADAXA.xml:S1:7992:4	O
classified	PRADAXA.xml:S1:7997:10	O
as	PRADAXA.xml:S1:8008:2	O
major	PRADAXA.xml:S1:8011:5	B-Severity
bleeding	PRADAXA.xml:S1:8017:8	B-AdverseReaction
events	PRADAXA.xml:S1:8026:6	O
if	PRADAXA.xml:S1:8033:2	O
at	PRADAXA.xml:S1:8036:2	O
least	PRADAXA.xml:S1:8039:5	O
one	PRADAXA.xml:S1:8045:3	O
of	PRADAXA.xml:S1:8049:2	O
the	PRADAXA.xml:S1:8052:3	O
following	PRADAXA.xml:S1:8056:9	O
criteria	PRADAXA.xml:S1:8066:8	O
applied	PRADAXA.xml:S1:8075:7	O
:	PRADAXA.xml:S1:8082:1	O
fatal	PRADAXA.xml:S1:8084:5	B-AdverseReaction
bleeding	PRADAXA.xml:S1:8090:8	B-AdverseReaction
,	PRADAXA.xml:S1:8098:1	O
symptomatic	PRADAXA.xml:S1:8100:11	B-AdverseReaction
bleeding	PRADAXA.xml:S1:8112:8	I-AdverseReaction
in	PRADAXA.xml:S1:8121:2	I-AdverseReaction
a	PRADAXA.xml:S1:8124:1	I-AdverseReaction
critical	PRADAXA.xml:S1:8126:8	I-AdverseReaction
area	PRADAXA.xml:S1:8135:4	I-AdverseReaction
or	PRADAXA.xml:S1:8140:2	O
organ	PRADAXA.xml:S1:8143:5	I-AdverseReaction
(	PRADAXA.xml:S1:8149:1	O
intraocular	PRADAXA.xml:S1:8150:11	I-AdverseReaction
,	PRADAXA.xml:S1:8161:1	O
intracranial	PRADAXA.xml:S1:8163:12	I-AdverseReaction
,	PRADAXA.xml:S1:8175:1	O
intraspinal	PRADAXA.xml:S1:8177:11	I-AdverseReaction
or	PRADAXA.xml:S1:8189:2	O
intramuscular	PRADAXA.xml:S1:8192:13	I-AdverseReaction
with	PRADAXA.xml:S1:8206:4	O
compartment	PRADAXA.xml:S1:8211:11	B-AdverseReaction
syndrome	PRADAXA.xml:S1:8223:8	I-AdverseReaction
,	PRADAXA.xml:S1:8231:1	O
retroperitoneal	PRADAXA.xml:S1:8233:15	B-AdverseReaction
bleeding	PRADAXA.xml:S1:8249:8	I-AdverseReaction
,	PRADAXA.xml:S1:8257:1	O
intra	PRADAXA.xml:S1:8259:5	B-AdverseReaction
-	PRADAXA.xml:S1:8264:1	I-AdverseReaction
articular	PRADAXA.xml:S1:8265:9	I-AdverseReaction
bleeding	PRADAXA.xml:S1:8275:8	I-AdverseReaction
,	PRADAXA.xml:S1:8283:1	O
or	PRADAXA.xml:S1:8285:2	O
pericardial	PRADAXA.xml:S1:8288:11	B-AdverseReaction
bleeding	PRADAXA.xml:S1:8300:8	I-AdverseReaction
)	PRADAXA.xml:S1:8308:1	O
,	PRADAXA.xml:S1:8309:1	O
bleeding	PRADAXA.xml:S1:8311:8	B-AdverseReaction
causing	PRADAXA.xml:S1:8320:7	O
a	PRADAXA.xml:S1:8328:1	O
fall	PRADAXA.xml:S1:8330:4	B-AdverseReaction
in	PRADAXA.xml:S1:8335:2	I-AdverseReaction
hemoglobin	PRADAXA.xml:S1:8338:10	I-AdverseReaction
level	PRADAXA.xml:S1:8349:5	I-AdverseReaction
of	PRADAXA.xml:S1:8355:2	O
2.0	PRADAXA.xml:S1:8358:3	B-Severity
g	PRADAXA.xml:S1:8362:1	I-Severity
dL	PRADAXA.xml:S1:8364:2	I-Severity
(	PRADAXA.xml:S1:8367:1	O
1.24	PRADAXA.xml:S1:8368:4	O
mmol	PRADAXA.xml:S1:8373:4	O
L	PRADAXA.xml:S1:8378:1	O
or	PRADAXA.xml:S1:8380:2	O
more	PRADAXA.xml:S1:8383:4	O
,	PRADAXA.xml:S1:8387:1	O
or	PRADAXA.xml:S1:8389:2	O
leading	PRADAXA.xml:S1:8392:7	O
to	PRADAXA.xml:S1:8400:2	O
transfusion	PRADAXA.xml:S1:8403:11	O
of	PRADAXA.xml:S1:8415:2	O
2	PRADAXA.xml:S1:8418:1	O
or	PRADAXA.xml:S1:8420:2	O
more	PRADAXA.xml:S1:8423:4	O
units	PRADAXA.xml:S1:8428:5	O
of	PRADAXA.xml:S1:8434:2	O
whole	PRADAXA.xml:S1:8437:5	O
blood	PRADAXA.xml:S1:8443:5	O
or	PRADAXA.xml:S1:8449:2	O
red	PRADAXA.xml:S1:8452:3	O
cells	PRADAXA.xml:S1:8456:5	O
)	PRADAXA.xml:S1:8461:1	O
.	PRADAXA.xml:S1:8462:1	O

RE	PRADAXA.xml:S1:8468:2	O
-	PRADAXA.xml:S1:8470:1	O
COVER	PRADAXA.xml:S1:8471:5	O
and	PRADAXA.xml:S1:8477:3	O
RE	PRADAXA.xml:S1:8481:2	O
-	PRADAXA.xml:S1:8483:1	O
COVER	PRADAXA.xml:S1:8484:5	O
II	PRADAXA.xml:S1:8490:2	O
studies	PRADAXA.xml:S1:8493:7	O
compared	PRADAXA.xml:S1:8501:8	O
PRADAXA	PRADAXA.xml:S1:8510:7	O
150	PRADAXA.xml:S1:8518:3	O
mg	PRADAXA.xml:S1:8522:2	O
twice	PRADAXA.xml:S1:8525:5	O
daily	PRADAXA.xml:S1:8531:5	O
and	PRADAXA.xml:S1:8537:3	O
warfarin	PRADAXA.xml:S1:8541:8	O
for	PRADAXA.xml:S1:8550:3	O
the	PRADAXA.xml:S1:8554:3	O
treatment	PRADAXA.xml:S1:8558:9	O
of	PRADAXA.xml:S1:8568:2	O
deep	PRADAXA.xml:S1:8571:4	O
vein	PRADAXA.xml:S1:8576:4	O
thrombosis	PRADAXA.xml:S1:8581:10	O
and	PRADAXA.xml:S1:8592:3	O
pulmonary	PRADAXA.xml:S1:8596:9	O
embolism	PRADAXA.xml:S1:8606:8	O
.	PRADAXA.xml:S1:8614:1	O

Patients	PRADAXA.xml:S1:8616:8	O
received	PRADAXA.xml:S1:8625:8	O
5	PRADAXA.xml:S1:8634:1	O
-	PRADAXA.xml:S1:8635:1	O
10	PRADAXA.xml:S1:8636:2	O
days	PRADAXA.xml:S1:8639:4	O
of	PRADAXA.xml:S1:8644:2	O
an	PRADAXA.xml:S1:8647:2	O
approved	PRADAXA.xml:S1:8650:8	O
parenteral	PRADAXA.xml:S1:8659:10	O
anticoagulant	PRADAXA.xml:S1:8670:13	O
therapy	PRADAXA.xml:S1:8684:7	O
followed	PRADAXA.xml:S1:8692:8	O
by	PRADAXA.xml:S1:8701:2	O
6	PRADAXA.xml:S1:8704:1	O
months	PRADAXA.xml:S1:8706:6	O
,	PRADAXA.xml:S1:8712:1	O
with	PRADAXA.xml:S1:8714:4	O
mean	PRADAXA.xml:S1:8719:4	O
exposure	PRADAXA.xml:S1:8724:8	O
of	PRADAXA.xml:S1:8733:2	O
164	PRADAXA.xml:S1:8736:3	O
days	PRADAXA.xml:S1:8740:4	O
,	PRADAXA.xml:S1:8744:1	O
of	PRADAXA.xml:S1:8746:2	O
oral	PRADAXA.xml:S1:8749:4	O
only	PRADAXA.xml:S1:8754:4	O
treatment	PRADAXA.xml:S1:8759:9	O
;	PRADAXA.xml:S1:8768:1	O
warfarin	PRADAXA.xml:S1:8770:8	O
was	PRADAXA.xml:S1:8779:3	O
overlapped	PRADAXA.xml:S1:8783:10	O
with	PRADAXA.xml:S1:8794:4	O
parenteral	PRADAXA.xml:S1:8799:10	O
therapy	PRADAXA.xml:S1:8810:7	O
.	PRADAXA.xml:S1:8817:1	O

Table	PRADAXA.xml:S1:8819:5	O
3	PRADAXA.xml:S1:8825:1	O
shows	PRADAXA.xml:S1:8827:5	O
the	PRADAXA.xml:S1:8833:3	O
number	PRADAXA.xml:S1:8837:6	O
of	PRADAXA.xml:S1:8844:2	O
patients	PRADAXA.xml:S1:8847:8	O
experiencing	PRADAXA.xml:S1:8856:12	O
bleeding	PRADAXA.xml:S1:8869:8	B-AdverseReaction
events	PRADAXA.xml:S1:8878:6	O
in	PRADAXA.xml:S1:8885:2	O
the	PRADAXA.xml:S1:8888:3	O
pooled	PRADAXA.xml:S1:8892:6	O
analysis	PRADAXA.xml:S1:8899:8	O
of	PRADAXA.xml:S1:8908:2	O
RE	PRADAXA.xml:S1:8911:2	O
-	PRADAXA.xml:S1:8913:1	O
COVER	PRADAXA.xml:S1:8914:5	O
and	PRADAXA.xml:S1:8920:3	O
RE	PRADAXA.xml:S1:8924:2	O
-	PRADAXA.xml:S1:8926:1	O
COVER	PRADAXA.xml:S1:8927:5	O
II	PRADAXA.xml:S1:8933:2	O
studies	PRADAXA.xml:S1:8936:7	O
during	PRADAXA.xml:S1:8944:6	O
the	PRADAXA.xml:S1:8951:3	O
full	PRADAXA.xml:S1:8955:4	O
treatment	PRADAXA.xml:S1:8960:9	O
including	PRADAXA.xml:S1:8970:9	O
parenteral	PRADAXA.xml:S1:8980:10	O
and	PRADAXA.xml:S1:8991:3	O
oral	PRADAXA.xml:S1:8995:4	O
only	PRADAXA.xml:S1:9000:4	O
treatment	PRADAXA.xml:S1:9005:9	O
periods	PRADAXA.xml:S1:9015:7	O
after	PRADAXA.xml:S1:9023:5	O
randomization	PRADAXA.xml:S1:9029:13	O
.	PRADAXA.xml:S1:9042:1	O

Table	PRADAXA.xml:S1:9048:5	O
3	PRADAXA.xml:S1:9054:1	O
Bleeding	PRADAXA.xml:S1:9056:8	B-AdverseReaction
Events	PRADAXA.xml:S1:9065:6	O
in	PRADAXA.xml:S1:9072:2	O
RE	PRADAXA.xml:S1:9075:2	O
-	PRADAXA.xml:S1:9077:1	O
COVER	PRADAXA.xml:S1:9078:5	O
and	PRADAXA.xml:S1:9084:3	O
RE	PRADAXA.xml:S1:9088:2	O
-	PRADAXA.xml:S1:9090:1	O
COVER	PRADAXA.xml:S1:9091:5	O
II	PRADAXA.xml:S1:9097:2	O
Treated	PRADAXA.xml:S1:9100:7	O
Patients	PRADAXA.xml:S1:9108:8	O

Note	PRADAXA.xml:S1:9119:4	O
:	PRADAXA.xml:S1:9123:1	O
MBE	PRADAXA.xml:S1:9125:3	B-AdverseReaction
can	PRADAXA.xml:S1:9129:3	O
belong	PRADAXA.xml:S1:9133:6	O
to	PRADAXA.xml:S1:9140:2	O
more	PRADAXA.xml:S1:9143:4	O
than	PRADAXA.xml:S1:9148:4	O
one	PRADAXA.xml:S1:9153:3	O
criterion	PRADAXA.xml:S1:9157:9	O
.	PRADAXA.xml:S1:9166:1	O

a	PRADAXA.xml:S1:9169:1	O
Patients	PRADAXA.xml:S1:9172:8	O
with	PRADAXA.xml:S1:9181:4	O
at	PRADAXA.xml:S1:9186:2	O
least	PRADAXA.xml:S1:9189:5	O
one	PRADAXA.xml:S1:9195:3	O
MBE	PRADAXA.xml:S1:9199:3	B-AdverseReaction
.	PRADAXA.xml:S1:9202:1	O

b	PRADAXA.xml:S1:9205:1	O
Bleeding	PRADAXA.xml:S1:9208:8	B-AdverseReaction
site	PRADAXA.xml:S1:9217:4	O
based	PRADAXA.xml:S1:9222:5	O
on	PRADAXA.xml:S1:9228:2	O
investigator	PRADAXA.xml:S1:9231:12	O
assessment	PRADAXA.xml:S1:9244:10	O
.	PRADAXA.xml:S1:9254:1	O

Patients	PRADAXA.xml:S1:9256:8	O
can	PRADAXA.xml:S1:9265:3	O
have	PRADAXA.xml:S1:9269:4	O
more	PRADAXA.xml:S1:9274:4	O
than	PRADAXA.xml:S1:9279:4	O
one	PRADAXA.xml:S1:9284:3	O
site	PRADAXA.xml:S1:9288:4	O
of	PRADAXA.xml:S1:9293:2	O
bleeding	PRADAXA.xml:S1:9296:8	B-AdverseReaction
.	PRADAXA.xml:S1:9304:1	O

c	PRADAXA.xml:S1:9307:1	O
Confidence	PRADAXA.xml:S1:9310:10	O
interval	PRADAXA.xml:S1:9321:8	O

Patients	PRADAXA.xml:S1:9380:8	O

Major	PRADAXA.xml:S1:9397:5	B-Severity

bleeding	PRADAXA.xml:S1:9403:8	B-AdverseReaction

event	PRADAXA.xml:S1:9412:5	O

a	PRADAXA.xml:S1:9419:1	O

Bleeding	PRADAXA.xml:S1:9487:8	B-AdverseReaction

sites	PRADAXA.xml:S1:9496:5	O

for	PRADAXA.xml:S1:9502:3	O

MBE	PRADAXA.xml:S1:9506:3	B-AdverseReaction
b	PRADAXA.xml:S1:9511:1	O

Clinically	PRADAXA.xml:S1:9659:10	O

relevant	PRADAXA.xml:S1:9670:8	O

non	PRADAXA.xml:S1:9679:3	B-Severity

-	PRADAXA.xml:S1:9682:1	I-Severity

major	PRADAXA.xml:S1:9683:5	I-Severity

bleeding	PRADAXA.xml:S1:9689:8	B-AdverseReaction

Any	PRADAXA.xml:S1:9703:3	O

bleeding	PRADAXA.xml:S1:9707:8	B-AdverseReaction

The	PRADAXA.xml:S1:9727:3	O

rate	PRADAXA.xml:S1:9731:4	O
of	PRADAXA.xml:S1:9736:2	O
any	PRADAXA.xml:S1:9739:3	O
gastrointestinal	PRADAXA.xml:S1:9743:16	B-AdverseReaction
bleeds	PRADAXA.xml:S1:9760:6	I-AdverseReaction
in	PRADAXA.xml:S1:9767:2	O
patients	PRADAXA.xml:S1:9770:8	O
receiving	PRADAXA.xml:S1:9779:9	O
PRADAXA	PRADAXA.xml:S1:9789:7	O
150	PRADAXA.xml:S1:9797:3	O
mg	PRADAXA.xml:S1:9801:2	O
in	PRADAXA.xml:S1:9804:2	O
the	PRADAXA.xml:S1:9807:3	O
full	PRADAXA.xml:S1:9811:4	O
treatment	PRADAXA.xml:S1:9816:9	O
period	PRADAXA.xml:S1:9826:6	O
was	PRADAXA.xml:S1:9833:3	O
3.1%	PRADAXA.xml:S1:9837:4	O
(	PRADAXA.xml:S1:9842:1	O
2.4%	PRADAXA.xml:S1:9843:4	O
on	PRADAXA.xml:S1:9848:2	O
warfarin	PRADAXA.xml:S1:9851:8	O
)	PRADAXA.xml:S1:9859:1	O
.	PRADAXA.xml:S1:9860:1	O

The	PRADAXA.xml:S1:9866:3	O

RE	PRADAXA.xml:S1:9870:2	O
-	PRADAXA.xml:S1:9872:1	O
MEDY	PRADAXA.xml:S1:9873:4	O
and	PRADAXA.xml:S1:9878:3	O
RE	PRADAXA.xml:S1:9882:2	O
-	PRADAXA.xml:S1:9884:1	O
SONATE	PRADAXA.xml:S1:9885:6	O
studies	PRADAXA.xml:S1:9892:7	O
provided	PRADAXA.xml:S1:9900:8	O
safety	PRADAXA.xml:S1:9909:6	O
information	PRADAXA.xml:S1:9916:11	O
on	PRADAXA.xml:S1:9928:2	O
the	PRADAXA.xml:S1:9931:3	O
use	PRADAXA.xml:S1:9935:3	O
of	PRADAXA.xml:S1:9939:2	O
PRADAXA	PRADAXA.xml:S1:9942:7	O
for	PRADAXA.xml:S1:9950:3	O
the	PRADAXA.xml:S1:9954:3	O
reduction	PRADAXA.xml:S1:9958:9	O
in	PRADAXA.xml:S1:9968:2	O
the	PRADAXA.xml:S1:9971:3	O
risk	PRADAXA.xml:S1:9975:4	O
of	PRADAXA.xml:S1:9980:2	O
recurrence	PRADAXA.xml:S1:9983:10	O
of	PRADAXA.xml:S1:9994:2	O
deep	PRADAXA.xml:S1:9997:4	O
vein	PRADAXA.xml:S1:10002:4	O
thrombosis	PRADAXA.xml:S1:10007:10	O
and	PRADAXA.xml:S1:10018:3	O
pulmonary	PRADAXA.xml:S1:10022:9	O
embolism	PRADAXA.xml:S1:10032:8	O
.	PRADAXA.xml:S1:10040:1	O

RE	PRADAXA.xml:S1:10046:2	O
-	PRADAXA.xml:S1:10048:1	O
MEDY	PRADAXA.xml:S1:10049:4	O
was	PRADAXA.xml:S1:10054:3	O
an	PRADAXA.xml:S1:10058:2	O
active	PRADAXA.xml:S1:10061:6	O
-	PRADAXA.xml:S1:10067:1	O
controlled	PRADAXA.xml:S1:10068:10	O
study	PRADAXA.xml:S1:10079:5	O
(	PRADAXA.xml:S1:10085:1	O
warfarin	PRADAXA.xml:S1:10086:8	O
)	PRADAXA.xml:S1:10094:1	O
in	PRADAXA.xml:S1:10096:2	O
which	PRADAXA.xml:S1:10099:5	O
1430	PRADAXA.xml:S1:10105:4	O
patients	PRADAXA.xml:S1:10110:8	O
received	PRADAXA.xml:S1:10119:8	O
PRADAXA	PRADAXA.xml:S1:10128:7	O
150	PRADAXA.xml:S1:10136:3	O
mg	PRADAXA.xml:S1:10140:2	O
twice	PRADAXA.xml:S1:10143:5	O
daily	PRADAXA.xml:S1:10149:5	O
following	PRADAXA.xml:S1:10155:9	O
3	PRADAXA.xml:S1:10165:1	O
to	PRADAXA.xml:S1:10167:2	O
12	PRADAXA.xml:S1:10170:2	O
months	PRADAXA.xml:S1:10173:6	O
of	PRADAXA.xml:S1:10180:2	O
oral	PRADAXA.xml:S1:10183:4	O
anticoagulant	PRADAXA.xml:S1:10188:13	O
regimen	PRADAXA.xml:S1:10202:7	O
.	PRADAXA.xml:S1:10209:1	O

Patients	PRADAXA.xml:S1:10211:8	O
in	PRADAXA.xml:S1:10220:2	O
the	PRADAXA.xml:S1:10223:3	O
treatment	PRADAXA.xml:S1:10227:9	O
studies	PRADAXA.xml:S1:10237:7	O
who	PRADAXA.xml:S1:10245:3	O
rolled	PRADAXA.xml:S1:10249:6	O
over	PRADAXA.xml:S1:10256:4	O
into	PRADAXA.xml:S1:10261:4	O
the	PRADAXA.xml:S1:10266:3	O
RE	PRADAXA.xml:S1:10270:2	O
-	PRADAXA.xml:S1:10272:1	O
MEDY	PRADAXA.xml:S1:10273:4	O
study	PRADAXA.xml:S1:10278:5	O
had	PRADAXA.xml:S1:10284:3	O
a	PRADAXA.xml:S1:10288:1	O
combined	PRADAXA.xml:S1:10290:8	O
treatment	PRADAXA.xml:S1:10299:9	O
duration	PRADAXA.xml:S1:10309:8	O
of	PRADAXA.xml:S1:10318:2	O
up	PRADAXA.xml:S1:10321:2	O
to	PRADAXA.xml:S1:10324:2	O
more	PRADAXA.xml:S1:10327:4	O
than	PRADAXA.xml:S1:10332:4	O
3	PRADAXA.xml:S1:10337:1	O
years	PRADAXA.xml:S1:10339:5	O
,	PRADAXA.xml:S1:10344:1	O
with	PRADAXA.xml:S1:10346:4	O
mean	PRADAXA.xml:S1:10351:4	O
exposure	PRADAXA.xml:S1:10356:8	O
of	PRADAXA.xml:S1:10365:2	O
473	PRADAXA.xml:S1:10368:3	O
days	PRADAXA.xml:S1:10372:4	O
.	PRADAXA.xml:S1:10376:1	O

Table	PRADAXA.xml:S1:10378:5	O
4	PRADAXA.xml:S1:10384:1	O
shows	PRADAXA.xml:S1:10386:5	O
the	PRADAXA.xml:S1:10392:3	O
number	PRADAXA.xml:S1:10396:6	O
of	PRADAXA.xml:S1:10403:2	O
patients	PRADAXA.xml:S1:10406:8	O
experiencing	PRADAXA.xml:S1:10415:12	O
bleeding	PRADAXA.xml:S1:10428:8	B-AdverseReaction
events	PRADAXA.xml:S1:10437:6	O
in	PRADAXA.xml:S1:10444:2	O
the	PRADAXA.xml:S1:10447:3	O
study	PRADAXA.xml:S1:10451:5	O
.	PRADAXA.xml:S1:10456:1	O

Table	PRADAXA.xml:S1:10462:5	O
4	PRADAXA.xml:S1:10468:1	O
Bleeding	PRADAXA.xml:S1:10470:8	B-AdverseReaction
Events	PRADAXA.xml:S1:10479:6	O
in	PRADAXA.xml:S1:10486:2	O
RE	PRADAXA.xml:S1:10489:2	O
-	PRADAXA.xml:S1:10491:1	O
MEDY	PRADAXA.xml:S1:10492:4	O
Treated	PRADAXA.xml:S1:10497:7	O
Patients	PRADAXA.xml:S1:10505:8	O

Note	PRADAXA.xml:S1:10516:4	O
:	PRADAXA.xml:S1:10520:1	O
MBE	PRADAXA.xml:S1:10522:3	B-AdverseReaction
can	PRADAXA.xml:S1:10526:3	O
belong	PRADAXA.xml:S1:10530:6	O
to	PRADAXA.xml:S1:10537:2	O
more	PRADAXA.xml:S1:10540:4	O
than	PRADAXA.xml:S1:10545:4	O
one	PRADAXA.xml:S1:10550:3	O
criterion	PRADAXA.xml:S1:10554:9	O
.	PRADAXA.xml:S1:10563:1	O

a	PRADAXA.xml:S1:10566:1	O
Patients	PRADAXA.xml:S1:10569:8	O
with	PRADAXA.xml:S1:10578:4	O
at	PRADAXA.xml:S1:10583:2	O
least	PRADAXA.xml:S1:10586:5	O
one	PRADAXA.xml:S1:10592:3	O
MBE	PRADAXA.xml:S1:10596:3	B-AdverseReaction
.	PRADAXA.xml:S1:10599:1	O

b	PRADAXA.xml:S1:10602:1	O
Bleeding	PRADAXA.xml:S1:10605:8	B-AdverseReaction
site	PRADAXA.xml:S1:10614:4	O
based	PRADAXA.xml:S1:10619:5	O
on	PRADAXA.xml:S1:10625:2	O
investigator	PRADAXA.xml:S1:10628:12	O
assessment	PRADAXA.xml:S1:10641:10	O
.	PRADAXA.xml:S1:10651:1	O

Patients	PRADAXA.xml:S1:10653:8	O
can	PRADAXA.xml:S1:10662:3	O
have	PRADAXA.xml:S1:10666:4	O
more	PRADAXA.xml:S1:10671:4	O
than	PRADAXA.xml:S1:10676:4	O
one	PRADAXA.xml:S1:10681:3	O
site	PRADAXA.xml:S1:10685:4	O
of	PRADAXA.xml:S1:10690:2	O
bleeding	PRADAXA.xml:S1:10693:8	B-AdverseReaction
.	PRADAXA.xml:S1:10701:1	O

c	PRADAXA.xml:S1:10704:1	O
Confidence	PRADAXA.xml:S1:10707:10	O
interval	PRADAXA.xml:S1:10718:8	O

Patients	PRADAXA.xml:S1:10757:8	O

Major	PRADAXA.xml:S1:10774:5	B-Severity

bleeding	PRADAXA.xml:S1:10780:8	B-AdverseReaction

event	PRADAXA.xml:S1:10789:5	O
a	PRADAXA.xml:S1:10796:1	O

Bleeding	PRADAXA.xml:S1:10864:8	B-AdverseReaction

sites	PRADAXA.xml:S1:10873:5	O

for	PRADAXA.xml:S1:10879:3	O

MBE	PRADAXA.xml:S1:10883:3	B-AdverseReaction
b	PRADAXA.xml:S1:10888:1	O

Clinically	PRADAXA.xml:S1:11056:10	O

relevant	PRADAXA.xml:S1:11067:8	O

non	PRADAXA.xml:S1:11076:3	B-Severity

-	PRADAXA.xml:S1:11079:1	I-Severity

major	PRADAXA.xml:S1:11080:5	I-Severity

bleeding	PRADAXA.xml:S1:11086:8	B-AdverseReaction

Any	PRADAXA.xml:S1:11100:3	O

bleeding	PRADAXA.xml:S1:11104:8	B-AdverseReaction

In	PRADAXA.xml:S1:11124:2	O

the	PRADAXA.xml:S1:11127:3	O

RE	PRADAXA.xml:S1:11131:2	O
-	PRADAXA.xml:S1:11133:1	O
MEDY	PRADAXA.xml:S1:11134:4	O
study	PRADAXA.xml:S1:11139:5	O
,	PRADAXA.xml:S1:11144:1	O
the	PRADAXA.xml:S1:11146:3	O
rate	PRADAXA.xml:S1:11150:4	O
of	PRADAXA.xml:S1:11155:2	O
any	PRADAXA.xml:S1:11158:3	O
gastrointestinal	PRADAXA.xml:S1:11162:16	B-AdverseReaction
bleeds	PRADAXA.xml:S1:11179:6	I-AdverseReaction
in	PRADAXA.xml:S1:11186:2	O
patients	PRADAXA.xml:S1:11189:8	O
receiving	PRADAXA.xml:S1:11198:9	O
PRADAXA	PRADAXA.xml:S1:11208:7	O
150	PRADAXA.xml:S1:11216:3	O
mg	PRADAXA.xml:S1:11220:2	O
was	PRADAXA.xml:S1:11223:3	O
3.1%	PRADAXA.xml:S1:11227:4	O
(	PRADAXA.xml:S1:11232:1	O
2.2%	PRADAXA.xml:S1:11233:4	O
on	PRADAXA.xml:S1:11238:2	O
warfarin	PRADAXA.xml:S1:11241:8	O
)	PRADAXA.xml:S1:11249:1	O
.	PRADAXA.xml:S1:11250:1	O

RE	PRADAXA.xml:S1:11256:2	O

-	PRADAXA.xml:S1:11258:1	O
SONATE	PRADAXA.xml:S1:11259:6	O
was	PRADAXA.xml:S1:11266:3	O
a	PRADAXA.xml:S1:11270:1	O
placebo	PRADAXA.xml:S1:11272:7	O
-	PRADAXA.xml:S1:11279:1	O
controlled	PRADAXA.xml:S1:11280:10	O
study	PRADAXA.xml:S1:11291:5	O
in	PRADAXA.xml:S1:11297:2	O
which	PRADAXA.xml:S1:11300:5	O
684	PRADAXA.xml:S1:11306:3	O
patients	PRADAXA.xml:S1:11310:8	O
received	PRADAXA.xml:S1:11319:8	O
PRADAXA	PRADAXA.xml:S1:11328:7	O
150	PRADAXA.xml:S1:11336:3	O
mg	PRADAXA.xml:S1:11340:2	O
twice	PRADAXA.xml:S1:11343:5	O
daily	PRADAXA.xml:S1:11349:5	O
following	PRADAXA.xml:S1:11355:9	O
6	PRADAXA.xml:S1:11365:1	O
to	PRADAXA.xml:S1:11367:2	O
18	PRADAXA.xml:S1:11370:2	O
months	PRADAXA.xml:S1:11373:6	O
of	PRADAXA.xml:S1:11380:2	O
oral	PRADAXA.xml:S1:11383:4	O
anticoagulant	PRADAXA.xml:S1:11388:13	O
regimen	PRADAXA.xml:S1:11402:7	O
.	PRADAXA.xml:S1:11409:1	O

Patients	PRADAXA.xml:S1:11411:8	O
in	PRADAXA.xml:S1:11420:2	O
the	PRADAXA.xml:S1:11423:3	O
treatment	PRADAXA.xml:S1:11427:9	O
studies	PRADAXA.xml:S1:11437:7	O
who	PRADAXA.xml:S1:11445:3	O
rolled	PRADAXA.xml:S1:11449:6	O
over	PRADAXA.xml:S1:11456:4	O
into	PRADAXA.xml:S1:11461:4	O
the	PRADAXA.xml:S1:11466:3	O
RE	PRADAXA.xml:S1:11470:2	O
-	PRADAXA.xml:S1:11472:1	O
SONATE	PRADAXA.xml:S1:11473:6	O
study	PRADAXA.xml:S1:11480:5	O
had	PRADAXA.xml:S1:11486:3	O
combined	PRADAXA.xml:S1:11490:8	O
treatment	PRADAXA.xml:S1:11499:9	O
duration	PRADAXA.xml:S1:11509:8	O
up	PRADAXA.xml:S1:11518:2	O
to	PRADAXA.xml:S1:11521:2	O
9	PRADAXA.xml:S1:11524:1	O
months	PRADAXA.xml:S1:11526:6	O
,	PRADAXA.xml:S1:11532:1	O
with	PRADAXA.xml:S1:11534:4	O
mean	PRADAXA.xml:S1:11539:4	O
exposure	PRADAXA.xml:S1:11544:8	O
of	PRADAXA.xml:S1:11553:2	O
165	PRADAXA.xml:S1:11556:3	O
days	PRADAXA.xml:S1:11560:4	O
.	PRADAXA.xml:S1:11564:1	O

Table	PRADAXA.xml:S1:11566:5	O
5	PRADAXA.xml:S1:11572:1	O
shows	PRADAXA.xml:S1:11574:5	O
the	PRADAXA.xml:S1:11580:3	O
number	PRADAXA.xml:S1:11584:6	O
of	PRADAXA.xml:S1:11591:2	O
patients	PRADAXA.xml:S1:11594:8	O
experiencing	PRADAXA.xml:S1:11603:12	O
bleeding	PRADAXA.xml:S1:11616:8	B-AdverseReaction
events	PRADAXA.xml:S1:11625:6	O
in	PRADAXA.xml:S1:11632:2	O
the	PRADAXA.xml:S1:11635:3	O
study	PRADAXA.xml:S1:11639:5	O
.	PRADAXA.xml:S1:11644:1	O

Table	PRADAXA.xml:S1:11650:5	O
5	PRADAXA.xml:S1:11656:1	O
Bleeding	PRADAXA.xml:S1:11658:8	B-AdverseReaction
Events	PRADAXA.xml:S1:11667:6	O
in	PRADAXA.xml:S1:11674:2	O
RE	PRADAXA.xml:S1:11677:2	O
-	PRADAXA.xml:S1:11679:1	O
SONATE	PRADAXA.xml:S1:11680:6	O
Treated	PRADAXA.xml:S1:11687:7	O
Patients	PRADAXA.xml:S1:11695:8	O

Note	PRADAXA.xml:S1:11706:4	O
:	PRADAXA.xml:S1:11710:1	O
MBE	PRADAXA.xml:S1:11712:3	B-AdverseReaction
can	PRADAXA.xml:S1:11716:3	O
belong	PRADAXA.xml:S1:11720:6	O
to	PRADAXA.xml:S1:11727:2	O
more	PRADAXA.xml:S1:11730:4	O
than	PRADAXA.xml:S1:11735:4	O
one	PRADAXA.xml:S1:11740:3	O
criterion	PRADAXA.xml:S1:11744:9	O
.	PRADAXA.xml:S1:11753:1	O

a	PRADAXA.xml:S1:11756:1	O
Patients	PRADAXA.xml:S1:11759:8	O
with	PRADAXA.xml:S1:11768:4	O
at	PRADAXA.xml:S1:11773:2	O
least	PRADAXA.xml:S1:11776:5	O
one	PRADAXA.xml:S1:11782:3	O
MBE	PRADAXA.xml:S1:11786:3	B-AdverseReaction
.	PRADAXA.xml:S1:11789:1	O

b	PRADAXA.xml:S1:11792:1	O
Bleeding	PRADAXA.xml:S1:11795:8	B-AdverseReaction
site	PRADAXA.xml:S1:11804:4	O
based	PRADAXA.xml:S1:11809:5	O
on	PRADAXA.xml:S1:11815:2	O
investigator	PRADAXA.xml:S1:11818:12	O
assessment	PRADAXA.xml:S1:11831:10	O
.	PRADAXA.xml:S1:11841:1	O

Patients	PRADAXA.xml:S1:11843:8	O
can	PRADAXA.xml:S1:11852:3	O
have	PRADAXA.xml:S1:11856:4	O
more	PRADAXA.xml:S1:11861:4	O
than	PRADAXA.xml:S1:11866:4	O
one	PRADAXA.xml:S1:11871:3	O
site	PRADAXA.xml:S1:11875:4	O
of	PRADAXA.xml:S1:11880:2	O
bleeding	PRADAXA.xml:S1:11883:8	B-AdverseReaction
.	PRADAXA.xml:S1:11891:1	O

c	PRADAXA.xml:S1:11894:1	O
Confidence	PRADAXA.xml:S1:11897:10	O
interval	PRADAXA.xml:S1:11908:8	O

Patients	PRADAXA.xml:S1:11947:8	O

Major	PRADAXA.xml:S1:11964:5	B-Severity

bleeding	PRADAXA.xml:S1:11970:8	B-AdverseReaction

event	PRADAXA.xml:S1:11979:5	O
a	PRADAXA.xml:S1:11986:1	O

Clinically	PRADAXA.xml:S1:12034:10	O

relevant	PRADAXA.xml:S1:12045:8	O

non	PRADAXA.xml:S1:12054:3	B-Severity
-	PRADAXA.xml:S1:12057:1	I-Severity
major	PRADAXA.xml:S1:12058:5	I-Severity
bleeding	PRADAXA.xml:S1:12064:8	B-AdverseReaction

Any	PRADAXA.xml:S1:12078:3	O
bleeding	PRADAXA.xml:S1:12082:8	B-AdverseReaction

In	PRADAXA.xml:S1:12102:2	O
the	PRADAXA.xml:S1:12105:3	O
RE	PRADAXA.xml:S1:12109:2	O
-	PRADAXA.xml:S1:12111:1	O
SONATE	PRADAXA.xml:S1:12112:6	O
study	PRADAXA.xml:S1:12119:5	O
,	PRADAXA.xml:S1:12124:1	O
the	PRADAXA.xml:S1:12126:3	O
rate	PRADAXA.xml:S1:12130:4	O
of	PRADAXA.xml:S1:12135:2	O
any	PRADAXA.xml:S1:12138:3	O
gastrointestinal	PRADAXA.xml:S1:12142:16	B-AdverseReaction
bleeds	PRADAXA.xml:S1:12159:6	I-AdverseReaction
in	PRADAXA.xml:S1:12166:2	O
patients	PRADAXA.xml:S1:12169:8	O
receiving	PRADAXA.xml:S1:12178:9	O
PRADAXA	PRADAXA.xml:S1:12188:7	O
150	PRADAXA.xml:S1:12196:3	O
mg	PRADAXA.xml:S1:12200:2	O
was	PRADAXA.xml:S1:12203:3	O
0.7%	PRADAXA.xml:S1:12207:4	O
(	PRADAXA.xml:S1:12212:1	O
0.3%	PRADAXA.xml:S1:12213:4	O
on	PRADAXA.xml:S1:12218:2	O
placebo	PRADAXA.xml:S1:12221:7	O
)	PRADAXA.xml:S1:12228:1	O
.	PRADAXA.xml:S1:12229:1	O

Clinical	PRADAXA.xml:S1:12237:8	O

Myocardial	PRADAXA.xml:S1:12246:10	O
Infarction	PRADAXA.xml:S1:12257:10	O
Events	PRADAXA.xml:S1:12268:6	O
In	PRADAXA.xml:S1:12276:2	O
the	PRADAXA.xml:S1:12279:3	O
active	PRADAXA.xml:S1:12283:6	O
-	PRADAXA.xml:S1:12289:1	O
controlled	PRADAXA.xml:S1:12290:10	O
VTE	PRADAXA.xml:S1:12301:3	O
studies	PRADAXA.xml:S1:12305:7	O
,	PRADAXA.xml:S1:12312:1	O
a	PRADAXA.xml:S1:12314:1	O
higher	PRADAXA.xml:S1:12316:6	O
rate	PRADAXA.xml:S1:12323:4	O
of	PRADAXA.xml:S1:12328:2	O
clinical	PRADAXA.xml:S1:12331:8	O
myocardial	PRADAXA.xml:S1:12340:10	B-AdverseReaction
infarction	PRADAXA.xml:S1:12351:10	I-AdverseReaction
was	PRADAXA.xml:S1:12362:3	O
reported	PRADAXA.xml:S1:12366:8	O
in	PRADAXA.xml:S1:12375:2	O
patients	PRADAXA.xml:S1:12378:8	O
who	PRADAXA.xml:S1:12387:3	O
received	PRADAXA.xml:S1:12391:8	O
PRADAXA	PRADAXA.xml:S1:12400:7	O
[	PRADAXA.xml:S1:12408:1	O
20	PRADAXA.xml:S1:12409:2	O
(	PRADAXA.xml:S1:12412:1	O
0.66	PRADAXA.xml:S1:12413:4	O
per	PRADAXA.xml:S1:12418:3	O
100	PRADAXA.xml:S1:12422:3	O
patient	PRADAXA.xml:S1:12426:7	O
-	PRADAXA.xml:S1:12433:1	O
years	PRADAXA.xml:S1:12434:5	O
)]	PRADAXA.xml:S1:12439:2	O
than	PRADAXA.xml:S1:12442:4	O
in	PRADAXA.xml:S1:12447:2	O
those	PRADAXA.xml:S1:12450:5	O
who	PRADAXA.xml:S1:12456:3	O
received	PRADAXA.xml:S1:12460:8	O
warfarin	PRADAXA.xml:S1:12469:8	O
[	PRADAXA.xml:S1:12478:1	O
5	PRADAXA.xml:S1:12479:1	O
(	PRADAXA.xml:S1:12481:1	O
0.17	PRADAXA.xml:S1:12482:4	O
per	PRADAXA.xml:S1:12487:3	O
100	PRADAXA.xml:S1:12491:3	O
patient	PRADAXA.xml:S1:12495:7	O
-	PRADAXA.xml:S1:12502:1	O
years	PRADAXA.xml:S1:12503:5	O
)]	PRADAXA.xml:S1:12508:2	O
.	PRADAXA.xml:S1:12510:1	O

In	PRADAXA.xml:S1:12512:2	O
the	PRADAXA.xml:S1:12515:3	O
placebo	PRADAXA.xml:S1:12519:7	O
-	PRADAXA.xml:S1:12526:1	O
controlled	PRADAXA.xml:S1:12527:10	O
study	PRADAXA.xml:S1:12538:5	O
,	PRADAXA.xml:S1:12543:1	O
a	PRADAXA.xml:S1:12545:1	O
similar	PRADAXA.xml:S1:12547:7	O
rate	PRADAXA.xml:S1:12555:4	O
of	PRADAXA.xml:S1:12560:2	O
non	PRADAXA.xml:S1:12563:3	B-Severity
-	PRADAXA.xml:S1:12566:1	I-Severity
fatal	PRADAXA.xml:S1:12567:5	I-Severity
and	PRADAXA.xml:S1:12573:3	O
fatal	PRADAXA.xml:S1:12577:5	B-AdverseReaction
clinical	PRADAXA.xml:S1:12583:8	O
myocardial	PRADAXA.xml:S1:12592:10	B-AdverseReaction
infarction	PRADAXA.xml:S1:12603:10	I-AdverseReaction
was	PRADAXA.xml:S1:12614:3	O
reported	PRADAXA.xml:S1:12618:8	O
in	PRADAXA.xml:S1:12627:2	O
patients	PRADAXA.xml:S1:12630:8	O
who	PRADAXA.xml:S1:12639:3	O
received	PRADAXA.xml:S1:12643:8	O
PRADAXA	PRADAXA.xml:S1:12652:7	O
[	PRADAXA.xml:S1:12660:1	O
1	PRADAXA.xml:S1:12661:1	O
(	PRADAXA.xml:S1:12663:1	O
0.32	PRADAXA.xml:S1:12664:4	O
per	PRADAXA.xml:S1:12669:3	O
100	PRADAXA.xml:S1:12673:3	O
patient	PRADAXA.xml:S1:12677:7	O
-	PRADAXA.xml:S1:12684:1	O
years	PRADAXA.xml:S1:12685:5	O
)]	PRADAXA.xml:S1:12690:2	O
and	PRADAXA.xml:S1:12693:3	O
in	PRADAXA.xml:S1:12697:2	O
those	PRADAXA.xml:S1:12700:5	O
who	PRADAXA.xml:S1:12706:3	O
received	PRADAXA.xml:S1:12710:8	O
placebo	PRADAXA.xml:S1:12719:7	O
[	PRADAXA.xml:S1:12727:1	O
1	PRADAXA.xml:S1:12728:1	O
(	PRADAXA.xml:S1:12730:1	O
0.34	PRADAXA.xml:S1:12731:4	O
per	PRADAXA.xml:S1:12736:3	O
100	PRADAXA.xml:S1:12740:3	O
patient	PRADAXA.xml:S1:12744:7	O
-	PRADAXA.xml:S1:12751:1	O
years	PRADAXA.xml:S1:12752:5	O
)]	PRADAXA.xml:S1:12757:2	O
.	PRADAXA.xml:S1:12759:1	O

Gastrointestinal	PRADAXA.xml:S1:12767:16	O
Adverse	PRADAXA.xml:S1:12784:7	O
Reactions	PRADAXA.xml:S1:12792:9	O
In	PRADAXA.xml:S1:12803:2	O
the	PRADAXA.xml:S1:12806:3	O
four	PRADAXA.xml:S1:12810:4	O
pivotal	PRADAXA.xml:S1:12815:7	O
studies	PRADAXA.xml:S1:12823:7	O
,	PRADAXA.xml:S1:12830:1	O
patients	PRADAXA.xml:S1:12832:8	O
on	PRADAXA.xml:S1:12841:2	O
PRADAXA	PRADAXA.xml:S1:12844:7	O
150	PRADAXA.xml:S1:12852:3	O
mg	PRADAXA.xml:S1:12856:2	O
had	PRADAXA.xml:S1:12859:3	O
a	PRADAXA.xml:S1:12863:1	O
similar	PRADAXA.xml:S1:12865:7	O
incidence	PRADAXA.xml:S1:12873:9	O
of	PRADAXA.xml:S1:12883:2	O
gastrointestinal	PRADAXA.xml:S1:12886:16	B-AdverseReaction
adverse	PRADAXA.xml:S1:12903:7	I-AdverseReaction
reactions	PRADAXA.xml:S1:12911:9	I-AdverseReaction
(	PRADAXA.xml:S1:12921:1	O
24.7%	PRADAXA.xml:S1:12922:5	O
vs	PRADAXA.xml:S1:12928:2	O
.	PRADAXA.xml:S1:12930:1	O

22.7%	PRADAXA.xml:S1:12932:5	O
on	PRADAXA.xml:S1:12938:2	O
warfarin	PRADAXA.xml:S1:12941:8	O
)	PRADAXA.xml:S1:12949:1	O
.	PRADAXA.xml:S1:12950:1	O

Dyspepsia	PRADAXA.xml:S1:12952:9	B-AdverseReaction
(	PRADAXA.xml:S1:12962:1	O
including	PRADAXA.xml:S1:12963:9	O
abdominal	PRADAXA.xml:S1:12973:9	B-AdverseReaction
pain	PRADAXA.xml:S1:12983:4	I-AdverseReaction
upper	PRADAXA.xml:S1:12988:5	I-AdverseReaction
,	PRADAXA.xml:S1:12993:1	O
abdominal	PRADAXA.xml:S1:12995:9	B-AdverseReaction
pain	PRADAXA.xml:S1:13005:4	I-AdverseReaction
,	PRADAXA.xml:S1:13009:1	O
abdominal	PRADAXA.xml:S1:13011:9	B-AdverseReaction
discomfort	PRADAXA.xml:S1:13021:10	I-AdverseReaction
,	PRADAXA.xml:S1:13031:1	O
and	PRADAXA.xml:S1:13033:3	O
epigastric	PRADAXA.xml:S1:13037:10	B-AdverseReaction
discomfort	PRADAXA.xml:S1:13048:10	I-AdverseReaction
)	PRADAXA.xml:S1:13058:1	O
occurred	PRADAXA.xml:S1:13060:8	O
in	PRADAXA.xml:S1:13069:2	O
patients	PRADAXA.xml:S1:13072:8	O
on	PRADAXA.xml:S1:13081:2	O
PRADAXA	PRADAXA.xml:S1:13084:7	O
in	PRADAXA.xml:S1:13092:2	O
7.5%	PRADAXA.xml:S1:13095:4	O
vs	PRADAXA.xml:S1:13100:2	O
.	PRADAXA.xml:S1:13102:1	O

5.5%	PRADAXA.xml:S1:13104:4	O
on	PRADAXA.xml:S1:13109:2	O
warfarin	PRADAXA.xml:S1:13112:8	O
,	PRADAXA.xml:S1:13120:1	O
and	PRADAXA.xml:S1:13122:3	O
gastritis	PRADAXA.xml:S1:13126:9	B-AdverseReaction
-	PRADAXA.xml:S1:13135:1	O
like	PRADAXA.xml:S1:13136:4	O
symptoms	PRADAXA.xml:S1:13141:8	O
(	PRADAXA.xml:S1:13150:1	O
including	PRADAXA.xml:S1:13151:9	O
gastritis	PRADAXA.xml:S1:13161:9	B-AdverseReaction
,	PRADAXA.xml:S1:13170:1	O
GERD	PRADAXA.xml:S1:13172:4	B-AdverseReaction
,	PRADAXA.xml:S1:13176:1	O
esophagitis	PRADAXA.xml:S1:13178:11	B-AdverseReaction
,	PRADAXA.xml:S1:13189:1	O
erosive	PRADAXA.xml:S1:13191:7	B-AdverseReaction
gastritis	PRADAXA.xml:S1:13199:9	I-AdverseReaction
and	PRADAXA.xml:S1:13209:3	O
gastric	PRADAXA.xml:S1:13213:7	B-AdverseReaction
hemorrhage	PRADAXA.xml:S1:13221:10	I-AdverseReaction
)	PRADAXA.xml:S1:13231:1	O
occurred	PRADAXA.xml:S1:13233:8	O
at	PRADAXA.xml:S1:13242:2	O
3.0%	PRADAXA.xml:S1:13245:4	O
vs	PRADAXA.xml:S1:13250:2	O
.	PRADAXA.xml:S1:13252:1	O

1.7%	PRADAXA.xml:S1:13254:4	O
,	PRADAXA.xml:S1:13258:1	O
respectively	PRADAXA.xml:S1:13260:12	O
.	PRADAXA.xml:S1:13272:1	O

Hypersensitivity	PRADAXA.xml:S1:13280:16	O
Reactions	PRADAXA.xml:S1:13297:9	O
In	PRADAXA.xml:S1:13308:2	O
the	PRADAXA.xml:S1:13311:3	O
4	PRADAXA.xml:S1:13315:1	O
pivotal	PRADAXA.xml:S1:13317:7	O
studies	PRADAXA.xml:S1:13325:7	O
,	PRADAXA.xml:S1:13332:1	O
drug	PRADAXA.xml:S1:13334:4	O
hypersensitivity	PRADAXA.xml:S1:13339:16	B-AdverseReaction
(	PRADAXA.xml:S1:13356:1	O
including	PRADAXA.xml:S1:13357:9	O
urticaria	PRADAXA.xml:S1:13367:9	B-AdverseReaction
,	PRADAXA.xml:S1:13376:1	O
rash	PRADAXA.xml:S1:13378:4	B-AdverseReaction
,	PRADAXA.xml:S1:13382:1	O
and	PRADAXA.xml:S1:13384:3	O
pruritus	PRADAXA.xml:S1:13388:8	B-AdverseReaction
)	PRADAXA.xml:S1:13396:1	O
,	PRADAXA.xml:S1:13397:1	O
allergic	PRADAXA.xml:S1:13399:8	B-AdverseReaction
edema	PRADAXA.xml:S1:13408:5	I-AdverseReaction
,	PRADAXA.xml:S1:13413:1	O
anaphylactic	PRADAXA.xml:S1:13415:12	B-AdverseReaction
reaction	PRADAXA.xml:S1:13428:8	I-AdverseReaction
,	PRADAXA.xml:S1:13436:1	O
and	PRADAXA.xml:S1:13438:3	O
anaphylactic	PRADAXA.xml:S1:13442:12	B-AdverseReaction
shock	PRADAXA.xml:S1:13455:5	I-AdverseReaction
were	PRADAXA.xml:S1:13461:4	O
reported	PRADAXA.xml:S1:13466:8	O
in	PRADAXA.xml:S1:13475:2	O
0.1%	PRADAXA.xml:S1:13478:4	O
of	PRADAXA.xml:S1:13483:2	O
patients	PRADAXA.xml:S1:13486:8	O
receiving	PRADAXA.xml:S1:13495:9	O
PRADAXA	PRADAXA.xml:S1:13505:7	O
.	PRADAXA.xml:S1:13512:1	O

6.2	PRADAXA.xml:S1:13520:3	O
Postmarketing	PRADAXA.xml:S1:13524:13	O
Experience	PRADAXA.xml:S1:13538:10	O

The	PRADAXA.xml:S1:13552:3	O
following	PRADAXA.xml:S1:13556:9	O
adverse	PRADAXA.xml:S1:13566:7	O
reactions	PRADAXA.xml:S1:13574:9	O
have	PRADAXA.xml:S1:13584:4	O
been	PRADAXA.xml:S1:13589:4	O
identified	PRADAXA.xml:S1:13594:10	O
during	PRADAXA.xml:S1:13605:6	O
post	PRADAXA.xml:S1:13612:4	O
approval	PRADAXA.xml:S1:13617:8	O
use	PRADAXA.xml:S1:13626:3	O
of	PRADAXA.xml:S1:13630:2	O
PRADAXA	PRADAXA.xml:S1:13633:7	O
.	PRADAXA.xml:S1:13640:1	O

Because	PRADAXA.xml:S1:13642:7	O
these	PRADAXA.xml:S1:13650:5	O
reactions	PRADAXA.xml:S1:13656:9	O
are	PRADAXA.xml:S1:13666:3	O
reported	PRADAXA.xml:S1:13670:8	O
voluntarily	PRADAXA.xml:S1:13679:11	O
from	PRADAXA.xml:S1:13691:4	O
a	PRADAXA.xml:S1:13696:1	O
population	PRADAXA.xml:S1:13698:10	O
of	PRADAXA.xml:S1:13709:2	O
uncertain	PRADAXA.xml:S1:13712:9	O
size	PRADAXA.xml:S1:13722:4	O
,	PRADAXA.xml:S1:13726:1	O
it	PRADAXA.xml:S1:13728:2	O
is	PRADAXA.xml:S1:13731:2	O
not	PRADAXA.xml:S1:13734:3	O
always	PRADAXA.xml:S1:13738:6	O
possible	PRADAXA.xml:S1:13745:8	O
to	PRADAXA.xml:S1:13754:2	O
reliably	PRADAXA.xml:S1:13757:8	O
estimate	PRADAXA.xml:S1:13766:8	O
their	PRADAXA.xml:S1:13775:5	O
frequency	PRADAXA.xml:S1:13781:9	O
or	PRADAXA.xml:S1:13791:2	O
establish	PRADAXA.xml:S1:13794:9	O
a	PRADAXA.xml:S1:13804:1	O
causal	PRADAXA.xml:S1:13806:6	O
relationship	PRADAXA.xml:S1:13813:12	O
to	PRADAXA.xml:S1:13826:2	O
drug	PRADAXA.xml:S1:13829:4	O
exposure	PRADAXA.xml:S1:13834:8	O
.	PRADAXA.xml:S1:13842:1	O

The	PRADAXA.xml:S1:13844:3	O
following	PRADAXA.xml:S1:13848:9	O
adverse	PRADAXA.xml:S1:13858:7	O
reactions	PRADAXA.xml:S1:13866:9	O
have	PRADAXA.xml:S1:13876:4	O
been	PRADAXA.xml:S1:13881:4	O
identified	PRADAXA.xml:S1:13886:10	O
during	PRADAXA.xml:S1:13897:6	O
post	PRADAXA.xml:S1:13904:4	O
approval	PRADAXA.xml:S1:13909:8	O
use	PRADAXA.xml:S1:13918:3	O
of	PRADAXA.xml:S1:13922:2	O
PRADAXA	PRADAXA.xml:S1:13925:7	O
:	PRADAXA.xml:S1:13932:1	O
angioedema	PRADAXA.xml:S1:13934:10	B-AdverseReaction
,	PRADAXA.xml:S1:13944:1	O
thrombocytopenia	PRADAXA.xml:S1:13946:16	B-AdverseReaction
,	PRADAXA.xml:S1:13962:1	O
esophageal	PRADAXA.xml:S1:13964:10	B-AdverseReaction
ulcer	PRADAXA.xml:S1:13975:5	I-AdverseReaction
.	PRADAXA.xml:S1:13980:1	O
\n\n	PRADAXA.xml:S2:0:2	O
BOXED	PRADAXA.xml:S2:6:5	O
WARNING	PRADAXA.xml:S2:12:7	O
:	PRADAXA.xml:S2:19:1	O
WARNING	PRADAXA.xml:S2:21:7	O
:	PRADAXA.xml:S2:28:1	O
(	PRADAXA.xml:S2:30:1	O
A	PRADAXA.xml:S2:31:1	O
)	PRADAXA.xml:S2:32:1	O
PREMATURE	PRADAXA.xml:S2:34:9	O
DISCONTINUATION	PRADAXA.xml:S2:44:15	O
OF	PRADAXA.xml:S2:60:2	O
PRADAXA	PRADAXA.xml:S2:63:7	O
INCREASES	PRADAXA.xml:S2:71:9	O
THE	PRADAXA.xml:S2:81:3	O
RISK	PRADAXA.xml:S2:85:4	O
\n\n	PRADAXA.xml:S2:89:2	O
OF	PRADAXA.xml:S2:91:2	O
THROMBOTIC	PRADAXA.xml:S2:94:10	O
EVENTS	PRADAXA.xml:S2:105:6	O
,	PRADAXA.xml:S2:111:1	O
(	PRADAXA.xml:S2:113:1	O
B	PRADAXA.xml:S2:114:1	O
)	PRADAXA.xml:S2:115:1	O
SPINAL	PRADAXA.xml:S2:117:6	B-AdverseReaction
EPIDURAL	PRADAXA.xml:S2:124:8	B-AdverseReaction
HEMATOMA	PRADAXA.xml:S2:133:8	I-AdverseReaction
\n\n	PRADAXA.xml:S2:141:2	O
WARNING	PRADAXA.xml:S2:145:7	O
:	PRADAXA.xml:S2:152:1	O
(	PRADAXA.xml:S2:154:1	O
A	PRADAXA.xml:S2:155:1	O
)	PRADAXA.xml:S2:156:1	O
PREMATURE	PRADAXA.xml:S2:158:9	O
DISCONTINUATION	PRADAXA.xml:S2:168:15	O
OF	PRADAXA.xml:S2:184:2	O
PRADAXA	PRADAXA.xml:S2:187:7	O
INCREASES	PRADAXA.xml:S2:195:9	O
THE	PRADAXA.xml:S2:205:3	O
RISK	PRADAXA.xml:S2:209:4	O
\n\n	PRADAXA.xml:S2:213:2	O
OF	PRADAXA.xml:S2:215:2	O
THROMBOTIC	PRADAXA.xml:S2:218:10	O
EVENTS	PRADAXA.xml:S2:229:6	O
,	PRADAXA.xml:S2:235:1	O
(	PRADAXA.xml:S2:237:1	O
B	PRADAXA.xml:S2:238:1	O
)	PRADAXA.xml:S2:239:1	O
SPINAL	PRADAXA.xml:S2:241:6	B-AdverseReaction
EPIDURAL	PRADAXA.xml:S2:248:8	B-AdverseReaction
HEMATOMA	PRADAXA.xml:S2:257:8	I-AdverseReaction
\n\n	PRADAXA.xml:S2:265:2	O
(	PRADAXA.xml:S2:271:1	O
A	PRADAXA.xml:S2:272:1	O
)	PRADAXA.xml:S2:273:1	O
PREMATURE	PRADAXA.xml:S2:275:9	O
DISCONTINUATION	PRADAXA.xml:S2:285:15	O
\n\n	PRADAXA.xml:S2:300:2	O
OF	PRADAXA.xml:S2:302:2	O
PRADAXA	PRADAXA.xml:S2:305:7	O
INCREASES	PRADAXA.xml:S2:313:9	O
THE	PRADAXA.xml:S2:323:3	O
RISK	PRADAXA.xml:S2:327:4	O
OF	PRADAXA.xml:S2:332:2	O
THROMBOTIC	PRADAXA.xml:S2:335:10	O
EVENTSPremature	PRADAXA.xml:S2:346:15	O
\n\n	PRADAXA.xml:S2:361:2	O
discontinuation	PRADAXA.xml:S2:363:15	O
of	PRADAXA.xml:S2:379:2	O
any	PRADAXA.xml:S2:382:3	O
oral	PRADAXA.xml:S2:386:4	O
anticoagulant	PRADAXA.xml:S2:391:13	O
,	PRADAXA.xml:S2:404:1	O
including	PRADAXA.xml:S2:406:9	O
PRADAXA	PRADAXA.xml:S2:416:7	O
,	PRADAXA.xml:S2:423:1	O
increases	PRADAXA.xml:S2:425:9	O
\n\n	PRADAXA.xml:S2:434:2	O
the	PRADAXA.xml:S2:436:3	O
risk	PRADAXA.xml:S2:440:4	O
of	PRADAXA.xml:S2:445:2	O
thrombotic	PRADAXA.xml:S2:448:10	O
events	PRADAXA.xml:S2:459:6	O
.	PRADAXA.xml:S2:465:1	O

If	PRADAXA.xml:S2:467:2	O
anticoagulation	PRADAXA.xml:S2:470:15	O
with	PRADAXA.xml:S2:486:4	O
PRADAXA	PRADAXA.xml:S2:491:7	O
is	PRADAXA.xml:S2:499:2	O
\n\n	PRADAXA.xml:S2:501:2	O
discontinued	PRADAXA.xml:S2:503:12	O
for	PRADAXA.xml:S2:516:3	O
a	PRADAXA.xml:S2:520:1	O
reason	PRADAXA.xml:S2:522:6	O
other	PRADAXA.xml:S2:529:5	O
than	PRADAXA.xml:S2:535:4	O
pathological	PRADAXA.xml:S2:540:12	O
bleeding	PRADAXA.xml:S2:553:8	O
or	PRADAXA.xml:S2:562:2	O
completion	PRADAXA.xml:S2:565:10	O
\n\n	PRADAXA.xml:S2:575:2	O
of	PRADAXA.xml:S2:577:2	O
a	PRADAXA.xml:S2:580:1	O
course	PRADAXA.xml:S2:582:6	O
of	PRADAXA.xml:S2:589:2	O
therapy	PRADAXA.xml:S2:592:7	O
,	PRADAXA.xml:S2:599:1	O
consider	PRADAXA.xml:S2:601:8	O
coverage	PRADAXA.xml:S2:610:8	O
with	PRADAXA.xml:S2:619:4	O
another	PRADAXA.xml:S2:624:7	O
anticoagulant	PRADAXA.xml:S2:632:13	O
[	PRADAXA.xml:S2:648:1	O
see	PRADAXA.xml:S2:649:3	O
Dosage	PRADAXA.xml:S2:653:6	O
and	PRADAXA.xml:S2:660:3	O
Administration	PRADAXA.xml:S2:664:14	O
(	PRADAXA.xml:S2:681:1	O
2.4	PRADAXA.xml:S2:682:3	O
,	PRADAXA.xml:S2:687:1	O
2.5	PRADAXA.xml:S2:691:3	O
,	PRADAXA.xml:S2:696:1	O
2.6	PRADAXA.xml:S2:700:3	O
)	PRADAXA.xml:S2:703:1	O
and	PRADAXA.xml:S2:707:3	O
Warnings	PRADAXA.xml:S2:711:8	O
and	PRADAXA.xml:S2:720:3	O
Precautions	PRADAXA.xml:S2:724:11	O
(	PRADAXA.xml:S2:738:1	O
5.1	PRADAXA.xml:S2:739:3	O
)	PRADAXA.xml:S2:742:1	O
]	PRADAXA.xml:S2:745:1	O
.	PRADAXA.xml:S2:748:1	O

(	PRADAXA.xml:S2:753:1	O
B	PRADAXA.xml:S2:754:1	O
)	PRADAXA.xml:S2:755:1	O
SPINAL	PRADAXA.xml:S2:757:6	O
EPIDURAL	PRADAXA.xml:S2:764:8	O
\n\n	PRADAXA.xml:S2:772:2	O
HEMATOMAEpidural	PRADAXA.xml:S2:774:16	B-AdverseReaction
or	PRADAXA.xml:S2:791:2	O
spinal	PRADAXA.xml:S2:794:6	B-AdverseReaction
hematomas	PRADAXA.xml:S2:801:9	I-AdverseReaction
may	PRADAXA.xml:S2:811:3	B-Factor
occur	PRADAXA.xml:S2:815:5	O
in	PRADAXA.xml:S2:821:2	O
patients	PRADAXA.xml:S2:824:8	O
\n\n	PRADAXA.xml:S2:832:2	O
treated	PRADAXA.xml:S2:834:7	O
with	PRADAXA.xml:S2:842:4	O
PRADAXA	PRADAXA.xml:S2:847:7	O
who	PRADAXA.xml:S2:855:3	O
are	PRADAXA.xml:S2:859:3	O
receiving	PRADAXA.xml:S2:863:9	O
neuraxial	PRADAXA.xml:S2:873:9	O
anesthesia	PRADAXA.xml:S2:883:10	O
or	PRADAXA.xml:S2:894:2	O
undergoing	PRADAXA.xml:S2:897:10	O
\n\n	PRADAXA.xml:S2:907:2	O
spinal	PRADAXA.xml:S2:909:6	O
puncture	PRADAXA.xml:S2:916:8	O
.	PRADAXA.xml:S2:924:1	O

These	PRADAXA.xml:S2:926:5	O
hematomas	PRADAXA.xml:S2:932:9	B-AdverseReaction
may	PRADAXA.xml:S2:942:3	B-Factor
result	PRADAXA.xml:S2:946:6	O
in	PRADAXA.xml:S2:953:2	O
long	PRADAXA.xml:S2:956:4	B-AdverseReaction
-	PRADAXA.xml:S2:960:1	I-AdverseReaction
term	PRADAXA.xml:S2:961:4	I-AdverseReaction
or	PRADAXA.xml:S2:966:2	O
permanent	PRADAXA.xml:S2:969:9	B-AdverseReaction
\n\n	PRADAXA.xml:S2:978:2	I-AdverseReaction
paralysis	PRADAXA.xml:S2:980:9	I-AdverseReaction
.	PRADAXA.xml:S2:989:1	O

Consider	PRADAXA.xml:S2:991:8	O
these	PRADAXA.xml:S2:1000:5	O
risks	PRADAXA.xml:S2:1006:5	O
when	PRADAXA.xml:S2:1012:4	O
scheduling	PRADAXA.xml:S2:1017:10	O
patients	PRADAXA.xml:S2:1028:8	O
for	PRADAXA.xml:S2:1037:3	O
spinal	PRADAXA.xml:S2:1041:6	O
\n\n	PRADAXA.xml:S2:1047:2	O
procedures	PRADAXA.xml:S2:1049:10	O
.	PRADAXA.xml:S2:1059:1	O

Factors	PRADAXA.xml:S2:1061:7	O
that	PRADAXA.xml:S2:1069:4	O
can	PRADAXA.xml:S2:1074:3	O
increase	PRADAXA.xml:S2:1078:8	O
the	PRADAXA.xml:S2:1087:3	O
risk	PRADAXA.xml:S2:1091:4	O
of	PRADAXA.xml:S2:1096:2	O
developing	PRADAXA.xml:S2:1099:10	O
epidural	PRADAXA.xml:S2:1110:8	O
\n\n	PRADAXA.xml:S2:1118:2	O
or	PRADAXA.xml:S2:1120:2	O
spinal	PRADAXA.xml:S2:1123:6	O
hematomas	PRADAXA.xml:S2:1130:9	O
in	PRADAXA.xml:S2:1140:2	O
these	PRADAXA.xml:S2:1143:5	O
patients	PRADAXA.xml:S2:1149:8	O
include	PRADAXA.xml:S2:1158:7	O
:	PRADAXA.xml:S2:1165:1	O
\n\n\n\n	PRADAXA.xml:S2:1168:4	O
use	PRADAXA.xml:S2:1177:3	O
of	PRADAXA.xml:S2:1181:2	O
indwelling	PRADAXA.xml:S2:1184:10	O
epidural	PRADAXA.xml:S2:1195:8	O
catheters	PRADAXA.xml:S2:1204:9	O
concomitant	PRADAXA.xml:S2:1215:11	O
use	PRADAXA.xml:S2:1227:3	O
of	PRADAXA.xml:S2:1231:2	O
other	PRADAXA.xml:S2:1234:5	O
drugs	PRADAXA.xml:S2:1240:5	O
that	PRADAXA.xml:S2:1246:4	O
affect	PRADAXA.xml:S2:1251:6	O
hemostasis	PRADAXA.xml:S2:1258:10	O
,	PRADAXA.xml:S2:1268:1	O
such	PRADAXA.xml:S2:1270:4	O
as	PRADAXA.xml:S2:1275:2	O
\n\n	PRADAXA.xml:S2:1277:2	O
non	PRADAXA.xml:S2:1279:3	O
-	PRADAXA.xml:S2:1282:1	O
steroidal	PRADAXA.xml:S2:1283:9	O
anti	PRADAXA.xml:S2:1293:4	O
-	PRADAXA.xml:S2:1297:1	O
inflammatory	PRADAXA.xml:S2:1298:12	O
drugs	PRADAXA.xml:S2:1311:5	O
(	PRADAXA.xml:S2:1317:1	O
NSAIDs	PRADAXA.xml:S2:1318:6	O
)	PRADAXA.xml:S2:1324:1	O
,	PRADAXA.xml:S2:1325:1	O
platelet	PRADAXA.xml:S2:1327:8	O
inhibitors	PRADAXA.xml:S2:1336:10	O
,	PRADAXA.xml:S2:1346:1	O
\n\n	PRADAXA.xml:S2:1347:2	O
other	PRADAXA.xml:S2:1349:5	O
anticoagulants	PRADAXA.xml:S2:1355:14	O
a	PRADAXA.xml:S2:1371:1	O
history	PRADAXA.xml:S2:1373:7	O
of	PRADAXA.xml:S2:1381:2	O
traumatic	PRADAXA.xml:S2:1384:9	O
or	PRADAXA.xml:S2:1394:2	O
repeated	PRADAXA.xml:S2:1397:8	O
\n\n	PRADAXA.xml:S2:1405:2	O
epidural	PRADAXA.xml:S2:1407:8	O
or	PRADAXA.xml:S2:1416:2	O
spinal	PRADAXA.xml:S2:1419:6	O
punctures	PRADAXA.xml:S2:1426:9	O
a	PRADAXA.xml:S2:1437:1	O
history	PRADAXA.xml:S2:1439:7	O
of	PRADAXA.xml:S2:1447:2	O
spinal	PRADAXA.xml:S2:1450:6	O
deformity	PRADAXA.xml:S2:1457:9	O
\n\n	PRADAXA.xml:S2:1466:2	O
or	PRADAXA.xml:S2:1468:2	O
spinal	PRADAXA.xml:S2:1471:6	O
surgery	PRADAXA.xml:S2:1478:7	O
optimal	PRADAXA.xml:S2:1487:7	O
timing	PRADAXA.xml:S2:1495:6	O
between	PRADAXA.xml:S2:1502:7	O
the	PRADAXA.xml:S2:1510:3	O
administration	PRADAXA.xml:S2:1514:14	O
\n\n	PRADAXA.xml:S2:1528:2	O
of	PRADAXA.xml:S2:1530:2	O
PRADAXA	PRADAXA.xml:S2:1533:7	O
and	PRADAXA.xml:S2:1541:3	O
neuraxial	PRADAXA.xml:S2:1545:9	O
procedures	PRADAXA.xml:S2:1555:10	O
is	PRADAXA.xml:S2:1566:2	O
not	PRADAXA.xml:S2:1569:3	O
known	PRADAXA.xml:S2:1573:5	O
[	PRADAXA.xml:S2:1581:1	O
see	PRADAXA.xml:S2:1582:3	O
Warnings	PRADAXA.xml:S2:1586:8	O
\n\n	PRADAXA.xml:S2:1594:2	O
and	PRADAXA.xml:S2:1596:3	O
Precautions	PRADAXA.xml:S2:1600:11	O
(	PRADAXA.xml:S2:1614:1	O
5.3	PRADAXA.xml:S2:1615:3	O
)	PRADAXA.xml:S2:1618:1	O
]	PRADAXA.xml:S2:1621:1	O
.	PRADAXA.xml:S2:1624:1	O

Monitor	PRADAXA.xml:S2:1634:7	O
patients	PRADAXA.xml:S2:1642:8	O
\n\n	PRADAXA.xml:S2:1650:2	O
frequently	PRADAXA.xml:S2:1652:10	O
for	PRADAXA.xml:S2:1663:3	O
signs	PRADAXA.xml:S2:1667:5	O
and	PRADAXA.xml:S2:1673:3	O
symptoms	PRADAXA.xml:S2:1677:8	O
of	PRADAXA.xml:S2:1686:2	O
neurological	PRADAXA.xml:S2:1689:12	O
impairment	PRADAXA.xml:S2:1702:10	O
.	PRADAXA.xml:S2:1712:1	O

If	PRADAXA.xml:S2:1714:2	O
neurological	PRADAXA.xml:S2:1717:12	O
\n\n	PRADAXA.xml:S2:1729:2	O
compromise	PRADAXA.xml:S2:1731:10	O
is	PRADAXA.xml:S2:1742:2	O
noted	PRADAXA.xml:S2:1745:5	O
,	PRADAXA.xml:S2:1750:1	O
urgent	PRADAXA.xml:S2:1752:6	O
treatment	PRADAXA.xml:S2:1759:9	O
is	PRADAXA.xml:S2:1769:2	O
necessary	PRADAXA.xml:S2:1772:9	O
[	PRADAXA.xml:S2:1784:1	O
see	PRADAXA.xml:S2:1785:3	O
Warnings	PRADAXA.xml:S2:1789:8	O
\n\n	PRADAXA.xml:S2:1797:2	O
and	PRADAXA.xml:S2:1799:3	O
Precautions	PRADAXA.xml:S2:1803:11	O
(	PRADAXA.xml:S2:1817:1	O
5.3	PRADAXA.xml:S2:1818:3	O
)	PRADAXA.xml:S2:1821:1	O
]	PRADAXA.xml:S2:1824:1	O
.	PRADAXA.xml:S2:1827:1	O
Consider	PRADAXA.xml:S2:1828:8	O
the	PRADAXA.xml:S2:1837:3	O
benefits	PRADAXA.xml:S2:1841:8	O
and	PRADAXA.xml:S2:1850:3	O
risks	PRADAXA.xml:S2:1854:5	O
before	PRADAXA.xml:S2:1860:6	O
neuraxial	PRADAXA.xml:S2:1867:9	O
intervention	PRADAXA.xml:S2:1877:12	O
\n\n	PRADAXA.xml:S2:1889:2	O
in	PRADAXA.xml:S2:1891:2	O
patients	PRADAXA.xml:S2:1894:8	O
anticoagulated	PRADAXA.xml:S2:1903:14	O
or	PRADAXA.xml:S2:1918:2	O
to	PRADAXA.xml:S2:1921:2	O
be	PRADAXA.xml:S2:1924:2	O
anticoagulated	PRADAXA.xml:S2:1927:14	O
[	PRADAXA.xml:S2:1944:1	O
see	PRADAXA.xml:S2:1945:3	O
Warnings	PRADAXA.xml:S2:1949:8	O
\n\n	PRADAXA.xml:S2:1957:2	O
and	PRADAXA.xml:S2:1959:3	O
Precautions	PRADAXA.xml:S2:1963:11	O
(	PRADAXA.xml:S2:1977:1	O
5.3	PRADAXA.xml:S2:1978:3	O
)	PRADAXA.xml:S2:1981:1	O
]	PRADAXA.xml:S2:1984:1	O
.	PRADAXA.xml:S2:1987:1	O

EXCERPT	PRADAXA.xml:S2:1997:7	O
:	PRADAXA.xml:S2:2004:1	O
WARNING	PRADAXA.xml:S2:2010:7	O
:	PRADAXA.xml:S2:2017:1	O
(	PRADAXA.xml:S2:2019:1	O
A	PRADAXA.xml:S2:2020:1	O
)	PRADAXA.xml:S2:2021:1	O
PREMATURE	PRADAXA.xml:S2:2023:9	O
DISCONTINUATION	PRADAXA.xml:S2:2033:15	O
\n\n	PRADAXA.xml:S2:2048:2	O
OF	PRADAXA.xml:S2:2050:2	O
PRADAXA	PRADAXA.xml:S2:2053:7	O
INCREASES	PRADAXA.xml:S2:2061:9	O
THE	PRADAXA.xml:S2:2071:3	O
RISK	PRADAXA.xml:S2:2075:4	O
OF	PRADAXA.xml:S2:2080:2	O
THROMBOTIC	PRADAXA.xml:S2:2083:10	O
EVENTS	PRADAXA.xml:S2:2094:6	O
,	PRADAXA.xml:S2:2100:1	O
and	PRADAXA.xml:S2:2102:3	O
(	PRADAXA.xml:S2:2106:1	O
B	PRADAXA.xml:S2:2107:1	O
)	PRADAXA.xml:S2:2108:1	O
SPINAL	PRADAXA.xml:S2:2110:6	B-AdverseReaction
EPIDURAL	PRADAXA.xml:S2:2117:8	B-AdverseReaction
\n\n	PRADAXA.xml:S2:2125:2	I-AdverseReaction
HEMATOMA	PRADAXA.xml:S2:2127:8	I-AdverseReaction
See	PRADAXA.xml:S2:2139:3	O
full	PRADAXA.xml:S2:2143:4	O
prescribing	PRADAXA.xml:S2:2148:11	O
information	PRADAXA.xml:S2:2160:11	O
\n\n	PRADAXA.xml:S2:2171:2	O
for	PRADAXA.xml:S2:2173:3	O
complete	PRADAXA.xml:S2:2177:8	O
boxed	PRADAXA.xml:S2:2186:5	O
warning	PRADAXA.xml:S2:2192:7	O
(	PRADAXA.xml:S2:2203:1	O
A	PRADAXA.xml:S2:2204:1	O
)\n\n	PRADAXA.xml:S2:2205:3	O
PREMATURE	PRADAXA.xml:S2:2208:9	O
DISCONTINUATION	PRADAXA.xml:S2:2218:15	O
OF	PRADAXA.xml:S2:2234:2	O
PRADAXA	PRADAXA.xml:S2:2237:7	O
INCREASES	PRADAXA.xml:S2:2245:9	O
THE	PRADAXA.xml:S2:2255:3	O
RISK	PRADAXA.xml:S2:2259:4	O
OF	PRADAXA.xml:S2:2264:2	O
THROMBOTIC	PRADAXA.xml:S2:2267:10	O
\n\n	PRADAXA.xml:S2:2277:2	O
EVENTS	PRADAXA.xml:S2:2279:6	O
:	PRADAXA.xml:S2:2285:1	O
Premature	PRADAXA.xml:S2:2287:9	O
discontinuation	PRADAXA.xml:S2:2297:15	O
of	PRADAXA.xml:S2:2313:2	O
any	PRADAXA.xml:S2:2316:3	O
oral	PRADAXA.xml:S2:2320:4	O
anticoagulant	PRADAXA.xml:S2:2325:13	O
,	PRADAXA.xml:S2:2338:1	O
including	PRADAXA.xml:S2:2340:9	O
\n\n	PRADAXA.xml:S2:2349:2	O
PRADAXA	PRADAXA.xml:S2:2351:7	O
,	PRADAXA.xml:S2:2358:1	O
increases	PRADAXA.xml:S2:2360:9	O
the	PRADAXA.xml:S2:2370:3	O
risk	PRADAXA.xml:S2:2374:4	O
of	PRADAXA.xml:S2:2379:2	O
thrombotic	PRADAXA.xml:S2:2382:10	O
events	PRADAXA.xml:S2:2393:6	O
.	PRADAXA.xml:S2:2399:1	O

To	PRADAXA.xml:S2:2402:2	O
reduce	PRADAXA.xml:S2:2405:6	O
this	PRADAXA.xml:S2:2412:4	O
\n\n	PRADAXA.xml:S2:2416:2	O
risk	PRADAXA.xml:S2:2418:4	O
,	PRADAXA.xml:S2:2422:1	O
consider	PRADAXA.xml:S2:2424:8	O
coverage	PRADAXA.xml:S2:2433:8	O
with	PRADAXA.xml:S2:2442:4	O
another	PRADAXA.xml:S2:2447:7	O
anticoagulant	PRADAXA.xml:S2:2455:13	O
if	PRADAXA.xml:S2:2469:2	O
PRADAXA	PRADAXA.xml:S2:2472:7	O
is	PRADAXA.xml:S2:2480:2	O
discontinued	PRADAXA.xml:S2:2483:12	O
\n\n	PRADAXA.xml:S2:2495:2	O
for	PRADAXA.xml:S2:2497:3	O
a	PRADAXA.xml:S2:2501:1	O
reason	PRADAXA.xml:S2:2503:6	O
other	PRADAXA.xml:S2:2510:5	O
than	PRADAXA.xml:S2:2516:4	O
pathological	PRADAXA.xml:S2:2521:12	O
bleeding	PRADAXA.xml:S2:2534:8	O
or	PRADAXA.xml:S2:2543:2	O
completion	PRADAXA.xml:S2:2546:10	O
of	PRADAXA.xml:S2:2557:2	O
a	PRADAXA.xml:S2:2560:1	O
course	PRADAXA.xml:S2:2562:6	O
\n\n	PRADAXA.xml:S2:2568:2	O
of	PRADAXA.xml:S2:2570:2	O
therapy	PRADAXA.xml:S2:2573:7	O
(	PRADAXA.xml:S2:2581:1	O
2.4	PRADAXA.xml:S2:2584:3	O
,	PRADAXA.xml:S2:2589:1	O
2.5	PRADAXA.xml:S2:2593:3	O
,	PRADAXA.xml:S2:2598:1	O
2.6	PRADAXA.xml:S2:2602:3	O
,	PRADAXA.xml:S2:2607:1	O
5.1	PRADAXA.xml:S2:2611:3	O
)	PRADAXA.xml:S2:2616:1	O
.	PRADAXA.xml:S2:2617:1	O

(	PRADAXA.xml:S2:2622:1	O
B	PRADAXA.xml:S2:2623:1	O
)	PRADAXA.xml:S2:2624:1	O
SPINAL	PRADAXA.xml:S2:2626:6	O
EPIDURAL	PRADAXA.xml:S2:2633:8	O
HEMATOMA	PRADAXA.xml:S2:2642:8	O
:	PRADAXA.xml:S2:2650:1	O
Epidural	PRADAXA.xml:S2:2652:8	B-AdverseReaction
or	PRADAXA.xml:S2:2661:2	O
spinal	PRADAXA.xml:S2:2664:6	B-AdverseReaction
hematomas	PRADAXA.xml:S2:2671:9	I-AdverseReaction
\n\n	PRADAXA.xml:S2:2680:2	O
may	PRADAXA.xml:S2:2682:3	B-Factor
occur	PRADAXA.xml:S2:2686:5	O
in	PRADAXA.xml:S2:2692:2	O
patients	PRADAXA.xml:S2:2695:8	O
treated	PRADAXA.xml:S2:2704:7	O
with	PRADAXA.xml:S2:2712:4	O
PRADAXA	PRADAXA.xml:S2:2717:7	O
who	PRADAXA.xml:S2:2725:3	O
are	PRADAXA.xml:S2:2729:3	O
receiving	PRADAXA.xml:S2:2733:9	O
neuraxial	PRADAXA.xml:S2:2743:9	O
\n\n	PRADAXA.xml:S2:2752:2	O
anesthesia	PRADAXA.xml:S2:2754:10	O
or	PRADAXA.xml:S2:2765:2	O
undergoing	PRADAXA.xml:S2:2768:10	O
spinal	PRADAXA.xml:S2:2779:6	O
puncture	PRADAXA.xml:S2:2786:8	O
.	PRADAXA.xml:S2:2794:1	O

These	PRADAXA.xml:S2:2796:5	O
hematomas	PRADAXA.xml:S2:2802:9	B-AdverseReaction
may	PRADAXA.xml:S2:2812:3	B-Factor
result	PRADAXA.xml:S2:2816:6	O
\n\n	PRADAXA.xml:S2:2822:2	O
in	PRADAXA.xml:S2:2824:2	O
long	PRADAXA.xml:S2:2827:4	B-AdverseReaction
-	PRADAXA.xml:S2:2831:1	I-AdverseReaction
term	PRADAXA.xml:S2:2832:4	I-AdverseReaction
or	PRADAXA.xml:S2:2837:2	O
permanent	PRADAXA.xml:S2:2840:9	B-AdverseReaction
paralysis	PRADAXA.xml:S2:2850:9	I-AdverseReaction
(	PRADAXA.xml:S2:2860:1	O
5.3	PRADAXA.xml:S2:2863:3	O
)	PRADAXA.xml:S2:2868:1	O
.	PRADAXA.xml:S2:2869:1	O

Monitor	PRADAXA.xml:S2:2871:7	O
patients	PRADAXA.xml:S2:2879:8	O
frequently	PRADAXA.xml:S2:2888:10	O
for	PRADAXA.xml:S2:2899:3	O
signs	PRADAXA.xml:S2:2903:5	O
and	PRADAXA.xml:S2:2909:3	O
symptoms	PRADAXA.xml:S2:2913:8	O
of	PRADAXA.xml:S2:2922:2	O
neurological	PRADAXA.xml:S2:2925:12	O
\n\n	PRADAXA.xml:S2:2937:2	O
impairment	PRADAXA.xml:S2:2939:10	O
and	PRADAXA.xml:S2:2950:3	O
if	PRADAXA.xml:S2:2954:2	O
observed	PRADAXA.xml:S2:2957:8	O
,	PRADAXA.xml:S2:2965:1	O
treat	PRADAXA.xml:S2:2967:5	O
urgently	PRADAXA.xml:S2:2973:8	O
.	PRADAXA.xml:S2:2981:1	O

Consider	PRADAXA.xml:S2:2983:8	O
the	PRADAXA.xml:S2:2992:3	O
benefits	PRADAXA.xml:S2:2996:8	O
\n\n	PRADAXA.xml:S2:3004:2	O
and	PRADAXA.xml:S2:3006:3	O
risks	PRADAXA.xml:S2:3010:5	O
before	PRADAXA.xml:S2:3016:6	O
neuraxial	PRADAXA.xml:S2:3023:9	O
intervention	PRADAXA.xml:S2:3033:12	O
in	PRADAXA.xml:S2:3046:2	O
patients	PRADAXA.xml:S2:3049:8	O
who	PRADAXA.xml:S2:3058:3	O
are	PRADAXA.xml:S2:3062:3	O
or	PRADAXA.xml:S2:3066:2	O
who	PRADAXA.xml:S2:3069:3	O
\n\n	PRADAXA.xml:S2:3072:2	O
need	PRADAXA.xml:S2:3074:4	O
to	PRADAXA.xml:S2:3079:2	O
be	PRADAXA.xml:S2:3082:2	O
anticoagulated	PRADAXA.xml:S2:3085:14	O
(	PRADAXA.xml:S2:3100:1	O
5.3	PRADAXA.xml:S2:3103:3	O
)	PRADAXA.xml:S2:3108:1	O
.	PRADAXA.xml:S2:3109:1	O
\n	PRADAXA.xml:S2:3112:1	O
5	PRADAXA.xml:S3:4:1	O
WARNINGS	PRADAXA.xml:S3:7:8	O
AND	PRADAXA.xml:S3:16:3	O
PRECAUTIONS	PRADAXA.xml:S3:20:11	O

EXCERPT	PRADAXA.xml:S3:38:7	O
:	PRADAXA.xml:S3:45:1	O
Bleeding	PRADAXA.xml:S3:53:8	B-AdverseReaction
:	PRADAXA.xml:S3:61:1	O
PRADAXA	PRADAXA.xml:S3:63:7	O
can	PRADAXA.xml:S3:71:3	B-Factor
cause	PRADAXA.xml:S3:75:5	O
serious	PRADAXA.xml:S3:81:7	B-Severity
and	PRADAXA.xml:S3:89:3	O
fatal	PRADAXA.xml:S3:93:5	B-AdverseReaction
bleeding	PRADAXA.xml:S3:99:8	B-AdverseReaction
(	PRADAXA.xml:S3:109:1	O
5.2	PRADAXA.xml:S3:110:3	O
)	PRADAXA.xml:S3:113:1	O

Bioprosthetic	PRADAXA.xml:S3:122:13	O
heart	PRADAXA.xml:S3:136:5	O
valves	PRADAXA.xml:S3:142:6	O
:	PRADAXA.xml:S3:148:1	O
PRADAXA	PRADAXA.xml:S3:150:7	O
use	PRADAXA.xml:S3:158:3	O
not	PRADAXA.xml:S3:162:3	O
recommended	PRADAXA.xml:S3:166:11	O
(	PRADAXA.xml:S3:179:1	O
5.4	PRADAXA.xml:S3:180:3	O
)	PRADAXA.xml:S3:183:1	O

5.1	PRADAXA.xml:S3:199:3	O

Increased	PRADAXA.xml:S3:203:9	O

Risk	PRADAXA.xml:S3:213:4	O
of	PRADAXA.xml:S3:218:2	O
Thrombotic	PRADAXA.xml:S3:221:10	O
Events	PRADAXA.xml:S3:232:6	O
after	PRADAXA.xml:S3:239:5	O
Premature	PRADAXA.xml:S3:245:9	O
Discontinuation	PRADAXA.xml:S3:255:15	O

Premature	PRADAXA.xml:S3:276:9	O
discontinuation	PRADAXA.xml:S3:286:15	O
of	PRADAXA.xml:S3:302:2	O
any	PRADAXA.xml:S3:305:3	O
oral	PRADAXA.xml:S3:309:4	O
anticoagulant	PRADAXA.xml:S3:314:13	O
,	PRADAXA.xml:S3:327:1	O
including	PRADAXA.xml:S3:329:9	O
PRADAXA	PRADAXA.xml:S3:339:7	O
,	PRADAXA.xml:S3:346:1	O
in	PRADAXA.xml:S3:348:2	O
the	PRADAXA.xml:S3:351:3	O
absence	PRADAXA.xml:S3:355:7	O
of	PRADAXA.xml:S3:363:2	O
adequate	PRADAXA.xml:S3:366:8	O
alternative	PRADAXA.xml:S3:375:11	O
anticoagulation	PRADAXA.xml:S3:387:15	O
increases	PRADAXA.xml:S3:403:9	O
the	PRADAXA.xml:S3:413:3	O
risk	PRADAXA.xml:S3:417:4	O
of	PRADAXA.xml:S3:422:2	O
thrombotic	PRADAXA.xml:S3:425:10	O
events	PRADAXA.xml:S3:436:6	O
.	PRADAXA.xml:S3:442:1	O

If	PRADAXA.xml:S3:444:2	O
PRADAXA	PRADAXA.xml:S3:447:7	O
is	PRADAXA.xml:S3:455:2	O
discontinued	PRADAXA.xml:S3:458:12	O
for	PRADAXA.xml:S3:471:3	O
a	PRADAXA.xml:S3:475:1	O
reason	PRADAXA.xml:S3:477:6	O
other	PRADAXA.xml:S3:484:5	O
than	PRADAXA.xml:S3:490:4	O
pathological	PRADAXA.xml:S3:495:12	O
bleeding	PRADAXA.xml:S3:508:8	O
or	PRADAXA.xml:S3:517:2	O
completion	PRADAXA.xml:S3:520:10	O
of	PRADAXA.xml:S3:531:2	O
a	PRADAXA.xml:S3:534:1	O
course	PRADAXA.xml:S3:536:6	O
of	PRADAXA.xml:S3:543:2	O
therapy	PRADAXA.xml:S3:546:7	O
,	PRADAXA.xml:S3:553:1	O
consider	PRADAXA.xml:S3:555:8	O
coverage	PRADAXA.xml:S3:564:8	O
with	PRADAXA.xml:S3:573:4	O
another	PRADAXA.xml:S3:578:7	O
anticoagulant	PRADAXA.xml:S3:586:13	O
[	PRADAXA.xml:S3:600:1	O
see	PRADAXA.xml:S3:601:3	O
Dosage	PRADAXA.xml:S3:605:6	O
and	PRADAXA.xml:S3:612:3	O
Administration	PRADAXA.xml:S3:616:14	O
(	PRADAXA.xml:S3:632:1	O
2.4	PRADAXA.xml:S3:633:3	O
,	PRADAXA.xml:S3:638:1	O
2.5	PRADAXA.xml:S3:641:3	O
,	PRADAXA.xml:S3:646:1	O
2.6	PRADAXA.xml:S3:649:3	O
)	PRADAXA.xml:S3:652:1	O
]	PRADAXA.xml:S3:655:1	O
.	PRADAXA.xml:S3:656:1	O

5.2	PRADAXA.xml:S3:667:3	O
Risk	PRADAXA.xml:S3:671:4	O
of	PRADAXA.xml:S3:676:2	O
Bleeding	PRADAXA.xml:S3:679:8	O

PRADAXA	PRADAXA.xml:S3:693:7	O
increases	PRADAXA.xml:S3:701:9	O
the	PRADAXA.xml:S3:711:3	O
risk	PRADAXA.xml:S3:715:4	B-Factor
of	PRADAXA.xml:S3:720:2	O
bleeding	PRADAXA.xml:S3:723:8	B-AdverseReaction
and	PRADAXA.xml:S3:732:3	O
can	PRADAXA.xml:S3:736:3	B-Factor
cause	PRADAXA.xml:S3:740:5	O
significant	PRADAXA.xml:S3:746:11	B-Severity
and	PRADAXA.xml:S3:758:3	O
,	PRADAXA.xml:S3:761:1	O
sometimes	PRADAXA.xml:S3:763:9	O
,	PRADAXA.xml:S3:772:1	O
fatal	PRADAXA.xml:S3:774:5	B-AdverseReaction
bleeding	PRADAXA.xml:S3:780:8	B-AdverseReaction
.	PRADAXA.xml:S3:788:1	O

Promptly	PRADAXA.xml:S3:790:8	O
evaluate	PRADAXA.xml:S3:799:8	O
any	PRADAXA.xml:S3:808:3	O
signs	PRADAXA.xml:S3:812:5	O
or	PRADAXA.xml:S3:818:2	O
symptoms	PRADAXA.xml:S3:821:8	O
of	PRADAXA.xml:S3:830:2	O
blood	PRADAXA.xml:S3:833:5	O
loss	PRADAXA.xml:S3:839:4	O
(	PRADAXA.xml:S3:844:1	O
e	PRADAXA.xml:S3:845:1	O
.	PRADAXA.xml:S3:846:1	O
g	PRADAXA.xml:S3:847:1	O
.	PRADAXA.xml:S3:848:1	O
,	PRADAXA.xml:S3:849:1	O
a	PRADAXA.xml:S3:851:1	O
drop	PRADAXA.xml:S3:853:4	O
in	PRADAXA.xml:S3:858:2	O
hemoglobin	PRADAXA.xml:S3:861:10	O
and	PRADAXA.xml:S3:872:3	O
or	PRADAXA.xml:S3:876:2	O
hematocrit	PRADAXA.xml:S3:879:10	O
or	PRADAXA.xml:S3:890:2	O
hypotension	PRADAXA.xml:S3:893:11	O
)	PRADAXA.xml:S3:904:1	O
.	PRADAXA.xml:S3:905:1	O

Discontinue	PRADAXA.xml:S3:907:11	O
PRADAXA	PRADAXA.xml:S3:919:7	O
in	PRADAXA.xml:S3:927:2	O
patients	PRADAXA.xml:S3:930:8	O
with	PRADAXA.xml:S3:939:4	O
active	PRADAXA.xml:S3:944:6	O
pathological	PRADAXA.xml:S3:951:12	O
bleeding	PRADAXA.xml:S3:964:8	O
[	PRADAXA.xml:S3:974:1	O
see	PRADAXA.xml:S3:975:3	O
Dosage	PRADAXA.xml:S3:979:6	O
and	PRADAXA.xml:S3:986:3	O
Administration	PRADAXA.xml:S3:990:14	O
(	PRADAXA.xml:S3:1006:1	O
2.2	PRADAXA.xml:S3:1007:3	O
)	PRADAXA.xml:S3:1010:1	O
]	PRADAXA.xml:S3:1013:1	O
.	PRADAXA.xml:S3:1018:1	O

Risk	PRADAXA.xml:S3:1024:4	O
factors	PRADAXA.xml:S3:1029:7	O
for	PRADAXA.xml:S3:1037:3	O
bleeding	PRADAXA.xml:S3:1041:8	O
include	PRADAXA.xml:S3:1050:7	O
the	PRADAXA.xml:S3:1058:3	O
concomitant	PRADAXA.xml:S3:1062:11	O
use	PRADAXA.xml:S3:1074:3	O
of	PRADAXA.xml:S3:1078:2	O
other	PRADAXA.xml:S3:1081:5	O
drugs	PRADAXA.xml:S3:1087:5	O
that	PRADAXA.xml:S3:1093:4	O
increase	PRADAXA.xml:S3:1098:8	O
the	PRADAXA.xml:S3:1107:3	O
risk	PRADAXA.xml:S3:1111:4	O
of	PRADAXA.xml:S3:1116:2	O
bleeding	PRADAXA.xml:S3:1119:8	O
(	PRADAXA.xml:S3:1128:1	O
e	PRADAXA.xml:S3:1129:1	O
.	PRADAXA.xml:S3:1130:1	O
g	PRADAXA.xml:S3:1131:1	O
.	PRADAXA.xml:S3:1132:1	O
,	PRADAXA.xml:S3:1133:1	O
anti	PRADAXA.xml:S3:1135:4	O
-	PRADAXA.xml:S3:1139:1	O
platelet	PRADAXA.xml:S3:1140:8	O
agents	PRADAXA.xml:S3:1149:6	O
,	PRADAXA.xml:S3:1155:1	O
heparin	PRADAXA.xml:S3:1157:7	O
,	PRADAXA.xml:S3:1164:1	O
fibrinolytic	PRADAXA.xml:S3:1166:12	O
therapy	PRADAXA.xml:S3:1179:7	O
,	PRADAXA.xml:S3:1186:1	O
and	PRADAXA.xml:S3:1188:3	O
chronic	PRADAXA.xml:S3:1192:7	O
use	PRADAXA.xml:S3:1200:3	O
of	PRADAXA.xml:S3:1204:2	O
NSAIDs	PRADAXA.xml:S3:1207:6	O
)	PRADAXA.xml:S3:1213:1	O
.	PRADAXA.xml:S3:1214:1	O

PRADAXA	PRADAXA.xml:S3:1216:7	O
's	PRADAXA.xml:S3:1223:2	O
anticoagulant	PRADAXA.xml:S3:1226:13	O
activity	PRADAXA.xml:S3:1240:8	O
and	PRADAXA.xml:S3:1249:3	O
half	PRADAXA.xml:S3:1253:4	O
-	PRADAXA.xml:S3:1257:1	O
life	PRADAXA.xml:S3:1258:4	O
are	PRADAXA.xml:S3:1263:3	O
increased	PRADAXA.xml:S3:1267:9	O
in	PRADAXA.xml:S3:1277:2	O
patients	PRADAXA.xml:S3:1280:8	O
with	PRADAXA.xml:S3:1289:4	O
renal	PRADAXA.xml:S3:1294:5	O
impairment	PRADAXA.xml:S3:1300:10	O
[	PRADAXA.xml:S3:1312:1	O
see	PRADAXA.xml:S3:1313:3	O
Clinical	PRADAXA.xml:S3:1317:8	O
Pharmacology	PRADAXA.xml:S3:1326:12	O
(	PRADAXA.xml:S3:1340:1	O
12.2	PRADAXA.xml:S3:1341:4	O
)	PRADAXA.xml:S3:1345:1	O
]	PRADAXA.xml:S3:1348:1	O
.	PRADAXA.xml:S3:1353:1	O

Reversal	PRADAXA.xml:S3:1360:8	O
of	PRADAXA.xml:S3:1369:2	O
Anticoagulant	PRADAXA.xml:S3:1372:13	O
Effect	PRADAXA.xml:S3:1386:6	O
:	PRADAXA.xml:S3:1392:1	O
A	PRADAXA.xml:S3:1395:1	O
specific	PRADAXA.xml:S3:1397:8	O
reversal	PRADAXA.xml:S3:1406:8	O
agent	PRADAXA.xml:S3:1415:5	O
for	PRADAXA.xml:S3:1421:3	O
dabigatran	PRADAXA.xml:S3:1425:10	O
is	PRADAXA.xml:S3:1436:2	O
not	PRADAXA.xml:S3:1439:3	O
available	PRADAXA.xml:S3:1443:9	O
.	PRADAXA.xml:S3:1452:1	O

Hemodialysis	PRADAXA.xml:S3:1454:12	O
can	PRADAXA.xml:S3:1467:3	O
remove	PRADAXA.xml:S3:1471:6	O
dabigatran	PRADAXA.xml:S3:1478:10	O
;	PRADAXA.xml:S3:1488:1	O
however	PRADAXA.xml:S3:1490:7	O
the	PRADAXA.xml:S3:1498:3	O
clinical	PRADAXA.xml:S3:1502:8	O
experience	PRADAXA.xml:S3:1511:10	O
supporting	PRADAXA.xml:S3:1522:10	O
the	PRADAXA.xml:S3:1533:3	O
use	PRADAXA.xml:S3:1537:3	O
of	PRADAXA.xml:S3:1541:2	O
hemodialysis	PRADAXA.xml:S3:1544:12	O
as	PRADAXA.xml:S3:1557:2	O
a	PRADAXA.xml:S3:1560:1	O
treatment	PRADAXA.xml:S3:1562:9	O
for	PRADAXA.xml:S3:1572:3	O
bleeding	PRADAXA.xml:S3:1576:8	O
is	PRADAXA.xml:S3:1585:2	O
limited	PRADAXA.xml:S3:1588:7	O
[	PRADAXA.xml:S3:1596:1	O
see	PRADAXA.xml:S3:1597:3	O
Overdosage	PRADAXA.xml:S3:1601:10	O
(	PRADAXA.xml:S3:1613:1	O
10	PRADAXA.xml:S3:1614:2	O
)	PRADAXA.xml:S3:1616:1	O
]	PRADAXA.xml:S3:1619:1	O
.	PRADAXA.xml:S3:1622:1	O

Activated	PRADAXA.xml:S3:1624:9	O
prothrombin	PRADAXA.xml:S3:1634:11	O
complex	PRADAXA.xml:S3:1646:7	O
concentrates	PRADAXA.xml:S3:1654:12	O
(	PRADAXA.xml:S3:1667:1	O
aPCCs	PRADAXA.xml:S3:1668:5	O
,	PRADAXA.xml:S3:1673:1	O
e	PRADAXA.xml:S3:1675:1	O
.	PRADAXA.xml:S3:1676:1	O
g	PRADAXA.xml:S3:1677:1	O
.	PRADAXA.xml:S3:1678:1	O
,	PRADAXA.xml:S3:1679:1	O
FEIBA	PRADAXA.xml:S3:1681:5	O
)	PRADAXA.xml:S3:1686:1	O
,	PRADAXA.xml:S3:1687:1	O
or	PRADAXA.xml:S3:1689:2	O
recombinant	PRADAXA.xml:S3:1692:11	O
Factor	PRADAXA.xml:S3:1704:6	O
VIIa	PRADAXA.xml:S3:1711:4	O
,	PRADAXA.xml:S3:1715:1	O
or	PRADAXA.xml:S3:1717:2	O
concentrates	PRADAXA.xml:S3:1720:12	O
of	PRADAXA.xml:S3:1733:2	O
coagulation	PRADAXA.xml:S3:1736:11	O
factors	PRADAXA.xml:S3:1748:7	O
II	PRADAXA.xml:S3:1756:2	O
,	PRADAXA.xml:S3:1758:1	O
IX	PRADAXA.xml:S3:1760:2	O
or	PRADAXA.xml:S3:1763:2	O
X	PRADAXA.xml:S3:1766:1	O
may	PRADAXA.xml:S3:1768:3	O
be	PRADAXA.xml:S3:1772:2	O
considered	PRADAXA.xml:S3:1775:10	O
but	PRADAXA.xml:S3:1786:3	O
their	PRADAXA.xml:S3:1790:5	O
use	PRADAXA.xml:S3:1796:3	O
has	PRADAXA.xml:S3:1800:3	O
not	PRADAXA.xml:S3:1804:3	O
been	PRADAXA.xml:S3:1808:4	O
evaluated	PRADAXA.xml:S3:1813:9	O
in	PRADAXA.xml:S3:1823:2	O
clinical	PRADAXA.xml:S3:1826:8	O
trials	PRADAXA.xml:S3:1835:6	O
.	PRADAXA.xml:S3:1841:1	O

Protamine	PRADAXA.xml:S3:1843:9	O
sulfate	PRADAXA.xml:S3:1853:7	O
and	PRADAXA.xml:S3:1861:3	O
vitamin	PRADAXA.xml:S3:1865:7	O
K	PRADAXA.xml:S3:1873:1	O
are	PRADAXA.xml:S3:1875:3	O
not	PRADAXA.xml:S3:1879:3	O
expected	PRADAXA.xml:S3:1883:8	O
to	PRADAXA.xml:S3:1892:2	O
affect	PRADAXA.xml:S3:1895:6	O
the	PRADAXA.xml:S3:1902:3	O
anticoagulant	PRADAXA.xml:S3:1906:13	O
activity	PRADAXA.xml:S3:1920:8	O
of	PRADAXA.xml:S3:1929:2	O
dabigatran	PRADAXA.xml:S3:1932:10	O
.	PRADAXA.xml:S3:1942:1	O

Consider	PRADAXA.xml:S3:1944:8	O
administration	PRADAXA.xml:S3:1953:14	O
of	PRADAXA.xml:S3:1968:2	O
platelet	PRADAXA.xml:S3:1971:8	O
concentrates	PRADAXA.xml:S3:1980:12	O
in	PRADAXA.xml:S3:1993:2	O
cases	PRADAXA.xml:S3:1996:5	O
where	PRADAXA.xml:S3:2002:5	O
thrombocytopenia	PRADAXA.xml:S3:2008:16	O
is	PRADAXA.xml:S3:2025:2	O
present	PRADAXA.xml:S3:2028:7	O
or	PRADAXA.xml:S3:2036:2	O
long	PRADAXA.xml:S3:2039:4	O
-	PRADAXA.xml:S3:2043:1	O
acting	PRADAXA.xml:S3:2044:6	O
antiplatelet	PRADAXA.xml:S3:2051:12	O
drugs	PRADAXA.xml:S3:2064:5	O
have	PRADAXA.xml:S3:2070:4	O
been	PRADAXA.xml:S3:2075:4	O
used	PRADAXA.xml:S3:2080:4	O
.	PRADAXA.xml:S3:2084:1	O

5.3	PRADAXA.xml:S3:2093:3	O
Spinal	PRADAXA.xml:S3:2097:6	O
Epidural	PRADAXA.xml:S3:2104:8	O
Anesthesia	PRADAXA.xml:S3:2113:10	O
or	PRADAXA.xml:S3:2124:2	O
Puncture	PRADAXA.xml:S3:2127:8	O

When	PRADAXA.xml:S3:2141:4	O
neuraxial	PRADAXA.xml:S3:2146:9	O
anesthesia	PRADAXA.xml:S3:2156:10	O
(	PRADAXA.xml:S3:2167:1	O
spinal	PRADAXA.xml:S3:2168:6	O
epidural	PRADAXA.xml:S3:2175:8	O
anesthesia	PRADAXA.xml:S3:2184:10	O
)	PRADAXA.xml:S3:2194:1	O
or	PRADAXA.xml:S3:2196:2	O
spinal	PRADAXA.xml:S3:2199:6	O
puncture	PRADAXA.xml:S3:2206:8	O
is	PRADAXA.xml:S3:2215:2	O
employed	PRADAXA.xml:S3:2218:8	O
,	PRADAXA.xml:S3:2226:1	O
patients	PRADAXA.xml:S3:2228:8	O
treated	PRADAXA.xml:S3:2237:7	O
with	PRADAXA.xml:S3:2245:4	O
anticoagulant	PRADAXA.xml:S3:2250:13	B-DrugClass
agents	PRADAXA.xml:S3:2264:6	I-DrugClass
are	PRADAXA.xml:S3:2271:3	O
at	PRADAXA.xml:S3:2275:2	O
risk	PRADAXA.xml:S3:2278:4	O
of	PRADAXA.xml:S3:2283:2	O
developing	PRADAXA.xml:S3:2286:10	O
an	PRADAXA.xml:S3:2297:2	O
epidural	PRADAXA.xml:S3:2300:8	B-AdverseReaction
or	PRADAXA.xml:S3:2309:2	O
spinal	PRADAXA.xml:S3:2312:6	B-AdverseReaction
hematoma	PRADAXA.xml:S3:2319:8	I-AdverseReaction
which	PRADAXA.xml:S3:2328:5	O
can	PRADAXA.xml:S3:2334:3	O
result	PRADAXA.xml:S3:2338:6	O
in	PRADAXA.xml:S3:2345:2	O
long	PRADAXA.xml:S3:2348:4	O
-	PRADAXA.xml:S3:2352:1	O
term	PRADAXA.xml:S3:2353:4	O
or	PRADAXA.xml:S3:2358:2	O
permanent	PRADAXA.xml:S3:2361:9	B-AdverseReaction
paralysis	PRADAXA.xml:S3:2371:9	I-AdverseReaction
[	PRADAXA.xml:S3:2381:1	O
see	PRADAXA.xml:S3:2382:3	O
Boxed	PRADAXA.xml:S3:2387:5	O
Warning	PRADAXA.xml:S3:2393:7	O
]	PRADAXA.xml:S3:2402:1	O
.	PRADAXA.xml:S3:2405:1	O

To	PRADAXA.xml:S3:2411:2	O
reduce	PRADAXA.xml:S3:2414:6	O
the	PRADAXA.xml:S3:2421:3	O
potential	PRADAXA.xml:S3:2425:9	O
risk	PRADAXA.xml:S3:2435:4	O
of	PRADAXA.xml:S3:2440:2	O
bleeding	PRADAXA.xml:S3:2443:8	O
associated	PRADAXA.xml:S3:2452:10	O
with	PRADAXA.xml:S3:2463:4	O
the	PRADAXA.xml:S3:2468:3	O
concurrent	PRADAXA.xml:S3:2472:10	O
use	PRADAXA.xml:S3:2483:3	O
of	PRADAXA.xml:S3:2487:2	O
dabigatran	PRADAXA.xml:S3:2490:10	O
and	PRADAXA.xml:S3:2501:3	O
epidural	PRADAXA.xml:S3:2505:8	O
or	PRADAXA.xml:S3:2514:2	O
spinal	PRADAXA.xml:S3:2517:6	O
anesthesia	PRADAXA.xml:S3:2524:10	O
analgesia	PRADAXA.xml:S3:2535:9	O
or	PRADAXA.xml:S3:2545:2	O
spinal	PRADAXA.xml:S3:2548:6	O
puncture	PRADAXA.xml:S3:2555:8	O
,	PRADAXA.xml:S3:2563:1	O
consider	PRADAXA.xml:S3:2565:8	O
the	PRADAXA.xml:S3:2574:3	O
pharmacokinetic	PRADAXA.xml:S3:2578:15	O
profile	PRADAXA.xml:S3:2594:7	O
of	PRADAXA.xml:S3:2602:2	O
dabigatran	PRADAXA.xml:S3:2605:10	O
[	PRADAXA.xml:S3:2616:1	O
see	PRADAXA.xml:S3:2617:3	O
Clinical	PRADAXA.xml:S3:2621:8	O
Pharmacology	PRADAXA.xml:S3:2630:12	O
(	PRADAXA.xml:S3:2644:1	O
12.3	PRADAXA.xml:S3:2645:4	O
)	PRADAXA.xml:S3:2649:1	O
]	PRADAXA.xml:S3:2652:1	O
.	PRADAXA.xml:S3:2655:1	O

Placement	PRADAXA.xml:S3:2657:9	O
or	PRADAXA.xml:S3:2667:2	O
removal	PRADAXA.xml:S3:2670:7	O
of	PRADAXA.xml:S3:2678:2	O
an	PRADAXA.xml:S3:2681:2	O
epidural	PRADAXA.xml:S3:2684:8	O
catheter	PRADAXA.xml:S3:2693:8	O
or	PRADAXA.xml:S3:2702:2	O
lumbar	PRADAXA.xml:S3:2705:6	O
puncture	PRADAXA.xml:S3:2712:8	O
is	PRADAXA.xml:S3:2721:2	O
best	PRADAXA.xml:S3:2724:4	O
performed	PRADAXA.xml:S3:2729:9	O
when	PRADAXA.xml:S3:2739:4	O
the	PRADAXA.xml:S3:2744:3	O
anticoagulant	PRADAXA.xml:S3:2748:13	O
effect	PRADAXA.xml:S3:2762:6	O
of	PRADAXA.xml:S3:2769:2	O
dabigatran	PRADAXA.xml:S3:2772:10	O
is	PRADAXA.xml:S3:2783:2	O
low	PRADAXA.xml:S3:2786:3	O
;	PRADAXA.xml:S3:2789:1	O
however	PRADAXA.xml:S3:2791:7	O
,	PRADAXA.xml:S3:2798:1	O
the	PRADAXA.xml:S3:2800:3	O
exact	PRADAXA.xml:S3:2804:5	O
timing	PRADAXA.xml:S3:2810:6	O
to	PRADAXA.xml:S3:2817:2	O
reach	PRADAXA.xml:S3:2820:5	O
a	PRADAXA.xml:S3:2826:1	O
sufficiently	PRADAXA.xml:S3:2828:12	O
low	PRADAXA.xml:S3:2841:3	O
anticoagulant	PRADAXA.xml:S3:2845:13	O
effect	PRADAXA.xml:S3:2859:6	O
in	PRADAXA.xml:S3:2866:2	O
each	PRADAXA.xml:S3:2869:4	O
patient	PRADAXA.xml:S3:2874:7	O
is	PRADAXA.xml:S3:2882:2	O
not	PRADAXA.xml:S3:2885:3	O
known	PRADAXA.xml:S3:2889:5	O
.	PRADAXA.xml:S3:2894:1	O

Should	PRADAXA.xml:S3:2900:6	O
the	PRADAXA.xml:S3:2907:3	O
physician	PRADAXA.xml:S3:2911:9	O
decide	PRADAXA.xml:S3:2921:6	O
to	PRADAXA.xml:S3:2928:2	O
administer	PRADAXA.xml:S3:2931:10	O
anticoagulation	PRADAXA.xml:S3:2942:15	O
in	PRADAXA.xml:S3:2958:2	O
the	PRADAXA.xml:S3:2961:3	O
context	PRADAXA.xml:S3:2965:7	O
of	PRADAXA.xml:S3:2973:2	O
epidural	PRADAXA.xml:S3:2976:8	O
or	PRADAXA.xml:S3:2985:2	O
spinal	PRADAXA.xml:S3:2988:6	O
anesthesia	PRADAXA.xml:S3:2995:10	O
analgesia	PRADAXA.xml:S3:3006:9	O
or	PRADAXA.xml:S3:3016:2	O
lumbar	PRADAXA.xml:S3:3019:6	O
puncture	PRADAXA.xml:S3:3026:8	O
,	PRADAXA.xml:S3:3034:1	O
monitor	PRADAXA.xml:S3:3036:7	O
frequently	PRADAXA.xml:S3:3044:10	O
to	PRADAXA.xml:S3:3055:2	O
detect	PRADAXA.xml:S3:3058:6	O
any	PRADAXA.xml:S3:3065:3	O
signs	PRADAXA.xml:S3:3069:5	O
or	PRADAXA.xml:S3:3075:2	O
symptoms	PRADAXA.xml:S3:3078:8	O
of	PRADAXA.xml:S3:3087:2	O
neurological	PRADAXA.xml:S3:3090:12	O
impairment	PRADAXA.xml:S3:3103:10	O
,	PRADAXA.xml:S3:3113:1	O
such	PRADAXA.xml:S3:3115:4	O
as	PRADAXA.xml:S3:3120:2	O
midline	PRADAXA.xml:S3:3123:7	O
back	PRADAXA.xml:S3:3131:4	O
pain	PRADAXA.xml:S3:3136:4	O
,	PRADAXA.xml:S3:3140:1	O
sensory	PRADAXA.xml:S3:3142:7	O
and	PRADAXA.xml:S3:3150:3	O
motor	PRADAXA.xml:S3:3154:5	O
deficits	PRADAXA.xml:S3:3160:8	O
(	PRADAXA.xml:S3:3169:1	O
numbness	PRADAXA.xml:S3:3170:8	O
,	PRADAXA.xml:S3:3178:1	O
tingling	PRADAXA.xml:S3:3180:8	O
,	PRADAXA.xml:S3:3188:1	O
or	PRADAXA.xml:S3:3190:2	O
weakness	PRADAXA.xml:S3:3193:8	O
in	PRADAXA.xml:S3:3202:2	O
lower	PRADAXA.xml:S3:3205:5	O
limbs	PRADAXA.xml:S3:3211:5	O
)	PRADAXA.xml:S3:3216:1	O
,	PRADAXA.xml:S3:3217:1	O
bowel	PRADAXA.xml:S3:3219:5	O
and	PRADAXA.xml:S3:3225:3	O
or	PRADAXA.xml:S3:3229:2	O
bladder	PRADAXA.xml:S3:3232:7	O
dysfunction	PRADAXA.xml:S3:3240:11	O
.	PRADAXA.xml:S3:3251:1	O

Instruct	PRADAXA.xml:S3:3253:8	O
patients	PRADAXA.xml:S3:3262:8	O
to	PRADAXA.xml:S3:3271:2	O
immediately	PRADAXA.xml:S3:3274:11	O
report	PRADAXA.xml:S3:3286:6	O
if	PRADAXA.xml:S3:3293:2	O
they	PRADAXA.xml:S3:3296:4	O
experience	PRADAXA.xml:S3:3301:10	O
any	PRADAXA.xml:S3:3312:3	O
of	PRADAXA.xml:S3:3316:2	O
the	PRADAXA.xml:S3:3319:3	O
above	PRADAXA.xml:S3:3323:5	O
signs	PRADAXA.xml:S3:3329:5	O
or	PRADAXA.xml:S3:3335:2	O
symptoms	PRADAXA.xml:S3:3338:8	O
.	PRADAXA.xml:S3:3346:1	O

If	PRADAXA.xml:S3:3348:2	O
signs	PRADAXA.xml:S3:3351:5	O
or	PRADAXA.xml:S3:3357:2	O
symptoms	PRADAXA.xml:S3:3360:8	O
of	PRADAXA.xml:S3:3369:2	O
spinal	PRADAXA.xml:S3:3372:6	O
hematoma	PRADAXA.xml:S3:3379:8	O
are	PRADAXA.xml:S3:3388:3	O
suspected	PRADAXA.xml:S3:3392:9	O
,	PRADAXA.xml:S3:3401:1	O
initiate	PRADAXA.xml:S3:3403:8	O
urgent	PRADAXA.xml:S3:3412:6	O
diagnosis	PRADAXA.xml:S3:3419:9	O
and	PRADAXA.xml:S3:3429:3	O
treatment	PRADAXA.xml:S3:3433:9	O
including	PRADAXA.xml:S3:3443:9	O
consideration	PRADAXA.xml:S3:3453:13	O
for	PRADAXA.xml:S3:3467:3	O
spinal	PRADAXA.xml:S3:3471:6	O
cord	PRADAXA.xml:S3:3478:4	O
decompression	PRADAXA.xml:S3:3483:13	O
even	PRADAXA.xml:S3:3497:4	O
though	PRADAXA.xml:S3:3502:6	O
such	PRADAXA.xml:S3:3509:4	O
treatment	PRADAXA.xml:S3:3514:9	O
may	PRADAXA.xml:S3:3524:3	O
not	PRADAXA.xml:S3:3528:3	O
prevent	PRADAXA.xml:S3:3532:7	O
or	PRADAXA.xml:S3:3540:2	O
reverse	PRADAXA.xml:S3:3543:7	O
neurological	PRADAXA.xml:S3:3551:12	O
sequelae	PRADAXA.xml:S3:3564:8	O
.	PRADAXA.xml:S3:3572:1	O

5.4	PRADAXA.xml:S3:3581:3	O
Thromboembolic	PRADAXA.xml:S3:3585:14	O
and	PRADAXA.xml:S3:3600:3	O
Bleeding	PRADAXA.xml:S3:3604:8	O
Events	PRADAXA.xml:S3:3613:6	O
in	PRADAXA.xml:S3:3620:2	O
Patients	PRADAXA.xml:S3:3623:8	O
with	PRADAXA.xml:S3:3632:4	O
Prosthetic	PRADAXA.xml:S3:3637:10	B-AdverseReaction
Heart	PRADAXA.xml:S3:3648:5	I-AdverseReaction
Valves	PRADAXA.xml:S3:3654:6	O

The	PRADAXA.xml:S3:3666:3	O
safety	PRADAXA.xml:S3:3670:6	O
and	PRADAXA.xml:S3:3677:3	O
efficacy	PRADAXA.xml:S3:3681:8	O
of	PRADAXA.xml:S3:3690:2	O
PRADAXA	PRADAXA.xml:S3:3693:7	O
in	PRADAXA.xml:S3:3701:2	O
patients	PRADAXA.xml:S3:3704:8	O
with	PRADAXA.xml:S3:3713:4	O
bileaflet	PRADAXA.xml:S3:3718:9	O
mechanical	PRADAXA.xml:S3:3728:10	O
prosthetic	PRADAXA.xml:S3:3739:10	O
heart	PRADAXA.xml:S3:3750:5	O
valves	PRADAXA.xml:S3:3756:6	O
was	PRADAXA.xml:S3:3763:3	O
evaluated	PRADAXA.xml:S3:3767:9	O
in	PRADAXA.xml:S3:3777:2	O
the	PRADAXA.xml:S3:3780:3	O
RE	PRADAXA.xml:S3:3784:2	O
-	PRADAXA.xml:S3:3786:1	O
ALIGN	PRADAXA.xml:S3:3787:5	O
trial	PRADAXA.xml:S3:3793:5	O
,	PRADAXA.xml:S3:3798:1	O
in	PRADAXA.xml:S3:3800:2	O
which	PRADAXA.xml:S3:3803:5	O
patients	PRADAXA.xml:S3:3809:8	O
with	PRADAXA.xml:S3:3818:4	O
bileaflet	PRADAXA.xml:S3:3823:9	O
mechanical	PRADAXA.xml:S3:3833:10	O
prosthetic	PRADAXA.xml:S3:3844:10	O
heart	PRADAXA.xml:S3:3855:5	O
valves	PRADAXA.xml:S3:3861:6	O
(	PRADAXA.xml:S3:3868:1	O
recently	PRADAXA.xml:S3:3869:8	O
implanted	PRADAXA.xml:S3:3878:9	O
or	PRADAXA.xml:S3:3888:2	O
implanted	PRADAXA.xml:S3:3891:9	O
more	PRADAXA.xml:S3:3901:4	O
than	PRADAXA.xml:S3:3906:4	O
three	PRADAXA.xml:S3:3911:5	O
months	PRADAXA.xml:S3:3917:6	O
prior	PRADAXA.xml:S3:3924:5	O
to	PRADAXA.xml:S3:3930:2	O
enrollment	PRADAXA.xml:S3:3933:10	O
)	PRADAXA.xml:S3:3943:1	O
were	PRADAXA.xml:S3:3945:4	O
randomized	PRADAXA.xml:S3:3950:10	O
to	PRADAXA.xml:S3:3961:2	O
dose	PRADAXA.xml:S3:3964:4	O
adjusted	PRADAXA.xml:S3:3969:8	O
warfarin	PRADAXA.xml:S3:3978:8	O
or	PRADAXA.xml:S3:3987:2	O
150	PRADAXA.xml:S3:3990:3	O
,	PRADAXA.xml:S3:3993:1	O
220	PRADAXA.xml:S3:3995:3	O
,	PRADAXA.xml:S3:3998:1	O
or	PRADAXA.xml:S3:4000:2	O
300	PRADAXA.xml:S3:4003:3	O
mg	PRADAXA.xml:S3:4007:2	O
of	PRADAXA.xml:S3:4010:2	O
PRADAXA	PRADAXA.xml:S3:4013:7	O
twice	PRADAXA.xml:S3:4021:5	O
a	PRADAXA.xml:S3:4027:1	O
day	PRADAXA.xml:S3:4029:3	O
.	PRADAXA.xml:S3:4032:1	O

RE	PRADAXA.xml:S3:4034:2	O
-	PRADAXA.xml:S3:4036:1	O
ALIGN	PRADAXA.xml:S3:4037:5	O
was	PRADAXA.xml:S3:4043:3	O
terminated	PRADAXA.xml:S3:4047:10	O
early	PRADAXA.xml:S3:4058:5	O
due	PRADAXA.xml:S3:4064:3	O
to	PRADAXA.xml:S3:4068:2	O
the	PRADAXA.xml:S3:4071:3	O
occurrence	PRADAXA.xml:S3:4075:10	O
of	PRADAXA.xml:S3:4086:2	O
significantly	PRADAXA.xml:S3:4089:13	O
more	PRADAXA.xml:S3:4103:4	O
thromboembolic	PRADAXA.xml:S3:4108:14	B-AdverseReaction
events	PRADAXA.xml:S3:4123:6	I-AdverseReaction
(	PRADAXA.xml:S3:4130:1	O
valve	PRADAXA.xml:S3:4131:5	I-AdverseReaction
thrombosis	PRADAXA.xml:S3:4137:10	I-AdverseReaction
,	PRADAXA.xml:S3:4147:1	O
stroke	PRADAXA.xml:S3:4149:6	I-AdverseReaction
,	PRADAXA.xml:S3:4155:1	O
transient	PRADAXA.xml:S3:4157:9	B-AdverseReaction
ischemic	PRADAXA.xml:S3:4167:8	I-AdverseReaction
attack	PRADAXA.xml:S3:4176:6	I-AdverseReaction
,	PRADAXA.xml:S3:4182:1	O
and	PRADAXA.xml:S3:4184:3	O
myocardial	PRADAXA.xml:S3:4188:10	B-AdverseReaction
infarction	PRADAXA.xml:S3:4199:10	I-AdverseReaction
)	PRADAXA.xml:S3:4209:1	O
and	PRADAXA.xml:S3:4211:3	O
an	PRADAXA.xml:S3:4215:2	O
excess	PRADAXA.xml:S3:4218:6	O
of	PRADAXA.xml:S3:4225:2	O
major	PRADAXA.xml:S3:4228:5	B-Severity
bleeding	PRADAXA.xml:S3:4234:8	B-AdverseReaction
(	PRADAXA.xml:S3:4243:1	O
predominantly	PRADAXA.xml:S3:4244:13	O
post	PRADAXA.xml:S3:4258:4	O
-	PRADAXA.xml:S3:4262:1	O
operative	PRADAXA.xml:S3:4263:9	O
pericardial	PRADAXA.xml:S3:4273:11	B-AdverseReaction
effusions	PRADAXA.xml:S3:4285:9	I-AdverseReaction
requiring	PRADAXA.xml:S3:4295:9	O
intervention	PRADAXA.xml:S3:4305:12	O
for	PRADAXA.xml:S3:4318:3	O
hemodynamic	PRADAXA.xml:S3:4322:11	O
compromise	PRADAXA.xml:S3:4334:10	O
)	PRADAXA.xml:S3:4344:1	O
in	PRADAXA.xml:S3:4346:2	O
the	PRADAXA.xml:S3:4349:3	O
PRADAXA	PRADAXA.xml:S3:4353:7	O
treatment	PRADAXA.xml:S3:4361:9	O
arm	PRADAXA.xml:S3:4371:3	O
as	PRADAXA.xml:S3:4375:2	O
compared	PRADAXA.xml:S3:4378:8	O
to	PRADAXA.xml:S3:4387:2	O
the	PRADAXA.xml:S3:4390:3	O
warfarin	PRADAXA.xml:S3:4394:8	O
treatment	PRADAXA.xml:S3:4403:9	O
arm	PRADAXA.xml:S3:4413:3	O
.	PRADAXA.xml:S3:4416:1	O

These	PRADAXA.xml:S3:4418:5	O
bleeding	PRADAXA.xml:S3:4424:8	B-AdverseReaction
and	PRADAXA.xml:S3:4433:3	O
thromboembolic	PRADAXA.xml:S3:4437:14	B-AdverseReaction
events	PRADAXA.xml:S3:4452:6	I-AdverseReaction
were	PRADAXA.xml:S3:4459:4	O
seen	PRADAXA.xml:S3:4464:4	O
both	PRADAXA.xml:S3:4469:4	O
in	PRADAXA.xml:S3:4474:2	O
patients	PRADAXA.xml:S3:4477:8	O
who	PRADAXA.xml:S3:4486:3	O
were	PRADAXA.xml:S3:4490:4	O
initiated	PRADAXA.xml:S3:4495:9	O
on	PRADAXA.xml:S3:4505:2	O
PRADAXA	PRADAXA.xml:S3:4508:7	O
post	PRADAXA.xml:S3:4516:4	O
-	PRADAXA.xml:S3:4520:1	O
operatively	PRADAXA.xml:S3:4521:11	O
within	PRADAXA.xml:S3:4533:6	O
three	PRADAXA.xml:S3:4540:5	O
days	PRADAXA.xml:S3:4546:4	O
of	PRADAXA.xml:S3:4551:2	O
mechanical	PRADAXA.xml:S3:4554:10	O
bileaflet	PRADAXA.xml:S3:4565:9	O
valve	PRADAXA.xml:S3:4575:5	O
implantation	PRADAXA.xml:S3:4581:12	O
,	PRADAXA.xml:S3:4593:1	O
as	PRADAXA.xml:S3:4595:2	O
well	PRADAXA.xml:S3:4598:4	O
as	PRADAXA.xml:S3:4603:2	O
in	PRADAXA.xml:S3:4606:2	O
patients	PRADAXA.xml:S3:4609:8	O
whose	PRADAXA.xml:S3:4618:5	O
valves	PRADAXA.xml:S3:4624:6	O
had	PRADAXA.xml:S3:4631:3	O
been	PRADAXA.xml:S3:4635:4	O
implanted	PRADAXA.xml:S3:4640:9	O
more	PRADAXA.xml:S3:4650:4	O
than	PRADAXA.xml:S3:4655:4	O
three	PRADAXA.xml:S3:4660:5	O
months	PRADAXA.xml:S3:4666:6	O
prior	PRADAXA.xml:S3:4673:5	O
to	PRADAXA.xml:S3:4679:2	O
enrollment	PRADAXA.xml:S3:4682:10	O
.	PRADAXA.xml:S3:4692:1	O

Therefore	PRADAXA.xml:S3:4694:9	O
,	PRADAXA.xml:S3:4703:1	O
the	PRADAXA.xml:S3:4705:3	O
use	PRADAXA.xml:S3:4709:3	O
of	PRADAXA.xml:S3:4713:2	O
PRADAXA	PRADAXA.xml:S3:4716:7	O
is	PRADAXA.xml:S3:4724:2	O
contraindicated	PRADAXA.xml:S3:4727:15	O
in	PRADAXA.xml:S3:4743:2	O
patients	PRADAXA.xml:S3:4746:8	O
with	PRADAXA.xml:S3:4755:4	O
mechanical	PRADAXA.xml:S3:4760:10	O
prosthetic	PRADAXA.xml:S3:4771:10	O
valves	PRADAXA.xml:S3:4782:6	O
[	PRADAXA.xml:S3:4789:1	O
see	PRADAXA.xml:S3:4790:3	O
Contraindications	PRADAXA.xml:S3:4794:17	O
(	PRADAXA.xml:S3:4813:1	O
4	PRADAXA.xml:S3:4814:1	O
)	PRADAXA.xml:S3:4815:1	O
]	PRADAXA.xml:S3:4818:1	O
.	PRADAXA.xml:S3:4819:1	O

The	PRADAXA.xml:S3:4827:3	O
use	PRADAXA.xml:S3:4831:3	O
of	PRADAXA.xml:S3:4835:2	O
PRADAXA	PRADAXA.xml:S3:4838:7	O
for	PRADAXA.xml:S3:4846:3	O
the	PRADAXA.xml:S3:4850:3	O
prophylaxis	PRADAXA.xml:S3:4854:11	O
of	PRADAXA.xml:S3:4866:2	O
thromboembolic	PRADAXA.xml:S3:4869:14	O
events	PRADAXA.xml:S3:4884:6	O
in	PRADAXA.xml:S3:4891:2	O
patients	PRADAXA.xml:S3:4894:8	O
with	PRADAXA.xml:S3:4903:4	O
atrial	PRADAXA.xml:S3:4908:6	O
fibrillation	PRADAXA.xml:S3:4915:12	O
in	PRADAXA.xml:S3:4928:2	O
the	PRADAXA.xml:S3:4931:3	O
setting	PRADAXA.xml:S3:4935:7	O
of	PRADAXA.xml:S3:4943:2	O
other	PRADAXA.xml:S3:4946:5	O
forms	PRADAXA.xml:S3:4952:5	O
of	PRADAXA.xml:S3:4958:2	O
valvular	PRADAXA.xml:S3:4961:8	O
heart	PRADAXA.xml:S3:4970:5	O
disease	PRADAXA.xml:S3:4976:7	O
,	PRADAXA.xml:S3:4983:1	O
including	PRADAXA.xml:S3:4985:9	O
the	PRADAXA.xml:S3:4995:3	O
presence	PRADAXA.xml:S3:4999:8	O
of	PRADAXA.xml:S3:5008:2	O
a	PRADAXA.xml:S3:5011:1	O
bioprosthetic	PRADAXA.xml:S3:5013:13	O
heart	PRADAXA.xml:S3:5027:5	O
valve	PRADAXA.xml:S3:5033:5	O
,	PRADAXA.xml:S3:5038:1	O
has	PRADAXA.xml:S3:5040:3	O
not	PRADAXA.xml:S3:5044:3	O
been	PRADAXA.xml:S3:5048:4	O
studied	PRADAXA.xml:S3:5053:7	O
and	PRADAXA.xml:S3:5061:3	O
is	PRADAXA.xml:S3:5065:2	O
not	PRADAXA.xml:S3:5068:3	O
recommended	PRADAXA.xml:S3:5072:11	O
.	PRADAXA.xml:S3:5083:1	O

5.5	PRADAXA.xml:S3:5092:3	O
Effect	PRADAXA.xml:S3:5096:6	O
of	PRADAXA.xml:S3:5103:2	O
P	PRADAXA.xml:S3:5106:1	O
-	PRADAXA.xml:S3:5107:1	O
gp	PRADAXA.xml:S3:5108:2	O
Inducers	PRADAXA.xml:S3:5111:8	O
and	PRADAXA.xml:S3:5120:3	O
Inhibitors	PRADAXA.xml:S3:5124:10	O
on	PRADAXA.xml:S3:5135:2	O
Dabigatran	PRADAXA.xml:S3:5138:10	O
Exposure	PRADAXA.xml:S3:5149:8	O

The	PRADAXA.xml:S3:5163:3	O
concomitant	PRADAXA.xml:S3:5167:11	O
use	PRADAXA.xml:S3:5179:3	O
of	PRADAXA.xml:S3:5183:2	O
PRADAXA	PRADAXA.xml:S3:5186:7	O
with	PRADAXA.xml:S3:5194:4	O
P	PRADAXA.xml:S3:5199:1	O
-	PRADAXA.xml:S3:5200:1	O
gp	PRADAXA.xml:S3:5201:2	O
inducers	PRADAXA.xml:S3:5204:8	O
(	PRADAXA.xml:S3:5213:1	O
e	PRADAXA.xml:S3:5214:1	O
.	PRADAXA.xml:S3:5215:1	O
g	PRADAXA.xml:S3:5216:1	O
.	PRADAXA.xml:S3:5217:1	O
,	PRADAXA.xml:S3:5218:1	O
rifampin	PRADAXA.xml:S3:5220:8	O
)	PRADAXA.xml:S3:5228:1	O
reduces	PRADAXA.xml:S3:5230:7	O
exposure	PRADAXA.xml:S3:5238:8	O
to	PRADAXA.xml:S3:5247:2	O
dabigatran	PRADAXA.xml:S3:5250:10	O
and	PRADAXA.xml:S3:5261:3	O
should	PRADAXA.xml:S3:5265:6	O
generally	PRADAXA.xml:S3:5272:9	O
be	PRADAXA.xml:S3:5282:2	O
avoided	PRADAXA.xml:S3:5285:7	O
[	PRADAXA.xml:S3:5293:1	O
see	PRADAXA.xml:S3:5294:3	O
Clinical	PRADAXA.xml:S3:5298:8	O
Pharmacology	PRADAXA.xml:S3:5307:12	O
(	PRADAXA.xml:S3:5321:1	O
12.3	PRADAXA.xml:S3:5322:4	O
)	PRADAXA.xml:S3:5326:1	O
]	PRADAXA.xml:S3:5329:1	O
.	PRADAXA.xml:S3:5332:1	O

P	PRADAXA.xml:S3:5338:1	O
-	PRADAXA.xml:S3:5339:1	O
gp	PRADAXA.xml:S3:5340:2	O
inhibition	PRADAXA.xml:S3:5343:10	O
and	PRADAXA.xml:S3:5354:3	O
impaired	PRADAXA.xml:S3:5358:8	O
renal	PRADAXA.xml:S3:5367:5	O
function	PRADAXA.xml:S3:5373:8	O
are	PRADAXA.xml:S3:5382:3	O
the	PRADAXA.xml:S3:5386:3	O
major	PRADAXA.xml:S3:5390:5	O
independent	PRADAXA.xml:S3:5396:11	O
factors	PRADAXA.xml:S3:5408:7	O
that	PRADAXA.xml:S3:5416:4	O
result	PRADAXA.xml:S3:5421:6	O
in	PRADAXA.xml:S3:5428:2	O
increased	PRADAXA.xml:S3:5431:9	O
exposure	PRADAXA.xml:S3:5441:8	O
to	PRADAXA.xml:S3:5450:2	O
dabigatran	PRADAXA.xml:S3:5453:10	O
[	PRADAXA.xml:S3:5464:1	O
see	PRADAXA.xml:S3:5465:3	O
Clinical	PRADAXA.xml:S3:5469:8	O
Pharmacology	PRADAXA.xml:S3:5478:12	O
(	PRADAXA.xml:S3:5492:1	O
12.3	PRADAXA.xml:S3:5493:4	O
)	PRADAXA.xml:S3:5497:1	O
]	PRADAXA.xml:S3:5500:1	O
.	PRADAXA.xml:S3:5501:1	O

Concomitant	PRADAXA.xml:S3:5504:11	O
use	PRADAXA.xml:S3:5516:3	O
of	PRADAXA.xml:S3:5520:2	O
P	PRADAXA.xml:S3:5523:1	O
-	PRADAXA.xml:S3:5524:1	O
gp	PRADAXA.xml:S3:5525:2	O
inhibitors	PRADAXA.xml:S3:5528:10	O
in	PRADAXA.xml:S3:5539:2	O
patients	PRADAXA.xml:S3:5542:8	O
with	PRADAXA.xml:S3:5551:4	O
renal	PRADAXA.xml:S3:5556:5	O
impairment	PRADAXA.xml:S3:5562:10	O
is	PRADAXA.xml:S3:5573:2	O
expected	PRADAXA.xml:S3:5576:8	O
to	PRADAXA.xml:S3:5585:2	O
produce	PRADAXA.xml:S3:5588:7	O
increased	PRADAXA.xml:S3:5596:9	O
exposure	PRADAXA.xml:S3:5606:8	O
of	PRADAXA.xml:S3:5615:2	O
dabigatran	PRADAXA.xml:S3:5618:10	O
compared	PRADAXA.xml:S3:5629:8	O
to	PRADAXA.xml:S3:5638:2	O
that	PRADAXA.xml:S3:5641:4	O
seen	PRADAXA.xml:S3:5646:4	O
with	PRADAXA.xml:S3:5651:4	O
either	PRADAXA.xml:S3:5656:6	O
factor	PRADAXA.xml:S3:5663:6	O
alone	PRADAXA.xml:S3:5670:5	O
.	PRADAXA.xml:S3:5675:1	O

Reduction	PRADAXA.xml:S3:5683:9	O
of	PRADAXA.xml:S3:5693:2	O
Risk	PRADAXA.xml:S3:5696:4	O
of	PRADAXA.xml:S3:5701:2	O
Stroke	PRADAXA.xml:S3:5704:6	O
and	PRADAXA.xml:S3:5711:3	O
Systemic	PRADAXA.xml:S3:5715:8	O
Embolism	PRADAXA.xml:S3:5724:8	O
in	PRADAXA.xml:S3:5733:2	O
Non	PRADAXA.xml:S3:5736:3	O
-	PRADAXA.xml:S3:5739:1	O
valvular	PRADAXA.xml:S3:5740:8	O
Atrial	PRADAXA.xml:S3:5749:6	O
Fibrillation	PRADAXA.xml:S3:5756:12	O

Reduce	PRADAXA.xml:S3:5777:6	O
the	PRADAXA.xml:S3:5784:3	O
dose	PRADAXA.xml:S3:5788:4	O
of	PRADAXA.xml:S3:5793:2	O
PRADAXA	PRADAXA.xml:S3:5796:7	O
to	PRADAXA.xml:S3:5804:2	O
75	PRADAXA.xml:S3:5807:2	O
mg	PRADAXA.xml:S3:5810:2	O
twice	PRADAXA.xml:S3:5813:5	O
daily	PRADAXA.xml:S3:5819:5	O
when	PRADAXA.xml:S3:5825:4	O
dronedarone	PRADAXA.xml:S3:5830:11	O
or	PRADAXA.xml:S3:5842:2	O
systemic	PRADAXA.xml:S3:5845:8	O
ketoconazole	PRADAXA.xml:S3:5854:12	O
is	PRADAXA.xml:S3:5867:2	O
coadministered	PRADAXA.xml:S3:5870:14	O
with	PRADAXA.xml:S3:5885:4	O
PRADAXA	PRADAXA.xml:S3:5890:7	O
in	PRADAXA.xml:S3:5898:2	O
patients	PRADAXA.xml:S3:5901:8	O
with	PRADAXA.xml:S3:5910:4	O
moderate	PRADAXA.xml:S3:5915:8	O
renal	PRADAXA.xml:S3:5924:5	O
impairment	PRADAXA.xml:S3:5930:10	O
(	PRADAXA.xml:S3:5941:1	O
CrCl	PRADAXA.xml:S3:5942:4	O
30	PRADAXA.xml:S3:5947:2	O
-	PRADAXA.xml:S3:5949:1	O
50	PRADAXA.xml:S3:5950:2	O
mL	PRADAXA.xml:S3:5953:2	O
min	PRADAXA.xml:S3:5956:3	O
)	PRADAXA.xml:S3:5959:1	O
.	PRADAXA.xml:S3:5960:1	O

Avoid	PRADAXA.xml:S3:5962:5	O
use	PRADAXA.xml:S3:5968:3	O
of	PRADAXA.xml:S3:5972:2	O
PRADAXA	PRADAXA.xml:S3:5975:7	O
and	PRADAXA.xml:S3:5983:3	O
P	PRADAXA.xml:S3:5987:1	O
-	PRADAXA.xml:S3:5988:1	O
gp	PRADAXA.xml:S3:5989:2	O
inhibitors	PRADAXA.xml:S3:5992:10	O
in	PRADAXA.xml:S3:6003:2	O
patients	PRADAXA.xml:S3:6006:8	O
with	PRADAXA.xml:S3:6015:4	O
severe	PRADAXA.xml:S3:6020:6	O
renal	PRADAXA.xml:S3:6027:5	O
impairment	PRADAXA.xml:S3:6033:10	O
(	PRADAXA.xml:S3:6044:1	O
CrCl	PRADAXA.xml:S3:6045:4	O
15	PRADAXA.xml:S3:6050:2	O
-	PRADAXA.xml:S3:6052:1	O
30	PRADAXA.xml:S3:6053:2	O
mL	PRADAXA.xml:S3:6056:2	O
min	PRADAXA.xml:S3:6059:3	O
)	PRADAXA.xml:S3:6062:1	O
[	PRADAXA.xml:S3:6064:1	O
see	PRADAXA.xml:S3:6065:3	O
Drug	PRADAXA.xml:S3:6069:4	O
Interactions	PRADAXA.xml:S3:6074:12	O
(	PRADAXA.xml:S3:6088:1	O
7.1	PRADAXA.xml:S3:6089:3	O
)	PRADAXA.xml:S3:6092:1	O
and	PRADAXA.xml:S3:6095:3	O
Use	PRADAXA.xml:S3:6099:3	O
in	PRADAXA.xml:S3:6103:2	O
Specific	PRADAXA.xml:S3:6106:8	O
Populations	PRADAXA.xml:S3:6115:11	O
(	PRADAXA.xml:S3:6128:1	O
8.6	PRADAXA.xml:S3:6129:3	O
)	PRADAXA.xml:S3:6132:1	O
]	PRADAXA.xml:S3:6135:1	O
.	PRADAXA.xml:S3:6138:1	O

Treatment	PRADAXA.xml:S3:6146:9	O
and	PRADAXA.xml:S3:6156:3	O
Reduction	PRADAXA.xml:S3:6160:9	O
in	PRADAXA.xml:S3:6170:2	O
the	PRADAXA.xml:S3:6173:3	O
Risk	PRADAXA.xml:S3:6177:4	O
of	PRADAXA.xml:S3:6182:2	O
Recurrence	PRADAXA.xml:S3:6185:10	O
of	PRADAXA.xml:S3:6196:2	O
Deep	PRADAXA.xml:S3:6199:4	O
Venous	PRADAXA.xml:S3:6204:6	O
Thrombosis	PRADAXA.xml:S3:6211:10	O
and	PRADAXA.xml:S3:6222:3	O
Pulmonary	PRADAXA.xml:S3:6226:9	O
Embolism	PRADAXA.xml:S3:6236:8	O

Avoid	PRADAXA.xml:S3:6253:5	O
use	PRADAXA.xml:S3:6259:3	O
of	PRADAXA.xml:S3:6263:2	O
PRADAXA	PRADAXA.xml:S3:6266:7	O
and	PRADAXA.xml:S3:6274:3	O
concomitant	PRADAXA.xml:S3:6278:11	O
P	PRADAXA.xml:S3:6290:1	O
-	PRADAXA.xml:S3:6291:1	O
gp	PRADAXA.xml:S3:6292:2	O
inhibitors	PRADAXA.xml:S3:6295:10	O
in	PRADAXA.xml:S3:6306:2	O
patients	PRADAXA.xml:S3:6309:8	O
with	PRADAXA.xml:S3:6318:4	O
CrCl	PRADAXA.xml:S3:6323:4	O
50	PRADAXA.xml:S3:6329:2	O
mL	PRADAXA.xml:S3:6332:2	O
min	PRADAXA.xml:S3:6335:3	O
[	PRADAXA.xml:S3:6339:1	O
see	PRADAXA.xml:S3:6340:3	O
Drug	PRADAXA.xml:S3:6344:4	O
Interactions	PRADAXA.xml:S3:6349:12	O
(	PRADAXA.xml:S3:6363:1	O
7.2	PRADAXA.xml:S3:6364:3	O
)	PRADAXA.xml:S3:6367:1	O
and	PRADAXA.xml:S3:6370:3	O
Use	PRADAXA.xml:S3:6374:3	O
in	PRADAXA.xml:S3:6378:2	O
Specific	PRADAXA.xml:S3:6381:8	O
Populations	PRADAXA.xml:S3:6390:11	O
(	PRADAXA.xml:S3:6403:1	O
8.6	PRADAXA.xml:S3:6404:3	O
)	PRADAXA.xml:S3:6407:1	O
]	PRADAXA.xml:S3:6410:1	O
.	PRADAXA.xml:S3:6413:1	O
